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Abstract 
A functional vascular system in the vertebrate is pivotal for normal development and 
maturation. Failure in the structure and function of such a system will inevitably lead to 
pathophysiological conditions, and in severe cases to death. The blood and lymphatic 
system are the two circulatory systems of vertebrates.  
Lymphatic vessels in particular are important routes for fluid drainage, lipid homeostasis 
and immune surveillance. Dysfunctional lymphatics will lead to numerous diseases, 
including lymphedema, metastasis of cancer cells and various inflammatory disorders. 
Mutations in SRY-box containing gene 18 (SOX18), Vascular Endothelial Growth Factor C 
(VEGFC) and Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) underlie the 
hereditary lymphatic disorders hypotrichosis–lymphedema–telangiectasia (HLT), Milroy-
like lymphedema and Milroy disease, respectively. Genes responsible for hereditary 
lymphedema are key regulators of lymphatic vascular development in the embryo.  
 
To identify novel modulators of lymphangiogenesis, in Chapter 3 of this thesis, a mouse 
model of HLT (Ragged Opossum) was used and gene expression profiling of aberrant 
dermal lymphatic vessels was performed. 289 genes were found dysregulated in purified 
lymphatic endothelial cells isolated from heterozygous Sox18 mutant mice (Sox18RaOp+/-) 
compared to wild-type. These genes were recognized as having known roles in other 
processes during development, but had previously not been implicated in lymphatic vessel 
development. Subsequent expression studies and functional analysis in zebrafish revealed 
one candidate, ArfGAP with RhoGAP domain, Ankyrin repeat and PH domain 3 (ARAP3), 
which was down-regulated in HLT mouse lymphatic vessels and necessary for lymphatic 
vascular development in zebrafish.  
 
To further understand how gene expression may alter vessel network formation, an in vivo 
model system was developed in Chapter 4. The dermal vascular assay allowed 
examination of changes in vessel morphology over time. Blood vessels remodelled into a 
dense network of loops at 14.5 days post coitum (dpc) and displayed a completed inter-
connected blood vascular network by 15.5 dpc. Following this, the first lymphatic vessels 
anastomosed at the midline of the mouse embryonic skin at 16.5 dpc, displaying a network 
of larger loops compared to blood vessels. Interestingly, at this time point not all lymphatic 
vessels appeared to be connected at the midline. These vessels are believed to function 
as blind-ended lymphatic capillaries.  
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In the final data section, Chapter 5, the function of Arap3 was further examined in mice. A 
conditional endothelial cell Arap3 knockout mouse was generated and displayed severe 
lymphatic vascular defects as observed in mouse embryonic skin at 14.5 dpc. Mutant 
lymphatic vessels appeared to be bulbous in morphology and did not migrate as far to the 
midline as wild type siblings. Further mechanistic analysis in vitro and in vivo, positioned 
this known regulator of cell behaviour during migration as a mediator of the cellular 
response to Vegfc signalling in lymphatic endothelial cells.  
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Preface 
Various diseases have been associated with the lymphatic vasculature, including 
lymphedema, characterized by an accumulation of fluid in interstitial spaces (Karkkainen 
et al., 2001; Koshima et al., 1996), obesity, characterized by defects in lymphatic function 
(Harvey et al., 2005) and tumor propagation (He et al., 2005; Mandriota et al., 2001; 
Skobe et al., 2001). Recent advances in molecular biology, gene targeting and imaging 
techniques, have facilitated the identification of master regulators that play a role during 
lymphatic vessel formation in the developing embryo. In this regard, the challenge that is 
currently presented is determining which other genes or new pathways are likely involved 
in this process, acting as either activators, repressors or in synergy with known molecular 
players. Discovery of novel regulators of lymphatic vessel formation and the role they play 
will inevitably aid in understanding molecular mechanisms during normal development. 
Consequently this knowledge can be applied to better understand disease conditions and 
give more insight into clinical implications. The work presented here gives an elaborate 
background of systems used for gene identification, the current knowledge of blood and 
lymphatic vessel development with their respective molecular regulators and lastly the 
research performed to identify and characterize novel lymphatic vessel regulators. 
 
1.1 Animal Models to Understand Disease and Development 
Model organisms have been, and continue to be, pivotal in the development and 
improvement of therapeutic treatments. In particular, to understand the effect that changes 
in gene expression, protein structure and function may have as the underlying cause of 
diseases.  To this end, genomic changes were induced in primitive organisms such as 
bacteria (Escherichia coli (1973)) and yeast (Saccharomyces cerevisiae (1978)). 
Subsequently, invertebrate animal species such as roundworms (Caenorhabditis elegans 
(1985)), fruit flies (Drosophila melanogaster (1982)), sea urchins (Strongylocentrotus 
purpuratus (1985)) as well as several vertebrate animal models, including amphibians 
(Xenopus laevis (1983)), fish (Danio rerio (1988)), chickens (Gallus gallus (1986)), and 
mice (Mus musculus (1981)) were used to study gene function (Doyle et al., 2012)) 
[Fig.1.1]. 
 
The mouse model soon became the most common animal model used to represent 
human diseases, given the high similarity to human anatomy, physiology and genetics with 
the mouse genome sharing over 95% similarity with the human genome (Doyle et al., 
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2012). Recently, the zebrafish became used as a complimentary model system.  Zebrafish 
also share a high genetic similarity to humans with approximately 70% of all human 
disease genes having functional homologs in zebrafish (Langheinrich, 2003). In addition, 
zebrafish provide advantages where the mouse model is limited. 
 
The two main animal models used in the following study are the mouse and zebrafish. 
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Figure 1.1 Model organisms for studying gene function 
Historically, the first group of model organisms that were used for genetic manipulation (as 
indicated by year annotation) were primitive organisms, such as bacteria and yeast. In 
subsequent years, invertebrate (fruitfly, roundworm and sea urchin) and vertebrate 
(mouse, frog, chicken and zebrafish) organisms were selected. The mouse and zebrafish 
have now become the most commonly used vertebrate animal models in genetic studies 
of human disease   
	   	   Introduction 
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1.1.1 The mouse model for genetics 
In order to delineate the molecular functions of genes and their interactions with one 
another, as well as their influence on cellular processes, the quest for gene targeting in 
mouse embryonic cells was developed as recently as 1977 (Capecchi, 1980). 
 
Gene targeting, the introduction of site-specific modifications into the genome, was first 
practiced by introducing DNA directly into nuclei of mammalian cells (Capecchi, 1980; 
Gordon et al., 1980). One in three cells that received the DNA stably passed the functional 
gene to the daughter cells. In addition, the exogenous randomly introduced DNA 
molecules appeared to be orderly integrated within the genome, revealing that mammalian 
cells were capable of mediating homologous recombination between newly added DNA 
molecules and the endogenous DNA in the recipient cell (Folger et al., 1982). With the 
observation that all chromosomal target positions in the mouse were equally accessible to 
the homologous recombination machinery it was hypothesized that the mouse genome at 
large could be modified by gene targeting strategies (Thomas et al., 1986). Consequently, 
using pronuclear microinjection, transgenic mice were generated. These mice had foreign 
genes incorporated into their genomes, whether this entailed the entire gene including its 
own promoter, exons and introns, or just the exons (complementary DNA - cDNA) fused to 
an appropriate promoter and injected into the nuclei of one-cell mouse zygotes, allowing 
these embryos to come to term after surgical transfer to foster mothers (Capecchi, 2005; 
Cho et al., 2009; Chung et al., 1997).  
 
The technology for creating transgenic mice has brought about the creation of mouse 
models with gene-specific null or loss-of-function mutations (knock-out mice) or gain-of-
function mutations (knock-in mice).  In addition, conditional and/or inducible knock-outs are 
widely used to knock-out a given gene only in specific cellular compartments and at 
specific time points, thus being able to control gene expression temporally and spatially 
(Reviewed in Doyle et al., 2012).   
Two members of the integrase family of site-specific recombinases, Cre from 
bacteriophage P1 (Sauer and Henderson, 1989) and Flp from Saccharomyces cerevisiae 
(O'Gorman et al., 1991), are used to date to conditionally control gene expression by site-
specifc DNA recombination. Cre and Flp recombinases catalyse a conservative 
recombination event between two 34-bp recognition sites (loxP and FRT, respectively). 
These gene transfer technologies, based on gene recombination events, are the most 
common approaches used in mice to generate conditional knock-out models.  
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Overall the above strategies are classified as “reverse genetics” approaches, where the 
function of a gene is modified in order to analyze the effect on the development or 
behavior of the organism  (Reviewed in Doyle et al., 2012). Less common in mice are 
“forward genetic” strategies, where mutagenic event(s) are initiated using radiation or 
chemical treatments (e.g. the chemical mutagen ethylnitrosourea (ENU)) (Russell et al., 
1979), followed by phenotypic screens to identify mice that manifest defects in 
development or function of a particular organ. The high expense that forward genetic 
strategies in mice engage as well as the difficulty of studying mutations acting early in 
embryogenesis (due to mouse embryos developing internally), triggered the search for 
alternative model organisms to perform large scale, systematic genetic screens. The use 
of C. elegans (Hirsh and Vanderslice, 1976) and Drosophila (Nusslein-Volhard and 
Wieschaus, 1980) embryos had for many years enabled detailed analysis of 
developmental pathways in invertebrate systems. In the hunt for a vertebrate equivalent, 
the zebrafish was recognized as a genetic system in which similar approaches to that used 
in these model organisms, including C. elegans, would be achievable (Streisinger et al., 
1981).  
 
1.1.2 The zebrafish model for genetics 
In contrast to mice, the virtually transparent zebrafish embryos allow direct observation of 
developmental processes such as vascular development (Isogai et al., 2001; Yaniv et al., 
2006). These features combined with rapid development and high fecundity enables 
genetic screens on a large scale, including forward genetics (phenotype to genotype) and 
reverse genetics (genotype to phenotype). In addition, the small size of the zebrafish 
embryo is enough to receive oxygen by passive diffusion to survive without cardiovascular 
function so that mutants with a defective cardiovascular system can continue to develop in 
a normal fashion for several days.  
 
The successful use of zebrafish embryos in genetic screens has resulted in the 
identification of numerous mutants defective for a variety of cellular and developmental 
processes. Among these were prominent classes of mutants for cardiovascular (Stainier et 
al., 1995) and central nervous system defects (Grunwald et al., 1988; Kimmel et al., 1991). 
Further mapping and characterization of the affected genes in these mutants has provided 
new insight into biological processes. The initial forward genetic screens in zebrafish were 
performed by gamma- or X-ray irradiation, identifying nine zebrafish mutations that 
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affected embryogenesis, some of which include neural degeneration mutations (Grunwald 
et al., 1988) and mutations in skeletal muscle fibrils (Felsenfeld et al., 1990). Subsequent 
large-scale mutagenesis screens (Driever et al., 1996; Haffter et al., 1996; Henion et al., 
1996) were performed using ENU to predominantly induce lesions limited to single genes. 
One screen in particular identified over 2000 mutations in genes that caused abnormal 
embryonic and early larval phenotypes (Driever et al., 1996), including mutations affecting 
patterning of the embryonic axes, gastrulation movements (Solnica-Krezel et al., 1996), 
and mutations controlling organ development and heart beat rate (Stainier et al., 1996). 
Some mutant phenotypes that were identified resemble human disease states, such as 
congenital heart disease (Gelb, 1997), emphasizing the power of this model system for 
studying biological processes relating to disease. 
 
In addition to these studies where mutant lines are identified with phenotypes resembling 
human disease or zebrafish orthologues/analogues of human disease-causing genes are 
isolated, other genetic tools have been applied in zebrafish to study gene function. The 
most commonly used methods for direct manipulation of genes and their expression have 
involved the microinjection of DNA or RNA sequences to transiently manipulate gene 
function. Specifically, common approaches include injection of:  
1) Short chemically stabilized anti-sense oligomers, known as morpholinos (MOs) due to 
the addition of a morpholino subunit in the oligomer backbone. When introduced into early 
zebrafish embryos, these highly stable oligomers bind to sequences based on base-pair 
complementarity and transiently block the normal function of the gene of interest during 
development (gene loss-of-function or gene knock-down analyses) (Nasevicius and Ekker, 
2000; Rosen et al., 2009).  
2) Microinjection of DNA or RNA into zebrafish zygotes for gain-of-function studies (gene 
overexpression or dominant active analyses), mosaic analysis, lineage-restricted studies 
and cell tracing experiments (Driever et al., 1994).  
 
The use of these genetic tools and generation of stable zebrafish transgenic lines that 
carry fluorescent proteins, such as Green Fluorescent Protein (GFP) (Amsterdam et al., 
1995), have shed light on our understanding of developmental processes, including 
vascular biology. For example, lineage-tracing experiments in zebrafish have elucidated 
the cellular origins of lymphatic endothelial cells (Yaniv et al., 2006) and early 
vasculogenic endothelium (Isogai et al., 2001; Kuchler et al., 2006; Srinivasan et al., 
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2007). The use of gene knock-down and mutant generation has shed light on the 
molecules that control vessel formation and lineage differentiation (Herbert et al., 2009). 
 
Given the close conservation between the mouse and zebrafish and their complementary 
contribution to model human disease conditions, both these organisms used together are 
ideal to gain rapid insights into vascular biology of relevance to human disease. Here, both 
the mouse and the zebrafish model were utilized to observe the identity and characterize 
novel genes controlling the development of the vasculature and in particular lymphatic 
vasculature in the embryo. 
 
1.2 The Vasculature 
A functional vascular network is critical for an organism to develop and survive. Much of 
what we know about vessel formation comes from studies of the embryo. The two most 
well studied systems are zebrafish and mice. Below, blood and lymphatic vascular 
development are reviewed in these model organisms.   
 
1.2.1 The blood vasculature 
1.2.1.1 Mouse blood vessel development 
The blood circulatory system comprises of a hierarchy of vessels: the arteries, veins and 
capillaries that branch throughout the body to supply blood, nutrients and oxygen to 
tissues and organs. During the initial events of vascular formation in mammals, precursor 
endothelial cells (angioblasts) migrate from the embryonic mesoderm, differentiate and 
assemble into solid cord-like structures, a process referred to as vasculogenesis (Noden, 
1989; Risau et al., 1988) [Fig.1.2]. Subsequent growth, expansion and remodelling of 
these primitive vessels will lead to the formation of a mature blood vascular network, 
through a process known as angiogenesis (Reviewed in Carmeliet, 2003).  
 
During angiogenesis, sprouting of new vessels from pre-existing vessels occurs, mainly 
through delamination and migration of endothelial cells from these pre-existing vessels 
(Reviewed in Carmeliet and Tessier-Lavigne, 2005). Angiogenic growth is further 
characterized by several morphogenetic events, including anastomosis of new vessel 
connections, lumen formation, the establishment of cell junctions, apical-basal cell polarity, 
and the deposition and stabilization of a basement membrane (Reviewed in Eilken and 
Adams, 2010). As activated endothelial cells continue to migrate and proliferate to form 
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new vessels, layers of peri-vascular cells start to surround the forming vessels – pericytes 
on small vessels and smooth muscle cells (SMC) on large vessels (Conway et al., 2001).  
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Figure 1.2 Overview of blood vessel formation in mammals 
Vasculogenesis is the process of angioblast assembly into cord-like structures that will 
subsequently remodel into vascular tubes. The major arterial and venous vessels are 
formed through vasculogenesis and are seeded by vascular smooth muscle cells (vSMC). 
In contrast, capillaries are covered by pericytes. Through angiogenic remodelling, 
subsequent vessels are formed from pre-existing vessels by branching and sprouting to 
ultimately give rise to a complete network of interconnected vessels.  
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Expansion of the blood vasculature may also involve non-angiogenic growth, which 
comprises bone-marrow-derived fusion of epithelial cells or longitudinal splitting of blood 
vessels (intussusception) through insertion of tissue pillars. Growth through 
intussusception is thought to involve endothelial cell (EC) proliferation, cell movement, 
extracellular matrix (ECM) degradation and deposition of new ECM molecules (Reviewed 
in Adams and Alitalo, 2007; Conway et al., 2001). 
 
1.2.1.2 Zebrafish blood vessel development 
The basic anatomy of the initial embryonic circulatory system holds similarities among 
vertebrates, including the zebrafish. In zebrafish, the cellular processes of blood vascular 
development have been defined mainly by studies in transgenic lines. 
 
Around 12-14 hours post-fertilization (hpf), angioblasts are located in two lateral stripes 
(Roman et al., 2002). In vivo imaging of a Tg(fli1a:EGFP) reporter fish line, which 
expresses Enhanced Green Fluorescent Protein (EGFP) in all endothelial cells, revealed 
that these angioblasts migrate toward the midline and aggregate to form a tube 
(vasculogenesis) (Jin et al., 2005). At commencement of vasculogenesis, these 
aggregates appear discontinuous along the anterior-posterior axis and contain spherical 
shaped cells. As this process continues, at around 17 hpf more flattened tube-forming 
cells are observed (Eriksson and Lofberg, 2000). The change in cell shape may suggest 
increased cell motility which is needed for angioblast migration.  
 
The formation of the dorsal aorta (DA) through vasculogenesis at approximately 16.5 hpf 
is followed by the formation of the posterior cardinal vein (PCV) (Isogai et al., 2001; Isogai 
et al., 2003). The further establishment of the blood vascular network from these major 
axial vessels, occurs in two waves of vessel formation through angiogenesis (Isogai et al., 
2003). During the first wave (primary angiogenesis) at 22 hpf, arterial intersegmental 
vessels (aISV) are formed through sprouting from the dorsal aorta (DA) [Fig.1.3B]. The 
second wave (secondary angiogenesis) at 36 hpf encompasses the formation of 
intersegmental veins (vISV), originating from the posterior cardinal vein (PCV) (Isogai et 
al., 2003; Yaniv et al., 2006) [Fig.1.3C]. 
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Figure 1.3 Stepwise overview of zebrafish angiogenesis 
A) The major artery and vein in the zebrafish, the dorsal aorta (DA) and posterior cardinal 
vein (PCV), run through the trunk. Blood flow of the embryos loops through the DA toward 
the tip of the tail and back through the PCV and the heart.  
B) The first angiogenic sprouts that bud from the DA at approximately at 22 hpf will grow 
dorsally, to form arterial intersegmental vessels (aISVs), and sprout further up toward 
dorsal aspect of the trunk where they branch left and right to form the dorsal longitudinal 
anastomotic vessel (DLAV).  
C) At 36 hpf the second wave of angiogenesis takes place and involves dorsal endothelial 
cell sprouting from the PCV.  
D) Half of the venous sprouts will anastomose to aISVs to form venous intersegmental 
vessels (vISV), whereas the other half will migrate toward the horizontal myoseptum (HM) 
to become precursor lymphatic endothelial cells (PLs).  
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At 54 hpf half of the venous sprouts elongate dorsally but do not connect to the primary 
vessel segments. These sprouts become lymphatic precursors (PLs) and will contribute to 
the formation of the lymphatic vasculature [Fig.1.3D]  (Isogai et al., 2003).  
 
1.2.1.2.1 Intersegmental vessel formation in the zebrafish embryo 
Isogai and colleagues (Isogai et al., 2003) demonstrated through time-lapse multiphoton 
live imaging of Tg(fli1a:EGFP)y1 zebrafish embryos that the primary sprouts grow dorsally 
between the somites and neural tube. As the growing ISVs reach the dorsal wall of the 
neural tube at approximately 28 hpf, they divide into two major branches that turn left and 
right, forming a T-shape structure. These branches elongate and connect to neighboring 
branches to form the bilateral dorsal longitudinal anastomotic vessels (DLAVs). By 1.5 
days post-fertilization (dpf) a completed network of primary ISVs, originating from the DA, 
is present with an active circulation (Isogai et al., 2003). 
 
Around 1.5 dpf a secondary set of vascular sprouts emerges, this time exclusively from the 
vein, as observed in Tg(fli1a:EGFP)y1 zebrafish embryos. These secondary sprouts grow 
dorsally, generally towards and/or alongside the nearest primary intersegmental vessel 
(Isogai et al., 2003). As they grow towards the primary vessel, approximately half of the 
venous sprouts will anastomose with the adjacent arterial intersegmental vessel and 
acquire their final venous fate, linking the PCV to the primary vascular network. Once the 
primary and secondary vessel networks are connected and this secondary network is 
lumenized, the adjacent ventral-most regions of the primary vessel will regress and 
disappear.  
 
The formation of ISVs has been described in more detail by in vivo time-lapse and 
immunofluorescent analyses (Blum et al., 2008; Childs et al., 2002; Isogai et al., 2003; 
Lawson and Weinstein, 2002a).  These studies suggested that one or two cells migrate 
out of the endothelium of the DA to form a sprout. During dorsal outgrowth, this sprout 
constitutes three cells that are arranged in a head-to-tail fashion (Childs et al., 2002), 
comprising of a leading tip cell and two stalk cells [Fig.1.4]. Subsequent mosaic analyses 
and analysis of endothelial cell junctions (Blum et al., 2008) revealed that in fact four to six 
cells make up the ISV, overlapping one another along the proximodistal axis of the vessel 
rather than being aligned in a head-to-tail configuration.  
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During the formation of the vascular network, the guidance of sprouting blood vessels is 
largely facilitated by these specialized endothelial tip cells that are present at the leading 
vessel forefront (Carmeliet and Tessier-Lavigne, 2005; De Smet et al., 2009; Gerhardt et 
al., 2003; Geudens and Gerhardt, 2011; Ruhrberg et al., 2002). The contribution of the tips 
cells and their adjacent stalk cells to a forming sprout will be discussed in further detail 
below.  
 
1.2.1.2.2 Navigating growing blood vessels 
The leading tip cell is migratory and polarised, and extends long filopodia protrusions to 
scope out the surroundings for attractant or repellent signals [Fig.1.4]. With their filopodia 
extensions, new blood vessels are guided in a certain direction (De Smet et al., 2009; 
Gerhardt et al., 2003; Ruhrberg et al., 2002). The following cells adjacent to the tip cell are 
the stalk cells [Fig.1.4]. These cells proliferate during sprouting extension and do not 
protrude filopodia. Instead, they permit extension of the nascent vessel by producing ECM, 
forming junctions and a vascular lumen (Gerhardt et al., 2003; Geudens and Gerhardt, 
2011; Siemerink et al., 2010). Decreased stalk cell proliferation is linked to branch 
regression (Phng et al., 2009).  
 
During sprouting outgrowth, the frequency of division of the proliferating stalk cell 
determines vessel elongation (Gerhardt et al., 2003). Tubule morphology, whether a 
vessel becomes longer or wider, is furthermore determined by the orientation of the cell 
division plane (Zeng et al., 2007). Imaging of embryonic stem (ES) cell-derived vessels 
showed cell divisions perpendicular to the long axis of the growing vessel, thereby 
promoting lengthening of the tube and maintenance of a constant tubule diameter (Zeng et 
al., 2007).  
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Figure 1.4 Inside a growing vessel sprout: tip and stalk cells 
Tip cells are present at the leading forefront of vascular sprouts. They protrude filopodia to 
sense cues in the microenvironment and guide the growing sprout. Stalk cells follow the tip 
cells and are connected to the extracellular matrix (ECM) or in the case of a blood vessel 
sprout, to the dorsal aorta (DA). Stalk cells are highly proliferative cells and ensure 
lengthening and extension of the growing sprout.   
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Defects in oriented cell division may lead to tubular enlargement and cyst formation in 
diverse contexts, as shown in rodent polycystic kidney models (Fischer et al., 2006).   
 
1.2.1.2.3 Vascular lumen formation 
Ultimately, stalk cells establish a vascular lumen [Fig.1.5]. The lumen size changes as 
vessels grow and remodel (De Smet et al., 2009). Analysis of a silent heart (sih) zebrafish 
mutant, where the pumping heart and blood flow is compromised, shows that the initial 
lumen formation in zebrafish ISVs is not dependent on blood flow. At 30 hpf, these 
mutants display ISVs with a normal primary lumen and the presence of vacuoles. 
However, at 48 hpf sih mutants exhibit clustering of endothelial cell junctions in ISVs, 
which reflect a collapsed primary lumen. These observations suggest that stabilization of a 
newly formed lumen is dependent upon blood flow (Wang et al., 2010).  
 
The understanding of how a vascular lumen is formed, is based on studies of EC behavior 
in in vitro models of two-dimensional and three-dimensional extracellular matrices. These 
studies show that coalescence of intracellular pinocytic vacuoles results in lumenization 
(Davis et al., 2002; Kamei et al., 2006) [Fig.1.5 i]. Vacuole formation is dependent on an 
interaction of integrins with the ECM, whereas the fusion of vacuoles requires 
rearrangement of the actin and microtubule cytoskeleton (Davis et al., 2002).  
These observations of intracellular pinocytic vacuole formation were further supported by 
studies in vivo of high-resolution time-lapse two-photon imaging of transgenic zebrafish 
(Kamei et al., 2006). Karmei et al., (Kamei et al., 2006) reported that intra- and intercellular 
fusion of vacuoles also generated a lumen in zebrafish trunk ISVs. 
 
However, in studying the cellular architecture of developing zebrafish ISVs by single cell 
live imaging, Blum et al., (Blum et al., 2008) reported that the overlapping endothelial cells 
that comprise a sprout form a multicellular tube that contains an extracellular lumen. They 
proposed a model by which the lumenal space of ISVs is formed between cells through 
exocytosis of vacuoles, subsequently to form an intercellular space [Fig.1.5 ii].  
Alternatively, observations of a developing aorta of mouse embryos (Strilic et al., 2009) 
and zebrafish ISVs (Wang et al., 2010) through live imaging, revealed a process of lumen 
formation through the relocation of junctional proteins and cell shape changes without any 
vacuoles forming  [Fig.1.5 iii].  
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The vascular lumen will ultimately support blood flow. A continuous filtration takes place, 
caused by blood pressure, of plasma constituents from the arterial side of capillaries into 
the interstitial space. Extravasated fluid is collected and returned back to the blood vessels 
by another vascular system, the lymphatic vasculature (Reviewed in Tammela and Alitalo, 
2010). 
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Figure 1.5   The formation of a vascular lumen 
A lumen in vessels is formed by one of three mechanisms:  
i) intracellular vacuole coalescence, where vacuoles within a cell merge to form a 
continuous lumen (cell hollowing);  
ii) through intercellular vacuole exocytosis, where cells are arranged in a paired fashion 
and form a lumen by cord hollowing, thus through exocytosis of vacuoles into the 
intercellular space;  
iii) by luminal repulsion, during which proteins at cell junctions will relocate and cause 
changes in cell shape, subsequently giving rise to intercellular lumen formation.   
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1.2.2 The lymphatic vasculature 
1.2.2.1 Structure and significance of lymphatic vessels 
The blood vasculature gives rise to a second vascular system – the lymphatic vasculature. 
Although ‘related’ to blood vessels, lymphatic vessels differ in their structure and function 
compared to blood vessels. The main function of lymphatic vessels is to drain interstitial 
fluid back to the main circulatory system. 
 
Lymphatic vessels display thin walls and a relatively wide lumen. Lymphatic capillary 
endothelial cells lack tight junctions and instead partly overlap neighboring cells, thereby 
forming valve-like openings, which facilitate access of fluid, macromolecules and cells into 
the vessel lumen (Reviewed in Karpanen and Alitalo, 2008). In addition, lymphatic 
capillaries lack SMC and have a discontinuous basement membrane. The endothelial cells 
of lymphatic capillaries are connected to the ECM by elastic fibers known as anchoring 
filaments, which maintain the vessel integrity during increased interstitial pressure 
[Fig.1.6A-B]. These small lymphatic capillaries begin blind-ended in the tissues and collect 
protein-rich fluid from the interstitial space. This fluid, now called lymph, then drains from 
the lymphatic capillaries into pre-collector lymphatics, a network of vessels that is larger in 
size, compared to the capillaries, and generally lies deeper in tissues. These precollecting 
ducts have the ability to also directly absorb lymph from the interstitium. 
 
The pre-collecting ducts drain into collecting lymphatics, which in turn connect to larger 
lymphatic trunks. These lymphatic trunks drain into the major lymphatic vessels, the 
thoracic duct (TD) and the right lymphatic duct. The TD runs alongside the aorta and 
drains most of the body fluid that passes between the periphery and blood vasculature. 
Subsequently, it returns the extravasated fluid back into the venous system at the junction 
of the left internal jugular and left subclavian veins (Baldwin et al., 2002; Karpanen and 
Alitalo, 2008; Tammela and Alitalo, 2010)) [Fig.1.6C]. 
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Figure 1.6 Structural representation of the lymphatic vasculature  
A) Extravasated fluid is collected by blind-ended lymphatic capillaries. Endothelial cells of 
lymphatic capillaries form valve-like structures and enable the access of fluid, 
macromolecules and cells into the lumen. Lymphatic capillaries are connected to the 
extracellular matrix via anchoring filaments and lack a basement membrane as opposed to 
the larger collecting lymphatic ducts.  
B) Collecting lymphatic ducts consist of an endothelial cell layer with tight junctions and a 
basement membrane. In addition, collecting lymphatic vessels display valves, which cause 
lymph to flow in only one direction.  
C) The thoracic duct (TD) is one of the major lymphatic vessels, which is entrusted with 
the drainage of extravasated fluid from tissues and the return of the fluid to the venous 
system at the junction of the left internal jugular and the left subclavian veins. 
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1.2.2.2 The origin of lymphatic vessels 
For many years, the origin of developing lymphatic vessels remained unclear as the lack 
of specific lymphatic markers made it challenging to study lymphatic vessel development. 
Fortunately, recent advances in molecular biology, genetics and microscopy techniques 
have opened up avenues to study this vascular system in depth.  
 
A debate regarding lymphatic origin continued for almost a century. In 1902, Sabin’s work 
in pig embryos demonstrated for the first time, through a series of injections of India ink, 
the gradual development of the lymphatic vasculature. She also described the budding off 
of precursor lymphatic endothelial cells (LECs) from venous endothelium (Sabin, 1905). 
Huntington (Huntington and McClure, 1908) described controversial observations, 
concluding that lymphatics develop independently of the blood vasculature, and originate 
from mesenchymal tissue. Subsequent genetic experiments in mice and zebrafish, 
performed more than one hundred years later, have definitively put this debate to rest, 
providing new evidence that lymphatic endothelial precursor cells (lymphangioblasts) 
originate from veins.  
 
1.2.2.3 Mouse lymphatic vessel development 
The formation of lymphatic vessels from veins (lymphangiogenesis) in mice starts around 
midgestation, approximately at 9.5-10.5 days post coitum (dpc). At this time a functional 
cardiovascular system is present.  
A subset of venous endothelial cells in the dorso-lateral wall that is specified to become 
LECs, delaminates from the anterior cardinal veins and migrates into the mesenchyme in 
dorso-anterior and dorsolateral streams to form the embryonic lymph sacs (Reviewed in 
Francois et al., 2011), also referred to as primordial TD (Hagerling et al., 2013) [Fig.1.7].    
 
The venous origin of precursor LECs was definitively demonstrated by genetically labeling 
precursor LECs with a Prox1-driven Tamoxifen (TM)-inducible Cre in a LacZ reporter 
background (R26R reporter line) (Srinivasan et al., 2007).   
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Figure 1.7 Lymphangiogenesis in mice 
At approximately 9 days post coitum (dpc), a subpopulation of venous endothelial cells is 
specified to the lymphatic lineage. These cells express high levels of transcription factors 
that induce progenitor LEC migration toward a VEGFC gradient and subsequently 
contribute to the formation of lymph sacs. Ultimately these lymph sacs differentiate into the 
mature lymphatic vasculature.  
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Prox1 (prospero-related homeobox-1) is a transcription factor required for LEC 
specification and maintenance (Wigle and Oliver, 1999) (see Section 1.3.3.1). 
Exposure of 9.5 dpc Prox1:CreERT2;R26 mouse embryos to TM, resulted in the detection of 
LacZ+ LEC precursors in and around the cardinal vein (Srinivasan et al., 2007; Wigle and 
Oliver, 1999). Subsequently these LacZ+ expressing cells were detected in jugular lymph 
sacs and peripheral lymphatics in 13.5 dpc embryos, strongly suggesting that 
lymphangiogenesis originates from veins. The LEC identity of LacZ-expressing cells was 
determined by the use of molecular lymphatic markers.  
 
The classic model holds the view that the pool of LEC precursors will give rise to lymph 
sacs and the early lymphatic plexus to ultimately remodel and expand to encompass the 
mature lymphatic vascular network (Reviewed in Francois et al., 2011) [Fig.1.7].  
However, recent studies have investigated in detail the path that these precursor LECs 
undertake when exiting the veins, since a few questions remained unanswered with this 
current model.  For instance key questions that remain unanswered from early studies 
include: 1) what is the cellular mechanism underlying the budding of precursor LECs from 
the cardinal vein and 2) how come the integrity of the cardinal veins is not compromised 
upon the loss of large numbers of LECs that leave the venous endothelium. 	  
Francois et al., (Francois et al., 2012) showed that a combination of ballooning and 
sprouting events is taking place during lymphangiogenesis. Through the use of three-
dimensional optical projection tomography (OPT), confocal microscopy and live imaging 
(Francois et al., 2012), they observed PROX1-positive precursor LECs clustering in 
defined regions along the antero-posterior axis, referred to as pre-lymphatic clusters 
(PLC). Via a ballooning mechanism, these PLCs generated primitive lymph sacs 
suggested to ultimately give rise to deeper lymphatic vessels. A transient connection of 
lymph sacs to the cardinal veins was maintained and may account for the presence of 
blood cells in lymph sacs. In addition, a distinct population of precursor LECs was 
identified that migrated directly from the cardinal veins as streams of cells to ultimately 
give rise to superficial lymphatic vessels, independently of lymph sac formation (27).  
 
In a second study, Hagerling et al., (Hagerling et al., 2013) used ultramicroscopy, a novel 
technology based on optical sectioning of cleared wholemount immunostained embryos, 
and observed that this stream of LEC progenitors that arise from the cardinal vein, termed 
initial LECs (iLECs), do not merely give rise to superficial lymphatic vessels. They 
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described that first an accumulation and condensation of iLECs occurs adjacent to the first 
lateral branch of the intersegmental vessels, which then form a peripheral longitudinal 
lymphatic vessel (PLLV).  The PLLV will subsequently give rise to superficial lymphatics 
(Hagerling et al., 2013). This study continued to show that immediately ventral to PLLV 
formation, a large lumenized structure is formed, which can be considered as the 
primordial thoracic duct (pTD), through clustering of LECs that are present more closely to 
the CV.  These studies demonstrate that LEC progenitors follow a well-coordinated route 
to ultimately encompass the mature lymphatic network. Notably, as PROX1-expressing 
progenitor LECs are budding off the vein, they undergo a change in cell shape, from 
squamous to spindle shape, taking on a more migratory phenotype (Hagerling et al., 
2013).  
 
With regards to the maintenance of integrity of the venous wall, despite the exiting of many 
LEC precursors, Yang et al., (Yang et al., 2012) demonstrated that upon exiting, LEC 
progenitors are accompanied by zipper-like junctions, which are identified as continuous 
lines of VE-cadherin at the cell borders. Further investigation revealed that both LEC 
progenitors in the CV and those actively budding off from the CV are interconnected by 
VE-cadherin-expressing zipper-like junctions at 10.5 and 11.5 dpc, thereby aiding to 
preserve the integrity of the veins (Yang et al., 2012).   
 
1.2.2.4 Zebrafish lymphatic vessel development 
The cellular origins of lymphatic vessels in zebrafish were demonstrated by lineage-tracing 
experiments of trunk lymphatic endothelial precursors, called parachordal 
lymphangioblasts (PLs), through time-lapse imaging (Yaniv et al., 2006). Tg(fli1:nEGFP)y7 
transgenic zebrafish were used that express fli1a-driven EGFP in endothelial cell nuclei. A 
three-day time-lapse confocal sequence was subsequently collected and traced backward 
in time the origin of any LEC nuclei present in the thoracic duct (TD), the major collecting 
lymphatic vessel.  Back tracing of PLs revealed that these cells were located in the 
parachordal vessel, a superficial vessel previously described to run through the midline 
(horizontal myoseptum - HM) of the zebrafish trunk (Isogai et al., 2003).  
 
The venous origin of the parachordal vessel has been demonstrated through live imaging 
of transgenic zebrafish lines where sprouts directly emerged from the PCV (Hogan et al., 
2009a). In fact, Hogan et al., (Hogan et al., 2009a) observed that no vascular tube is 
formed in the parachordal region (no lumen formation observed), but rather a population of 
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single PLs stream dorsally from the PCV and populate only transiently the HM at 2.5 dpf 
(Hogan et al., 2009a) [Fig.1.8]. These results demonstrate the direct contribution of veins 
to sprouting lymphangioblasts. After the PLs have populated the HM, they will proceed to 
migrate (then referred to as lymphatic endothelial cells) either dorsally to give rise to the 
dorsal longitudinal lymphatic vessel (DLLV) or ventrally to give rise to the thoracic duct 
(TD) at 4 dpf [Fig.1.8]. In contrast to mice, no intermediate structures of lymph sacs are 
formed (Hogan et al., 2009a; Kuchler et al., 2006; Yaniv et al., 2006) and the number of 
PLs differs significantly (with far fewer) compared to iLECs in mice (Reviewed in 
Koltowska et al., 2013).  
 
More recently, studies in transgenic zebrafish lines that label venous and lymphatic 
vasculature, have identified lymphatic vessels in other regions than the trunk. These 
include lymphatics in the face, along the lateral lines and in intestines, which connect to 
the TD (Okuda et al., 2012). Most notably, facial lymphatics (FL) form through a different 
cellular mechanism than lymphatic vessels in the trunk. A large facial lymphatic sprout 
(FLS) that originates from the common cardinal vein will branch into a network of lymphatic 
vessels that extends through the jaw, otolith and branchial arch region of the zebrafish 
head to ultimately encompass the FL network (Okuda et al., 2012). 
 
It has been reported that arterial ISVs (aISVs) are required for LEC migration and serve as 
chaperones to direct lymphatic growth in the zebrafish trunk. This data indicates that either 
arteries are secreting guidance molecules for LECs or that PLs/LECs and aISVs are 
regulated by common factors (Bussmann et al., 2010; Hogan et al., 2009a). Interestingly, 
several pathfinding molecules necessary for vessel guidance were first discovered in 
axons in the nervous system, suggesting that neuronal axons and vessel sprouts share 
common molecular mechanisms (Calvo et al., 2011). For instance, in zebrafish it was 
demonstrated that neuronal signals are present at the HM to guide axonal sprouting as 
well as PL navigation along the HM axis (Lim et al., 2011). Thus, it may well be that LECs 
and aISVs are regulated by shared genes. 
 
For these and other reasons, a comprehensive understanding of gene regulation is 
required in order to elucidate key mechanisms that are central to vessel network formation.  
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Figure 1.8 Lymphangiogenesis in zebrafish 
In zebrafish, no lymphatic sacs are present that ultimately differentiate into the mature 
network of lymphatic vessels. Instead, endothelial cells bud from the posterior cardinal 
vein (PCV) at 32 hpf and migrate toward the horizontal myoseptum (HM). Approximately 
half of these venous sprouts will differentiate into intersegmental veins (vISVs), whereas 
the other half will give rise to parachordal lymphangioblasts (PLs). These PLs, which 
reside at the HM, will subsequently from 2.5 dpf migrate dorsally to form the 
intersegmental lymphatic vessels (ISLV) and the dorsal longitudinal lymphatic vessel 
(DLLV) at 3 dpf, or ventrally to give rise to the thoracic duct (TD) at 4 dpf.  
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1.3 Key Pathways Controlling Vessel Formation 
Embryonic vessel development is controlled by a complex molecular network. There is 
evidence suggesting that endothelial cell identity, thus whether a cell will constitute an 
artery, vein or lymphatic vessel, is established before the onset of circulation by genetic 
cues during embryonic development (Adams et al., 1999). Below, a number of key 
molecular regulators of vessel formation are discussed. 
 
1.3.1 Vasculogenesis 
The first blood vessels are formed de novo through the aggregation and subsequent 
assembly of endothelial precursors, angioblasts, into a network of endothelial tubes. 
Several molecular factors play a role during this process of vasculogenesis, among which, 
the Hedgehog, VEGF and Eph-ephrin signalling are critical. 
 
1.3.1.1 Hedgehog 
As angioblasts originate from embryonic mesoderm, signals from the adjacent endodermal 
tissue, such as Sonic hedhehog (Shh), have been shown to be necessary for angioblasts 
to assemble into a vascular network and to undergo vascular tube formation (Vokes et al., 
2004). Avian embryos lacking the endoderm on one half of the embryo exhibit an 
extensive network of tubular vessels on the control side while the manipulated half shows 
abundant unassembled angioblasts, suggesting that signals from the endoderm are acting 
prior or during vasculogenesis and are required for angioblast assembly into a vascular 
tube (Vokes et al., 2004).  
 
To see whether Shh signalling is necessary during vasculogenesis, quail embryos were 
treated with cyclopamine, an inhibitor of the Shh co-receptor Smoothened (Smo). Treated 
embryos exhibited abnormal vasculature as observed by immunofluorescence analysis, 
suggesting that Shh signalling is involved in vascular tube formation (Vokes et al., 2004).  
Similarly, mouse embryos deficient of Smo fail to develop a dorsal aorta (Vokes et al., 
2004) and mutant zebrafish embryos, sonic you (syu) (Schauerte et al., 1998), encoding 
the zebrafish homologue of Shh, show defective trunk circulation (Chen et al., 1996) and 
concomitant defects in the formation of the DA and PCV (Brown et al., 2000). These 
vascular defects in zebrafish embryos lacking Shh activity were attributed to a failure in 
arterial differentiation, as defined by decreased RNA expression of artery-specific markers, 
such as ephrin-B2a, and the induction of ectopic vascular expression of ephrin-B2a upon 
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injection of Shh mRNA (Lawson et al., 2002). Together, these results suggest that Shh 
signalling is necessary and sufficient for embryonic blood vascular development, through 
mediation of arterial differentiation [Fig.1.9]. 
 
1.3.1.2 VEGF 
The family of vascular endothelial growth factors (VEGF) are also crucial regulators of 
vascular development. In mammals, the VEGF family consists of five members, VEGFA,  
-B, -C, -D (Reviewed in Tammela et al., 2005) and placenta growth factor (PlGF) 
(Maglione et al., 1991). High binding affinity exists between the ligands and their receptor 
tyrosine kinases (RTKs), known as VEGF receptor (VEGFR) -1, -2 and -3. VEGFA and –B 
bind to VEGFR1, as well as VEGFA to VEGFR2. VEGFC and –D bind to VEGFR3.  
 
VEGFR1 and VEGFR2 are expressed in blood vascular endothelial cells (ECs) (Flamme 
et al., 1997; Risau, 1997), whereas VEGFR3 is predominantly restricted to lymphatic 
endothelium (see Section 1.3.3.4) (Cleaver et al., 1997; Dumont et al., 1995; Flamme et 
al., 1995). Signalling through the VEGFA/VEGFR2 pathway is the major pathway through 
which vasculogenesis and angiogenesis is activated (Cleaver et al., 1997; Dumont et al., 
1995; Flamme et al., 1995; Shibuya and Claesson-Welsh, 2006) [Fig.1.10]. 
 
VEGFA was originally discovered as a vascular-permeability factor (VPF) (Senger et al., 
1983). It induces vessel permeability, which is essential for physiological processes such 
as wound healing. The importance of VEGFA in vascular development has been shown in 
mice where inactivation of a single Vegfa allele results in early lethality at 11–12 days post 
coitum (dpc) due to defective endothelial cell development and lack of vessels (Carmeliet 
et al., 1996; Ferrara et al., 1996). On the other hand overexpression of endogenous 
VEGFA results in malformation of the heart and lethality at 12.5 – 14.0 dpc, suggestive of 
the importance of a tight control of VEGFA expression levels during vascular development 
(Carmeliet et al., 1996; Ferrara et al., 1996).  
Depletion of VEGFA receptors VEGFR1 and VEGFR2 also results in severe defects in the 
blood vasculature. Vegfr2 null animals die at 8.5 dpc due to defects in vasculogenesis and 
blood cell formation (hematopoiesis). In Vegfr1-depleted embryos, endothelial cell 
development is apparent however ectopic endothelial cell proliferation and obstruction of 
the vessel lumen causes embryonic death at 8.5 – 9.0 dpc (Fong et al., 1995; Shalaby et 
al., 1995).  
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Taken together, it is clear that a tight regulation of VEGF/VEGFR signalling during 
embryonic cardiovascular development is crucial for the survival of the embryo. 
 
1.3.1.3 EphrinB2/EphB4 
Downstream effectors of Shh and VEGF are members of the Eph-ephrin subclass of 
receptor tyrosine kinases [Fig.1.9].  Ephs and ephrins were the first genes to be 
discovered that display complementary expression patterns in arterial and venous 
endothelium: the transmembrane ligand ephrinB2 is expressed in arteries and its receptor 
EphB4 in veins (Lawson et al., 2001; Moyon et al., 2001; Wang et al., 1998). 
 
To investigate the specific role of Eph-ephrin signalling during vasculogenesis, loss-of-
function studies in mutant mice were performed. Animals with EphrinB2 loss-of-function 
underwent normal vasculogenesis of arterial and venous trunk vessels but showed defects 
in the remodelling of these major trunk vessels (Adams et al., 1999; Wang et al., 1998). In 
Xenopus, overexpression of a dominant negative form of ephB4 gave rise to abnormal 
remodelling of ISVs (Helbling et al., 2000). These observations suggest that 
EphrinB2/EphB4 are required for correct remodelling of arterial and venous vasculature, 
but not for specification of these cell fates during embryonic vascular development (Wang 
et al., 1998). 
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1.3.2      Angiogenesis 
VEGFA not only controls vasculogenesis but is also the main driver of angiogenesis 
(Gerhardt et al., 2003; Ruhrberg, 2003).  
In a postnatal retinal blood vascular model, it has been demonstrated that angiogenic 
sprouting of vessels is guided by a VEGFA gradient to which tip cells respond (Gerhardt et 
al., 2003).  In addition to VEGFA, other pathways play a role during angiogenesis. The 
most relevant angiogenic pathways to this study will be highlighted below. 
 
1.3.2.1 Neuropilins/ Semaphorins/plexins  
During angiogenesis, new vessels are formed from pre-existing ones. Another family of 
vascular endothelial growth factors that is required during primary angiogenesis is the 
neuropilins. Neuropilin 1 (Nrp1) is expressed in arterial whereas Neuropilin 2 (Nrp2) is 
enriched in venous and lymphatic ECs (Herzog et al., 2001; Yuan et al., 2002).  
 
Neuropilins were originally identified as mediators of axon guidance by functioning as co-
receptors with plexins for semaphorin signalling (Dickson, 2002; Huber et al., 2003; 
Kolodkin et al., 1997). However, a role for semaphorins and plexins in regulating vessel 
guidance and branching has also been demonstrated in zebrafish (Torres-Vazquez et al., 
2004) and mice (Gu et al., 2005). Plxnd1 mouse and zebrafish null mutants display 
misguided ISV sprouts that fail to run close to the antero-posterior somite boundaries 
(Gitler et al., 2004; Gu et al., 2005; Torres-Vazquez et al., 2004).  
Similarly, zebrafish devoid of sema3a1 and sema3a2 show defects in proper patterning of 
trunk angiogenic vessels as observed by multiphoton imaging of developing vessels in 
Tg(fli1:EGFP)y1 morphants (Torres-Vazquez et al., 2004). These observations are 
suggestive of a Sema3A/Plxnd1-mediated mechanism for vascular guidance and are 
supportive of previous reports of a role of semaphorin signalling during blood vessel 
development (Bates et al., 2003; Miao et al., 1999; Shoji et al., 2003). 
 
Notably, it was unclear whether semaphorin signalling during vessel patterning in 
endothelial cells is also mediated by a Nrp/plexin complex as observed during axon 
guidance (Gu et al., 2005). Gu et al., generated Nrp1Sema–/–;Nrp2 double-mutant mice in 
order to assess in vivo whether Nrp contributes to Sema3e-Plexind1 signalling (Gu et al., 
2005). These mice exhibited loss of any interactions between Sema3 and neuropilins. 
They observed no severe vascular defects in mutants and no striking difference between 
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control and mutant embryos, suggesting that vessel patterning through semaphorin 
signalling is independent of neuropilin activity.   
 
However, neuropilins may mediate vessel patterning through VEGF signalling by 
functioning as co-receptors with VEGFRs (Adams et al., 1999; Soker et al., 1998; Wang et 
al., 1998). Nrp1 homozygous mutant mice display defects in yolk sac and embryonic 
vascular formation and die between 12.5 and 13.5 dpc, (Kawasaki et al., 1999). Gene 
targeting of both Nrp1 and Nrp2 in the same embryo triggered more severe phenotypes. 
Nrp1/Nrp2 double knock-outs died prematurely at 8.5 dpc and showed early defects in 
blood vessel development in yolk sacs and in the embryo (Takashima et al., 2002). 
Takashima et al., observed by platelet endothelial cell adhesion molecule-1 (PECAM-1) 
staining of yolk sacs that there was a lack of branching arteries and veins, a deficit of 
capillaries and a complete absence of vascularization in peripheral spaces. Interestingly, 
these phenotypes are similar to VEGFA/VEGFR2 double knock-outs (Ferrara et al., 1996; 
Shalaby et al., 1995), suggesting that neuropilins are critical for embryonic vessel 
development at very early stages.  
 
1.3.2.2 Notch 
Notch signalling has diverse roles during embryonic development, including regulating cell 
fate decisions, proliferation, apoptosis and maturation. An important role for Notch in 
promoting proper vessel formation has also been shown in both zebrafish (Lawson et al., 
2001) and mice (Krebs et al., 2000). 
 
Mice deficient for the Notch ligand Dll4 heterozygous mice exhibit severe vascular defects 
which are embryonic lethal (Krebs et al., 2000). Moreover, reduced EphrinB2 in situ 
hybridization expression and increased EphB4 immunostaining observed in these mutants 
at 9 dpc, was suggestive of an arterial differentiation defect (Duarte et al., 2004) that could 
contribute to the vascular defects observed in Dll4 mutants (Krebs et al., 2000). 
 
These observations indicated a role of Notch in arterial differentiation, were supportive of 
earlier reports where notch-deficient zebrafish mutants, mindbomb, showed properly 
located DA and PCV but repressed arterial ephrinB2 in situ hybridization expression and 
ectopic expression of venous markers EphB4 and vegfr3/flt4 in the DA (Lawson et al., 
2001). 
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In addition, constitutive active Notch signalling by ubiquitous expression of the activated 
Notch intracellular domain (NICD) resulted in reduced venous marker expression (Lawson 
et al., 2001). Taken together, these results provide evidence for a role of Notch in arterial 
specification by repression of venous cell fate and promotion of arterial fate, but 
vasculogenesis or tube morphogenesis is independent of this pathway.  
 
Furthermore, the Notch signalling pathway has been implicated in regulating tip and stalk 
cell specification. During angiogenesis, Notch activation leads to stalk cell formation, 
whereas inhibition of Notch allows a cell to become a tip cell (Hellstrom et al., 2007; Leslie 
et al., 2007; Siekmann and Lawson, 2007). Interestingly, recent findings suggested that tip 
versus stalk cell specification is dynamic and transient rather than fixed in cell fate 
(Jakobsson et al., 2010). Higher levels of VEGFR2 in comparison to neighbouring cells, 
resulted in higher levels of DLL4, consequently in the tendency of this cell to become the 
new tip cell (Jakobsson et al., 2010). This competitive behaviour of EC has challenged the 
hypothesis by Gerhardt et al., (Gerhardt et al., 2003) that the guidance of a growing sprout 
is entirely determined by a single tip cell.  
 
Several markers that regulate vasculogenesis and primary angiogenesis are also 
implicated in regulating lymphangiogenesis, where lymphatic vessels are formed from 
veins (lymphangiogenesis).  
For example, the Notch signalling pathway is also active in LECs. Zheng et al., (Zheng et 
al., 2011) reported that in three-dimensional fibrin gel assays inhibition of Notch by a 
soluble form of Dll4 promotes LEC sprouting. This work suggests a role of Notch in 
regulating LEC quiescence.   
 
In the next section lymphatic regulators will be discussed that are indispensable for driving 
lymphangiogenesis, including Prox1, VEGFC/VEGFR3, Ccbe1 and Sox18. 
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Figure 1.9 Model of signalling pathways required for arterial-venous differentiation 
View of a cross-section through the trunk of the zebrafish at ~24 hpf. Signalling through 
Shh from the notochord and Vegf from the somites, lie upstream of Notch signalling and 
regulate arterial differentiation (Lawson et al., 2002). Notch signalling represses venous 
cell fate through repression of VEGFR3/FLT4 signalling and promotes arterial fate via 
VEGFR2/FLK1 activation. NT, neural tube; NC, notochord, DA, dorsal aorta; PCV, 
posterior cardinal vein. 
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1.3.3      Lymphangiogenesis 
1.3.3.1 Prox1 
One of the earliest markers identified to be involved in lymphangiogenesis is the 
transcription factor Prox1 (prospero-related homeobox-1). ECs express Prox1 in a 
polarized fashion in the dorsolateral walls of the cardinal veins and progressively bud from 
the vein (Wigle and Oliver, 1999).  
 
Prox1 activity is crucial during initial stages of embryonic lymphangiogenesis. 
Homozygous Prox1-deficient mice, generated by an in-frame insertion of the ß-
galactosidase (lacZ) gene (Wigle and Oliver, 1999), show reduced ß-galactosidase (ß-
gal)-positive ECs lining the wall of the vein, based on histological analysis at 11.5 dpc. In 
addition, a reduced number of lymphatic precursors are budding from the venous wall, 
resulting in absence of lymphatic vessels and severe lymphedema. However, the normal 
development of the blood vascular system was observed as analyzed by whole-mount 
immunostaining of PECAM-1, and ink injection in the heart of 14.5 dpc Prox-/- embryos 
(Wigle and Oliver, 1999).  
 
Moreover, Prox1 is necessary for lymphatic cell fate specification. Prox1-deficient LEC 
progenitors retain high expression levels of blood vascular markers laminin, a protein 
present in the basal lamina, and transmembrane protein CD34, and fail to upregulate 
lymphatic markers such as VEGFR3 or lymphatic vessel endothelial hyaluronan receptor 1 
(LYVE-1) (Johnson et al., 2008; Wigle et al., 2002; Wigle and Oliver, 1999). These 
observations suggest that endothelial cells that are devoid of Prox1 expression fail to 
acquire a lymphatic phenotype and remain blood vascular endothelium instead, thus 
indicating a role for Prox1 in specification of LEC identity. 
 
To further characterize whether Prox1 activity is sufficient for LEC, Prox1 was 
overexpressed in cultured blood endothelial cells (BECs).   Over-expression of Prox1 in 
BECs led to ectopic upregulation of LEC markers, including the transmembrane 
mucoprotein Podoplanin and VEGFR3, and downregulation of BEC markers, including 
Nrp1 and intercellular adhesion molecule-1 (Hong et al., 2002). In the mouse, ectopic 
over-expression of Prox1 driven by the blood endothelial promoter from the Tie1 gene was 
also sufficient to induce LEC marker expression in BECs in vivo (Kim et al., 2010). Taken 
together, these experiments demonstrate that Prox1 overexpression is able to reprogram 
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(venous) blood endothelium to LEC identity, which identifes Prox1 as a master regulator of 
LEC fate, both in vitro and in vivo. 
 
In mature vessels, Prox1 is required for the maintenance of LEC fate. Johnson et al., used 
floxed Prox1 transgenic mice to deplete mature lymphatic vessels of Prox1. Upon removal 
of Prox1, LECs upregulate BEC markers and downregulate LEC markers. This study 
showed that Prox1 is essential for maintenance as well as specification of lymphatic 
endothelial cells (Johnson et al., 2008). 
 
1.3.3.2 Sox18 
A member of the SoxF group of transcription factors, Sox18, is pivotal during 
lymphangiogenesis. Structurally, the SoxF group of genes consists of transcription factors 
that contain a N-terminus, a HMG DNA-binding domain, a transactivation domain and a C-
terminus domain (Downes and Koopman, 2001). This sub-family of Sox factors regulates 
endothelial cell fate and differentiation in developing tissue, including the heart (Zhang et 
al., 2005), blood vessels (Pendeville et al., 2008) and lymphatic vessels (Francois et al., 
2008). Other members of the SoxF group include Sox7 and Sox17, which have shown to 
act in a redundant manner in the absence of Sox18 (Cermenati et al., 2008; Herpers et al., 
2008). 
 
In situ hybridization analysis in mice reveals that Sox18 expression is associated with 
vascular endothelial development (Pennisi et al., 2000a). Vegfr2-/- mouse embryos, in 
which endothelial cell differentiation is blocked very early on, displayed no Sox18 
expression. On the other hand, normal Sox18 expression was present in Vegfr1-/- 
embryos, which display normal differentiation of endothelial cells but fail to mature into 
functional vessels, indicating Sox18 involvement in developing vessels.  
Furthermore, Sox18 is expressed in a subset of venous endothelial cells that later co-
express Prox1 and migrate to form lymphatic vessels. Sox18 expression in vessels is only 
transient, indicating that Sox18 is not required once they have matured (Pennisi et al., 
2000a). 
 
A role for Sox18 during lymphangiogenesis has been demonstrated in Sox18 mutant mice. 
Sox18-null mutants show subcutaneous edema and are embryonic lethal (Francois et al., 
2008), whereas heterozygous mutants for Sox18 display a lymphatic network with finer, 
denser and more branched vessels compared to wild-type, based on lymphatic marker 
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LYVE-1 immunofluorescence analysis of whole ear tissue (Francois et al., 2008). These 
observations imply that lymphatic dysfunction underlies the edema seen in Sox18-null 
mutants.  
 
The Sox18-mediated regulation of lymphangiogenesis has been attributed to direct 
regulation of Prox1. Sox18 was shown to bind directly to the Prox1 promoter to activate 
the expression of Prox1 in an in vivo transgenic Prox1-promoter reporter mouse model 
(Francois et al., 2008). In the absence of Sox18 in either Ragged (Ra) mice (see Section 
1.5.3), which exhibit naturally occurring mutations in the Sox18 gene, or in Sox18 knock-
out mice (on a C57BL/6 background), Prox1 expression is lost in the dorsal wall of the 
cardinal vein (Francois et al., 2008).  
 
This regulatory relationship was further investigated in an in vitro model where wild-type 
Sox18 or dominant-negative Sox18RaOp (see Section 1.5.3), the most severely affected 
form of Ra, were over-expressed in mouse embryonic stem cells. Expression of both 
Prox1 and lymphatic-specific marker Podoplanin were upregulated when over-expressing 
Sox18 but not Sox18RaOp. In cells treated with VEGFA, that normally induces LEC 
marker expression, an inhibition of Prox1 and Podoplanin expression by Sox18RaOp was 
observed and was rescued when cells were infected with lentivirus overexpressing Sox18 
(Francois et al., 2008). Taken together, these experiments demonstrate a direct regulatory 
relationship between Sox18 and Prox1 during lymphatic vessel development. 
In humans, mutations in SOX18 causes the human syndrome hypothrichosis-
lymphedema-telangiectasia (HLT). This syndrome is characterised by alopecia, 
lymphoedema of the lower extremities and dilation of small blood vessels (Reviewed in 
Koltowska et al., 2013) [Fig.1.11]. Clinical studies of three families showed that mutation in 
SOX18 accounts for both a recessive and a dominant form of the disease (Irrthum et al., 
2003).  
Remarkably, the ragged mouse phenotype caused by Sox18 mutation closely mimics 
HLT, with similar characteristics such as lymphedema and hair follicle defects (Pennisi et 
al., 2000a). Phenotypes, affecting the coat and vasculature, observed in the ragged (Ra) 
allelic series, of which the most severely affected class of Ra mutants is the ragged 
opossum (RaOp) (Hosking et al., 2001; James et al., 2003), are attributable to a naturally 
occurring mouse mutation in the Sox18 gene. 
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Ra heterozygotes are viable and healthy, whereas homozygotes display severe edema 
and are not viable past weaning. When tested for the link between Sox18 and Ra in an 
interspecific backcross segregating for the Ra phenotype, no recombination occurred, 
indicating that the two loci are tightly linked (Pennisi et al., 2000a). Screening Sox18 for 
mutations by PCR amplification and sequencing revealed that Sox18Ra has a deletion of 
a cytosine residue. This deletion introduces a frameshift, consequently missense coding 
and premature truncation of the protein (Pennisi et al., 2000a). The RaOp phenotype is 
due to dominant-negative activity of mutant SOX18 protein, whereby mutant SOX18 is 
able to bind to promoters of target genes but fails to initiate transcription of these genes 
(Pennisi et al., 2000a).  
 
1.3.3.3 VEGFC 
During the initial steps of lymphangiogenesis, VEGFC promotes sprouting of Prox1-
positive LECs from the dorso-lateral wall of the cardinal vein and induces LEC proliferation 
and survival (Karkkainen et al., 2004). Further investigation of VEGFC function during 
lymphangiogenesis revealed that in Vegfc-null mice, EC commit to the lymphatic lineage 
but fail to sprout from the cardinal vein to form primary lymph sacs (Karkkainen et al., 
2004). Consequently, these mice lack a lymphatic vessel network, develop severe edema 
and die prematurely. Even loss of a single allele leads to defective lymphatic vessel 
growth (Dumont et al., 1998; Karkkainen et al., 2004) 
 
Paracrine VEGFC signal is suggested to form a gradient toward which LEC progenitors 
migrate to form lymph sacs. In Vegfc-/- mice, sprouting of these precursors is rescued by 
VEGFC and mouse VEGFD but not by VEGFA, suggesting that signalling through 
VEGFR3 is required in this process (Karkkainen et al., 2004).  
 
Mutations in VEGFC cause Milroy-like primary lymphedema. A truncated but stable protein 
is produced but inefficiently secreted, suggesting haploinsufficiency as a likely mechanism 
(Gordon et al., 2013). Exome sequencing of patients with clinical manifestations of Milroy 
disease, but without mutations in VEGFR3, revealed a novel frameshift variant, 
c.571_572insTT in VEGFC (Gordon et al., 2013). The biological function was investigated 
in zebrafish embryos where over-expression of wild-type human VEGFC in the floorplate 
displayed ectopic vessel sprouting. In contrast, overexpression of the human variant 
c.571_572insTT showed perturbed sprouting of vessels, indicating that the frameshift 
mutation in VEGFC is causal for the Milroy-like phenotype. 
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1.3.3.4 VEGFR3 
At the onset of lymphangiogenesis, VEGFR3 becomes downregulated in blood 
vasculature and restricted to lymphatic endothelium (Dumont et al., 1998) , suggestive that 
VEGFR3 may play a role during lymphangiogenesis. VEGFR3 has been implicated in 
remodeling and maturation of blood vessels at midgestation as Vegfr3 mutant mice display 
severe cardiovascular defects and die prematurely (Dumont et al., 1998), but a role in 
lymphangiogenesis was initially only demonstrated in vitro. VEGFR3 activation through 
binding of VEGFC or VEGFD in human adult microvascular LECs led to cell proliferation, 
migration and survival (Makinen et al., 2001) and induced lymphangiogenesis in adult 
tissues (Jeltsch et al., 1997) [Fig.1.10]. 
 
The early embryonic death of Vegfr3 mutant mice made it challenging to provide evidence 
of VEGFR3 function during lymphangiogenesis in vivo. However, expression of a soluble 
form of Vegfr3, a potent inhibitor of VEGFC signalling, in the skin of transgenic mice was 
sufficient to block lymphangiogenesis while a normal blood vasculature was present 
(Makinen et al., 2001). In zebrafish, depletion of either one of these genes, vegfc or 
vegfr3, led to a complete loss of the thoracic duct, while no defect in the blood vasculature 
was observed, indicating a specific role of the VEGFC/VEGFR3 signalling pathway in 
lymphangiogenesis (Hogan et al., 2009b; Kuchler et al., 2006; Yaniv et al., 2006). 
 
In pathogenesis, affected alleles contain missense mutations encoding tyrosine kinase-
negative VEGFR-3 proteins, thereby functioning as dominant negative receptors and 
perturbing downstream signalling [Fig.1.11]. These mutations cause Milroy disease, 
otherwise known as hereditary lymphedema type I (Reviewed in Karpanen and Alitalo, 
2008). This lymphatic disorder is apparent at birth and is characterized by congenital 
lymphoedema, hypoplastic cutaneous lymphatic vessels and functional insufficiencies in 
interstitial fluid absorption and transport (Reviewed in Koltowska et al., 2013).  
 
1.3.3.5 Ccbe1 
Finally, a recently characterized lymphatic regulator, calcium-binding EGF domain-1 
(Ccbe1), has been found crucial during lymphangiogensis. The full of fluid zebrafish 
mutant, which is caused by mutations in the ccbe1 gene, was identified in a forward 
genetic zebrafish mutagenesis screen that aimed at identifying novel lymphatic regulators 
(Hogan et al., 2009a). Characterization of this mutant revealed a lack of TD, 
intersegmental lymphatic vessels (ISLVs) and dorsal longitudinal lymphatic vessels 
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(DLLVs), while a normal blood vasculature was retained. In addition, lymphatic defects 
were conserved in mouse embryos lacking Ccbe1 (Bos et al., 2011), and it was shown that 
LEC budding and migration from the CV is prevented in mice (Hagerling et al., 2013), 
demonstrating an indispensable role for Ccbe1 in lymphatic development.   
 
Recent advances in the characterization of Ccbe1, has uncovered the mode of action 
during lymphangiogenesis. Le Guen et al., showed, by means of zebrafish genetics 
together with biochemical approaches, that Ccbe1 regulates Vegfc-mediated activation of 
Vegfr3 signalling through its processing and release from the ECM in order to regulate 
lymphangiogenesis and venous sprouting in the developing embryo (Le Guen et al., 
2014). Jeltch et al., showed that this regulation of processing occurs through the 
modulation of activity of ADAMST3 (Jeltsch et al., 2014). Thus identifying Ccbe1 as 
another important lymphatic regulator. Mutations in the gene Ccbe1 cause an autosomal 
recessive syndrome, Hennekam syndrome, which is characterized by generalized 
lymphatic dysplasia, lymphedema, facial abnormalities, growth and mental retardation 
(Alders et al., 2009). 
 
In conclusion, these key lymphatic vascular genes highlight that a tight regulation of 
lymphatic gene expression is essential, lest defects in structure and function of lymphatic 
vessels occur. Inevitably, this will result in pathophysiological conditions, and in severe 
cases to death. 
Understanding the mode of action of genes in normal physiology, may improve the 
understanding of the mechanism of disease, thus aiding in better prognosis in patients. In 
that regard, a continual surge of gene discovery is required to allow for subsequent 
therapeutic gene targeting in human pathology. 
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Figure 1.10 Signalling pathways driving blood and lymphatic vessel development 
Overview of VEGF signalling pathway in blood and lymphatic vessel development. NRP1 
and NRP2 may act as co-receptors for VEGFR2 and VEGFR3 respectively to mediate 
vessel patterning (Adams et al., 1999; Soker et al., 1998; Wang et al., 1998). Signalling of 
VEGFR2 through RAS/MAPK cascade leads to cell proliferation (Karkkainen et al., 2002). 
The PI3K signalling pathway has multiple cellular outputs. Downstream of VEGFR2, 
PI3K/AKT signalling leads to cell survival (Karar and Maity, 2011) and sprouting 
angiogenesis through RHOA-mediated actin cell cytoskeleton rearrangements (Krugmann 
et al., 2002; Krugmann et al., 2004). Studies in mice revealed a role for ARAP3 in 
sprouting angiogenesis downstream of PI3K (Gambardella et al., 2010). However, a role 
for ARAP3 during lymphangiogenesis is thus far unknown. SOX18 and PROX1 regulate 
LEC specification in mice (Francois et al., 2008).  
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Figure 1.11 Human mutations in genes required for lymphatic vessel development 
Table depicting developmental genes that underlie human syndromes in pathological 
conditions. Genes that are relevant to the current study have been described in Section 
1.3.3 and include FLT4 (encoding VEGFR3) (Dumont et al., 1998; Ferrell et al., 1998; 
Hogan et al., 2009b; Irrthum et al., 2000; Karkkainen et al., 2000; Karkkainen et al., 2004; 
Kuchler et al., 2006; Mellor et al., 2010; Veikkola et al., 2001; Yaniv et al., 2006), SOX18 
(Francois et al., 2008; Irrthum et al., 2003) and CCBE1 (Alders et al., 2009; Bos et al., 
2011; Connell et al., 2010; Hogan et al., 2009a). Additional genes that are depicted in the 
table, but have not been described here, include FOXC2 (Brice et al., 2002; Fang et al., 
2000; Finegold et al., 2001; Norrmen et al., 2009; Petrova et al., 2004; Sabine et al., 
2012), GJC2 (Ferrell et al., 2010; Kanady et al., 2011; Ostergaard et al., 2011a), GATA2 
(Kazenwadel et al., 2012; Lim et al., 2012; Ostergaard et al., 2011b), KIF11 (Hazan et al., 
2012; Ostergaard et al., 2012), PTPN14 (Au et al., 2010) and ITGA9 (Bazigou et al., 2009; 
Huang et al., 2000; Ma et al., 2008). 
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1.4 Background To This Study 
Gene discovery through expression profiling 
Gene discovery by means of gene expression profiling of cells and tissue, has become a 
major tool in medicine. DNA microarray analysis allows for high-throughput expression 
profiling of thousands of genes within a particular mRNA sample (Schena et al., 1995). 
Subsequently, this can be used to identify, among others, diagnostic and prognostic 
biomarkers and to gain understanding of mechanisms underlying disease through 
comparison of gene transcriptional levels in clinical conditions (Aguan et al., 2000). DNA 
microarrays may be applied in order to 1) find differences between predefined groups of 
samples and 2) to discover subgroups that share common features based on the gene 
expression profiles (Gibson and Muse, 2002). 
 
In the current study, we performed gene expression profiling of lymphatic endothelial cells 
extracted from tissue of Sox18 mutant mice, Ragged Opossum (see section 1.5.3), in 
order to discover differentially expressed genes in mutant versus wild-type samples. Our 
hypothesis was that these dysregulated genes would represent critical Sox18-driven 
effectors of pathological but also developmental lymphangiogenesis.   
 
1.5 Aims and Significance 
In summary, a number of genes, some of which share common expression profiles 
between blood and lymphatic endothelium, tightly coordinate embryonic vessel 
development.  
During lymphatic network formation, Prox1 has been identified as a master regulator of 
LEC specification and maintenance, and is a direct target of Sox18 in lymphangiogenesis. 
However, to date no known lymphatic regulators have been reported that act downstream 
of the Sox18/Prox1 transcriptional pathway. The goal of this study is to identify novel 
molecular regulators of lymphangiogenesis, functioning downstream of Sox18, through 
gene expression profiling of wild type versus mutant mouse LECs.  
 
We performed a microarray screen based on lymphatic endothelial cells of whole-mount 
ear tissues from wild-type and heterozygous Sox18 mutant mice and aimed at:  
1) Identifying genes that showed differential expression in mutant samples compared to 
controls, which have previous uncharacterized roles in lymphangiogenesis;  
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2) Analyzing a select group of genes for vascular expression by in situ hybridization in 
zebrafish;  
3) Assessing the identified vascular-expressed genes for their role in lymphangiogenesis 
by gene loss-of-function studies in zebrafish;  
4) An in depth characterization of the gene(s), which show(s) to be essential for 
lymphangiogenesis, using zebrafish, mouse and cell based model systems; 
5) Investigating whether a direct regulatory function exists between these genes and 
Sox18. 
 
Delineating the molecular regulators of developmental and pathological 
lymphangiogenesis is a necessary precursor to the development of therapeutic strategies, 
able to effectively target vascular pathologies. Using this powerful multidisciplinary 
approach, this study has uncovered a novel lymphatic regulator, which shows conserved 
roles in both zebrafish and mice, and human lymphatic endothelial cells. 
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Chapter 2 
 
Materials and Methods 
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2.1 Zebrafish lines 
Zebrafish lines were kept under standard conditions as previously described (Westerfield, 
1993). The Tg(lyve1:DsRed), Tg(-6.5kdrl:EGFP), Tg(fli1a:EGFP), Tg(-6.5kdrl:mCherry), 
Tg(-0.8flt1:tdTomato), Tg(fli1a:nlsEGFP) and Tg(hsp70l:Gal4)1.5kca4  lines were 
described previously (Bussmann et al., 2010; Hogan et al., 2009a; Jin et al., 2005; Lawson 
and Weinstein, 2002b; Okuda et al., 2012; Scheer et al., 2001).  
The Tg(4xUAS:vegfc) line was generated using the full length zebrafish vegfc  cDNA 
cloned using the Gateway system (Hartley et al., 2000; Hogan et al., 2009b; Walhout et 
al., 2000). 
 
2.2 Wholemount in situ hybridization analysis in zebrafish 
Probe synthesis was performed as previously described (Westerfield, 1993). A 400–800 
bp fragment of the gene of interest was amplified from wild-type zebrafish cDNA at 24 hpf. 
This cDNA was subsequently used as template for anti-sense mRNA probe synthesis. 
Sequences for primers designed to synthesize probes are shown in Table 1. Reverse 
primers were designed with a T3-sequence recognition site. ISH analysis of zebrafish was 
carried out as previously described (Thisse and Thisse, 2008; Westerfield, 1993). 
 
Table 1 Overview of primers used for generating zebrafish cDNA  
Gene name Primer sequence 
limch1a  For: 5’-TTGTGAGGAGTTGGGTTTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAACAGGTGAGGTTGCGTTAC-3’ 
mmp17a  For: 5’-TGAAGAGGGCTGTTTCTACC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTCTGTCACAGGAAGAGGTG-3’ 
c8orf4  For: 5’-CGACATGTACTCAGAGTCTCG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAGAAAGTTTCGCACCATC-3’ 
arap3a  For: 5’-TTTGGAGTCGTTCTGTACCC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacACGTGCTGCACCATTTG-3’ 
arap3b  For: 5’-ATCGAGAGAAATGGTGATGC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaac ATGTGCTTGCGTCCTTTC-3’ 
ilk  For: 5’-AGAAACTCCAATGGACAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAACTTTACATCTGCCATGC-3’ 
pdgfra  For: 5’-GGAGATCTGGTGAATTACCTTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGAAGCTGGAATCCACAACC-3’ 
pdgfb_1 For: 5’-ATGATGAGAAGCCAGAGACC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCATAAGCTGGCGTGTGTG-3’ 
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Gene name Primer sequence 
moxd1a For: 5’-GAGAGTGATCTGGGCGTTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATGAGTCTCTCCTGGCTGAG-3’ 
plp1 For: 5’-GTGGATGTGGGCATCAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCAGTCCATGGAAGTAAACC-3’ 
ngrf For: 5’-CGAGCATTTCTTCCTGTGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacACTGTCGCTGTGCAGTTTC-3’ 
wfdc1 For: 5’- CACGTATGATCAGGAAGAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTTCGTCCATCTGAGTTTCC-3’ 
rgs16a For: 5’-CTTCTGGCTTTACAATGTGC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGCAGATTTCGGTATGAAGC-3’ 
rgs16b For: 5’-TGCCAACAATACTGTCAACTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCAGACCTTAATCCCATTCG-3’ 
megf10 For: 5’-TCTGCAGTCACTGGGAAAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCACAAGTCCTCACAGAATGC-3’ 
csn3 For: 5’-TCAAACAGTGCCTGTCCTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGCAAGACGTATTTCTCAGC-3’ 
zgc:158671 For: 5’-CAGATGTGGACTGGGTTTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGTTCACTGCATTGTTTGAG-3’ 
mmp17b For: 5’-CTCGCATACGAAGACAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGGTATCCGAGGTCCATGC-3’ 
cpm For: 5’-TGGGTCAACATCCTAGAGAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGATAGCCGTTGGTGATG-3’ 
limch1b For: 5’- AACTTAACGGGCTCTGACTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTTCATCACGCATGTCAATC-3’ 
ankrd1 For: 5’-CATTGGAGCTGCGATATTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGGCGTGTCACCCTCTATG-3’ 
kcnk5 For: 5’- CATTGGAGCTGCGATATTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGGTGAAGGAGAAGTACAGG-3’ 
kcna6 For: 5’-ACATATCAGGTCTGCGCTTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCGTGTATGCGCTTAATCTTTG-3’ 
aldh1a3a For: 5’-GTGGAGGAGACACAGAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGCTCGCTGAGTTTGATAG-3’ 
aldh1a3b For: 5’- AACGGGGACTCTCGAAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCGATCTTCCACATCAGC-3’ 
col18a1a For: 5’-GATTCGCAGAGCTCCTATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTGATCCTCCACCAGACAC-3’ 
mal_1 For: 5’-GACTTCAGCTGAGCCTTCAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCAGGCGGGATATACTGG-3’ 
mal_2 For: 5’- TGAGTTACCAGCGAATGAAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTAGCTCCTCCAGGTTGG-3’ 
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thbs5 For: 5’-TGGAGATGCTTGTGATAACTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCTCAGGACAAACGTCAATG-3’ 
ptgisl For: 5’-CAACTCAATGCAGAACAACC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTGTCCTGCGTCACATC-3’ 
spp1 For: 5’-TGTTAAGCAGGACGAGTGTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGTCGATATCATCAAGCATGG-3’ 
mmp13 For: 5’-GTGGTGAGAAACGTTCCAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATTCCATTGACATCATCTCG-3’ 
itgbl1 For: 5’-GCTCAGGGTGTAGTTTGCTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTATCTCCAGGTGGGTGAC-3’ 
gsn_1 For: 5’- AAAGTTCCAGTTGACCCATC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCTTCTTGGGTCATCTCTCC-3’ 
gsn_2 For: 5’-TTGGCATTCGTGATAATGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGTCACCTCCAAAGAACTGG-3’ 
ppl For: 5’-TGAATACGATGCAGAAGAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGGAGTTCTGCAGTTTGTCAG-3’ 
fgf7 For: 5’-AGCTGCTGCAGGTGGTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTCGTCTTCTTGCCTTTCAG-3’ 
celc11a For: 5’-CAGAAAGGCCGTAAAATAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGAGGACATGGCTACACAG-3’ 
ltbp1 For: 5’- AAATGGCGAGTCCAAATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGTCGATACAGCGAGTGC-3’ 
twist1a For: 5’-TTTGAGGAAGAGGCGATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTAGTGGGATGTTGACATGG-3’ 
gbp28 For: 5’-GGGTGGTGACTACACACTGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGATTCGATGCCACTCCTC-3’ 
sod3a For: 5’-TCATATTACTGGCGCTTCAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGATGCCAATAACACATCCAG-3’ 
sod3b For: 5’-CTTCTGGCATTCCTGCTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGCAAGCTTCCCACATTC-3’ 
ddr2b For: 5’-CTGGAGTACAGCAGAGATGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTCGTTGTCTGTCAAACTGG-3’ 
cfd For: 5’-TGAACAGGCTGATTTTCTTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacACGTTATTCCGACAACAATG-3’ 
eps8 For: 5’-ATCTGACCACGTTTGTGATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGGATTTGCACATCTCTGTCC-3’ 
tubb2b For: 5’-CCACCGGCAGTTATCAAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCACTCATAGTCGCGGAAAC -3’ 
int3 For: 5’-GACCTGACGTTGGTGAATC-3’ 
Rev:5’-ggatccattaaccctcactaaagggaacCGTGAGGTTCTAGAGGTAAGG-3’ 
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gfra3 For: 5’-CCCTACACAGATGCCAATG -3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGTGAGCTCGGAGGGTTG -3’ 
fam89a For: 5’-CGGAGCGCTCGCTGTTA -3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCATTTCCATCAGGCGTTT -3’ 
ncam1 For: 5’-CAACTGCACAGCTACCAATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCAAGGTCCTGAAGGAGAG-3’ 
leprel1 For: 5’-TCATGCTGATGAGGATTGTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCCTCAGCTCTGGCAACTTAG-3’ 
rrm2a For: 5’-GAGCCTCTTCTGAAGGAGAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATGAGGCAGGCGAAGTC-3’ 
rrm2b For: 5’-AGAATCCCAAACGATTTGTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATGTCATTCACTCGGTCAAC-3’ 
aatk_1 For: 5’-CCACTGGGTGATGTTAAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGTTCCAGCGTCTCTCAAAG-3’ 
aatk_2 For: 5’-GCATGTGAGATTGCTTCTGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAAATGACGAGGAAGCTGAAG-3’ 
nme7 For: 5’-TAAAGATGGCTCGGTGGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATTTGGCTGTGTTTGAGAGG-3’ 
pcdh20a For: 5’-TGACTACCAGCGAGCACTAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATACGTAATCAAGGCGTTCG-3’ 
fhd1a For: 5’-CCCGCCACTACCATGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGAACAGAATGTGGACTGC-3’ 
fhd1b For: 5’-GCTGTCATCGAAGCTGAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCCTGTACCTTAGCCTCAAAG-3’ 
zfp91 For: 5’-AGACTGACATCAGCGAGGAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCTCTTGCACTGTAGGCTTG-3’ 
slc35f1 For: 5’-TGGTCTACACCACCACTCTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTGCGCTGGTTCTCTTG-3’ 
gfod1 For: 5’- GACATGAACGTGCCTTTCTAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTAACCTTCCAGCAGTTCC-3’ 
epb4.1l4b-116F For: 5’-ACCAGCAGCAGGTGATTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCCACTCCGTACATTTCCAG-3’ 
mest For: 5’-GGGTTTGTTGTGTGTTCCTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGGAAGTTCATCAGACGAG-3’ 
crym For: 5’-TATTGAACAAATGCGAGGTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTACATCAGCTCCCATCACAG-3’ 
d630003M21Ri
k_1 
For: 5’-CCAACATCTTCACTGAAACC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGTGGCATTTCTCTGATGTG-3’ 
d630003M21Ri
k_2 
For: 5’-TCACAGAGTCCTGGCTAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCGTGTTGCATGATCTCAG-3’ 
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d630003M21Ri
k_3 
For: 5’-GTGTGTTGCTGTACCACGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGTGCTGAAGGACAGGAG-3’ 
d630003M21Ri
k_4 
For: 5’-TTTCCCTTATGCACACAGC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTCACCTCATACACTTGCAG-3’ 
d630003M21Ri
k_5 
For: 5’-TTGGACACCTGTCTTGTGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGGCCGGATTGTCCATAC-3’ 
bdh1 For: 5’-CGTGTTAGGATTCGGTTTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTACATGCTGGCGATGTTC-3’ 
plxnb3a For: 5’-GGATCAGAGAGAGGAGAGTCC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCAAACCACACTCGAATCAC-3’ 
plxnb3b For: 5’-TAGGAGCGGTAAATGTCCTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCCTGAGCCAGATTATATCC-3’ 
plxnb3c For: 5’-AGTGTGTGTTGGTGATCGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCCTCTGACCTGCACTGAGAC-3’ 
ptprz For: 5’-TCAGACGGATCAGAACACAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTGGTAGGTGACGGAGTAGC-3’ 
lpcat2 For: 5’-TTAAGCACAGCCGACATAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGTGAGCAGCAGTAGTCTGG-3’ 
kank4 For: 5’-TCGTGTGTCAAGTCAGAAGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGTCAGGTCACAGTCTGGTC-3’ 
pkib For: 5’-CCTGTTGTCTCTGACTTTGC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTATGAACCCTCTGTCTTTGC-3’ 
serpine1 For: 5’-GCTACAGGTGTTTGCTGAAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTGAGTGGTTGTCATCATGG-3’ 
sema3b For: 5’-AAGCTGGAGCAACACTGAG-3’ 
Rev:5’-ggatccattaaccctcactaaagggaacCTGATAGGTCCATGTAATCTGG-3’ 
elmo1 For: 5’-GCTCTCCTTCACACTGACG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGTAGTCTCGGGTGTACATGG-3’ 
plexin For: 5’-GAAGCCCAAGTAGAGGTTTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTAGCGATGCTCCAGTCC-3’ 
gja4a For: 5’-CTGTGAGTCCGTCTGCTATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTATGAATCTGCACCTCTGC-3’ 
gja4b For: 5’-GGGTGACGAACAATCAAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGACATCCCACTCTGGTGAAC-3’ 
gja4c For: 5’-AAAGGTTTGGCTGACAGTTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAATGCAGACCAACACTAGG-3’ 
gja4d For: 5’-ACGGTCCTGTTTGTCTTCAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGAAGATGGTCTTCTCTGTGG-3’ 
gja4e For: 5’-GGATGAGCGTCCTATTCATC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTCTCCGACTGATCCTCCTAC-3’ 
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gabrb3 For: 5’-GAGACCCTCCCAAAGATCC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATGATCCGGGACCACTTG-3’ 
loxl4a For: 5’-ATGGTGGTGTGCAGACAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAGCAGCCTACTGAAATGC-3’ 
loxl4c For: 5’-GCTGCTCTTCATGTGTATGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCGGATTAGGAAGTTGCTGTC-3’ 
schip1a For: 5’-CTCTGGGCAGTTTCTTTGAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGAAGCTCATCTCGCATCAG-3’ 
schip1b For: 5’-CCCTTGGCAGTTTCTATGAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTGTTCCATGTGGAGTTCATC-3’ 
mfap3l For: 5’-GGTGGTCACCAAGACCAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGATCTCCTCCATGAATGTGC-3’ 
tspan15a For: 5’-GTATTTATGCCGAGGTGGAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAAGATGCCTAGAAGAAGTCCAG-3’ 
tspan15b For: 5’-GGGTCTTGTCATGTTCACTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTCCAGAAGACACAGCTCAG-3’ 
rab3a For: 5’-CTGAGCTCCAGCCAGAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGAATCCACCTCTTTGCACTC-3’ 
ppp1r3c For: 5’-CAATTATGCCTGTGGATGTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGCAGAACTCCACCTGCTC-3’ 
pcolce2 For: 5’-CTGTTTACCCACCCAACAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAATGAATCCATCAGCAGTC-3’ 
aldh1L1 For: 5’-CCTGTTTCCAGAGGGAGTC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAGCGCCAGACTTAAAGAAG-3’ 
bicc1b For: 5’-ATCACGTCTGTACGGCAAC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAAGAGTGCTCAGCCTCAGTC-3’ 
bicc1c For: 5’-CCTGGTGCTGACCTTTG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCTGGCCTCATACACATTGAC-3’ 
bicc1d For: 5’-AGAGCAACCAGGTGTCAATC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacTTTCACCACCACTGACTTTG-3’ 
pygl For: 5’-CGGATGACTGGTTAAGGTATG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacCAGTCAAGCTTCTCAATGTCC-3’ 
selenbp1 For: 5’-TCACACTTCTCATTGCTTGG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacATTCGTGGATTCTTCCTGTC-3’ 
ifitm1 For: 5’-CTACCCGCTTAGAGGAAACC-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacAGCATAGACAAGGATGACAATC-3’ 
tbx15 For: 5’-TGGATGAGACAAGTGGTCAG-3’ 
Rev: 5’-ggatccattaaccctcactaaagggaacGACAAGCCCAGGTTACACAG-3’ 
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Table 2 Overview of Proteinase K treatment and probe incubation  
Zebrafish stage Duration of Proteinase K treatment Duration of probe hybridization 
10 ss No treatment 4 hr, 65  oC 
21 ss 5 min, 37 oC 4 hr, 65  oC 
24 hpf 5 min, 37 oC 4 hr, 65  oC 
28 hpf 5 min, 37 oC 4 hr, 65  oC 
32 hpf 15 min, 37 oC 4 hr, 65  oC 
48 hpf 25-40 min, 37 oC 4 hr, 65  oC 
   
   
 
2.3 Morpholino loss-of-function studies in zebrafish 
MOs were dissolved in water to obtain a stock concentration of 50 ng/µl. For injections, a 
working concentration of 5 ng/µL was used and 1 nl per embryo injected. Injections were 
performed as previously described (Hogan et al., 2008). See Table 3 for an overview of 
morpholino sequences. Oligo sequences designed for validating the splice blocking 
morpholino by Q-PCR are displayed in Table 4.  
 
Table 3 Overview of morpholino oligo sequences 
Morpholino name Sequence 
limch1a ATG MO 5’-CTGCATCTGAAGCTGGACTCGCCAT-3’ 
limch1a spl MO 5’-ACTGCCTGCAACAAACGCACACAAA-3’ 
mmp17a ATG MO 5’-CTTTCTGAGAGACTTCATATTGTCC-3’ 
mmp17a spl MO 5’-AGGCTTGAAAATGCACCTACCACCC-3’ 
c8orf4 ATG MO 5’-AGTCTGAAGACACGTAGAAAGACAT-3’ 
c8orf4 spl MO 5’-TGCACAGCATCCAACTTTCCTCATC-3’ 
arap3a ATG MO 5’-GACCGATTGTTGCCATAGTGTGCAT-3’ 
arap3a spl MO 5’-TTTAGCAAAAAGGCTGTACCTATGA-3’ 
arap3b spl MO 5’-ACCATTTCTGTAAGAGATTTGAGCA-3’ 
ilk ATG MO 5’-GGCACTGAGTGAAGATGTCATCCAT-3’ 
ilk spl MO 5’-GAGAGTGCTTACCTTTTAGATTTGC-3’ 
pdgfra ATG MO 5’-ATGGTCACGTAGATTGTGCTCAGCT-3’ 
pdgfra spl MO 5’-TTCGAGACATCTGCAAGGAGATATT-3’ 
pdgfb ATG MO 5’-CGCGCACATCCAAATGTCTCTCTCT-3’ 
pdgfb ATG MO 5’-TCCCCCTGATGGAGAAAGAGAGAAA-3’ 
vegfc ATG MO 5’-GAAAATCCAAATAAGTGCATTTTAG-3’ 
vegfr3 ATG MO 5’-CTCTTCATTTCCAGGTTTCAAGTCC-3’ 
vegfaa MO 5’-TAAGAAAGCGAAGCTGCTGGGTATG-3’ 
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plc-gamma MO 5’-ATTAGCATAGGGAACTTACTTTCG-3’ 
kdr MO 5’-GTTTTCTTGATCTCACCTGAACCCT-3’ 
kdrl MO 5’-CACAAAAAGCGCACACTTACCATGT-3’ 
sox18 ATG MO 5’-ATATTCATTCCAGCAAGACCAACAC-3’ 
sox7 ATG MO 5’-CGCACTTATCAGAGCCGCCATGTGC-3’ 
 
Table 4 Overview of primers to validate the splice morpholino by Q-PCR 
Morpholino name Q-PCR oligo sequence 
limch1a spl MO For: 5’-CTCTGCAGGCTCATCATCAC-3’ 
Rev: 5’-CCTGTTCTGAAGTCCCTGTCTC-3’  
mmp17a spl MO For: 5’-GCTGCCCCTTCAATAACG-3’ 
Rev: 5’-CAGGATCAGAGGGTGGAAGA-3’ 
c8orf4 spl MO For: 5’-GAGATCTCCAAAGCGCTCAT-3’ 
Rev: 5’-CGTAATCAGCATGAATTTGTCC-3’ 
arap3a spl MO For: 5’-AGTCGTTCTGTACCCGTTCC-3’ 
Rev: 5’-GGATTCACTTGAGTTCGACTTTTC-3’ 
pdgfra spl MO For: 5’-TGTCTTACTAGGGGTGTTTTCAGG-3’ 
Rev: 5’-TGTTGAACGGTAATGGTTCG-3’ 
pdgfb spl MO For: 5’-GGGACCCTCTTCCTCCATC-3’ 
Rev: 5’-CTACAGTTGAAATTGGGCTGTTC-3’ 
 
 
2.4 Validation of arap3a expression in zebrafish VECs and BECs 
RNA extraction and cDNA synthesis  
Zebrafish at 3, 5 and 7 dpf were deyolked by pipetting with 200 µl pipette tip and rinsed in 
Calcium free ringers solution.  Embryos were dissociated via treatment with 5% trypsin in 
PBS for early time points or a 1/35 dilution of liberase iTm (Roche)n PBS at 28 oC with 
repeated pipetting. FACS analysis was performed at the Queensland Brain Institute 
(University of Queensland) using a Cytopeia Influx Cell Sorter (Cytopeia, Seattle USA).   
RNA extraction and genomic DNA removal was performed using a QIAGEN RNeasy micro 
kit (Qiagen Inc., Chatsworth, CA, USA) as per manufacturers recommendations.   
RNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA, USA) and the integrity confirmed using an Agilent bioanalyser.  
RNA was amplified using the Agilent low input Quick Amp Labelling kit. For cDNA 
synthesis, residual genomic DNA was removed using the genomic DNA wipeout buffer 
included in the Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, USA). 30-
50 ng of amplified mRNA was reverse transcribed into cDNA for 30 minutes at 42 oC using 
a Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, USA) as per 
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manufacturer's recommendations. To check for contaminating genomic DNA, a control 
reaction was performed which lacked the reverse transcriptase enzyme (at RT) and to 
confirm purity of primers, a no transcript control (NTC) was included.  For both negative 
controls, no amplification was observed indicating specificity of the Q-PCR reactions. 
 
Table 5 Overview of primers used for real-time RT-PCR in zebrafish  
Primer name Sequence 
rpl13 For: 5’-CATCTCTGTTGACTCACGTCG-3’ 
Rev: 5’-CATCTTGAGCTCCTCCTCAGTAC-3’ 
hprt1 For: 5’- ATCATGGACCGAACTGAACG-3’ 
Rev: 5’-AGCGATCACTGT TGCGATTA-3’ 
ef1a For: 5’-CTGGAGGCCAGCTCAAACAT-3’ 
Rev: 5’-ATCAAGAAGAGTAGTACCGCTAGCATTA-3’ 
rps29 For: 5’-TTTGCTCAAACCGTCACGGA-3’ 
Rev: 5’-ACTCGTTTAATCCAGCTTGACG-3’ 
 
Quantitative PCR  
Q-PCR was performed using an Applied Biosystems Viia 7 384 well Q-PCR machine 
(Applied Biosystems). Amplification was performed in duplicate in 384 well plates (Applied 
Biosystems) with the following thermal cycling conditions: initial UDG treatment 50 °C for 
10 minutes, followed by 40 cycles of 15s at 95 °C, 60s at 60 °C. Control reactions included 
a no template control (NTC) and a no reverse transcriptase control (-RT).  
Dissociation analysis of the PCR products was performed by running a gradient from 60 to 
95 °C to confirm the presence of a single PCR product.  
The efficiency of PCR amplification was determined using LinReg PCR (Ruijter et al., 
2009). The stability of several reference genes was analyzed including hprt1, ef1a, rps29, 
rpl13 and beta-actin.  Reference gene stability was determined using GeNorm 
(Vandesompele et al., 2002) with rps29, rpl13 and ef1a validated as the most stable genes 
across the sample populations.  As such the geometric average of rps29, rpl13 and ef1a 
was used for normalization of gene expression.   
 
 
 
 
 
 
  Materials and Methods 
	   82	  
Table 6 Overview of a Q-PCR reaction master mixture  
Component 
Volume per 
15 µl reaction 
Source 
2 x ABI SYBR green 
master mix 
7.5 Applied Biosystems 
Primer Forward (5µM) 0.75 - 
Primer Reverse (5µM) 0.75 - 
cDNA (1/80 dilution) 6 - 
 
2.5 Genotyping hsp70l:vegfc fish  
Oligo sequences for genotyping heatshock-inducible transgenic fish are given in Table 7. 
 
Table 7 Overview of primers used for genotyping assays in zebrafish  
Primer name Oligo sequence 
AN001 5’-CGCTACTCTCCCAAAACCAAAAGG-3’ 
AN002 5’-TCTCTTCCGATGATGATGTCGCAC-3’ 
 
2.6 Mouse lines 
All animal work conformed to ethical guidelines and was approved by the animal ethics 
committees at the University of Queensland. Pregnant wild-type CD1 mice were sacrificed 
and embryos dissected at the required stages for ISH.  
 
Table 8 Overview of mouse transgenic lines used in this study 
Fish Reference 
Arap3fl/+ Gambardella et al., 2010 (Gambardella et al., 2010) 
Sox18CreERT2+/-   A McMahon (USC, USA) (McMahon et al., 2008) 
Sox18CreERT2+/-Arap3fl/fl Generated in the lab 
Rosa26RLacZ/+ Jackson Laboratory 
Sox18GCE/+ Jackson Laboratory 
Sox18GCE/+; R26RacZ/+ Generated in the lab 
CD1 Jackson Laboratory 
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2.7 Genotyping of transgenic mice 
For induction of Cre activity in Sox18CreERT2+/-Arap3fl/fl mice, timed matings were 
established and the day of plug counted as 0.5 dpc. Tamoxifen was administered to 
pregnant females (10 mg/ml dissolved in sunflower oil, 40 mg/kg per mouse) by 
intraperitoneal injection once per day for 3 consecutive days prior to the time point at 
which embryos were harvested. Embryonic tissue was genotyped as previously described 
Table 9 gives an overview of the oligo sequences (Gambardella et al., 2010). 
 
Table 9 Overview of primers used for genotyping assays in mouse  
Primer name Sequence 
EcoRV For: GGGCTGAGTAGAGACTGACGCGCC 
 Rev: GGGTTTCATCTATCTCAGGCTGGCCTC 
BsmI For: GGCAGTGACAAGGTAGGGGACG 
 
2.8 Validation of Arap3 expression in isolated mouse endothelial cells 
Table 10 Overview of primers used for real-time RT-PCR in mouse 
Primer name Sequence 
Arap3 For: 5’-GGCATCCAGATCATAGCCAGC-3’ 
Rev: 5’-GGAAACCTCTGTAAGTGGCAGGC-3’ 
Prox1 For: 5’-AGACTTTGACCACCGTGTCC-3’ 
Rev: 5’-GGAGATGGCTGAGAACAAGC-3’ 
Vegfr3 For: 5’-GGTTCCTGATGGGCAAAGG-3’  
Rev: 5’-TCAGTGGGCTCAGCCATAGG-3’ 
 
2.9 ISH and Immunofluorescence staining in mouse 
Mouse embryos sectioning and ISH analysis was performed as described previously 
(Fowles et al., 2003). Immunofluorescence staining was performed as previously 
described (Francois et al., 2012) on dissected skin of mouse embryos. Table 11 and 12 
give and overview of dilutions used for antibodies.  
 
Table 11 Overview of primary antibodies 
Antigen Species Dilution Source 
PROX1 rabbit 1/500 Angiobio 
NEUROPILIN2 goat 1/400 R&D systems 
ENDOMUCIN rat 1/200 Santa Cruz Biotechnology, Inc. 
COLLAGEN IV rabbit 1/200 Millipore  
GOLPH4 rabbit 1/400 Abcam 
  Materials and Methods 
	   84	  
Table 12 Overview of secondary antibodies 
Antigen Conjugate Dilution Source 
Anti-rabbit IgA  Alexa 594 1/200 Invitrogen 
Anti-rabbit IgA Alexa 647 1/200 Invitrogen 
Anti-goat Alexa 488 1/200 Invitrogen 
Anti-rat Alexa 594 1/200 Invitrogen 
Anti-rat Alexa 647 1/200 Invitrogen 
 
2.10 Cell culture assays 
Cell isolation from mouse adult skin 
Adult LECs and blood endothelial cells (BECs) were isolated from the ears of wild type and 
RaOp+/- mice using a magnetic cell separation procedure (MACS), as previously described 
(Kazenwadel et al., 2010). Primary dermal LECs and BECs were isolated using rat anti-
mouse CD31 (PECAM-1) antibody (BD Biosciences) and subsequently used for RNA 
extraction (QIAGEN RNeasy micro kit) and Q-PCR analysis.  
 
HMVEC-dLyAd culture and ARAP3 siRNA knockdown 
HMVEC-dLyAd cells  (Lonza) were grown in EGM-2MV (Lonza). All experiments were 
performed with cells prior to P6. For ARAP3 knockdown studies, HMVEC-dLyAd cells  
(Lonza) were plated at 2 x 104 cells per well in 0.5 ml and transfected at plating with 2.5 
pmole Silencer Select control siRNA or ARAP3 siRNA (Ambion ID # s34712) using 
Lipofectamine 2000. Cells were harvested at 24 and 48 hours and total RNA was isolated 
from transfected cells using TRIzol® reagent (Invitrogen) according to the manufacturer’s 
instructions. For investigation of mRNA expression, total RNA was reverse transcribed 
using QuantiTect Reverse Transcriptase (Qiagen) with a mixture of oligo dT and random 
hexamer primers. Primers used for real-time RT-PCR analysis are shown in Table 13. 
PCR was performed with RT2 Real-Time SYBR Green/Rox PCR master mix (SA 
Biosciences) and analysed on a Corbett Rotor-Gene 6000. Data were normalised to the 
housekeeping gene ACTB as previously described (Livak and Schmittgen, 2001). 
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Table 13 Overview of primers used for real-time RT-PCR in HMVEC-dLyAd cells   
Primer name Sequence 
ARAP3 For: 5’-GCTCCCAGACAACTGTGTCA-3’ 
Rev: 5’-GCTCCCAGACAACTGTGTCA-3’ 
ACTB For: 5’-GATCATTGCTCCTCCTGAGC-3’ 
Rev: 5’-GTCATAGTCCGCCTAGAAGCAT-3’ 
 
Trans-well migration assay  
HMVEC-dLyAd cells were plated in 60mm dishes (5 x 105 cells in 5.5 ml ) and transfected 
at plating with 27.5 pmole Silencer Select control siRNA or Arap3 siRNA using 
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions.  Cells were 
cultured in 37 °C / 5% CO2 for 24 hours, harvested and replated at 2.5 x 104 cells per well 
in trans-wells (BD Biosciences) in base media consisting of EBM + 0.5% FCS. Base media 
was added to the lower wells and cells were incubated for 4 hours at 37 °C / 5% CO2. 
Media in the bottom wells was replaced with base media +/- VEGF-C (200 ng/ml) and 
incubated for a further 16 hours. Trans-wells were washed with PBS, fixed with ice-cold 
100% methanol for 10 minutes, washed twice with PBS and stained with haematoxylin for 
30 minutes. Following extensive washing with tap water, cells on the upper surface of the 
transwell were removed with a moistened cotton tip and the lower surface of the well was 
imaged. Migrated cell number was quantified from images using ImageQuant TL software 
(GE Healthcare). 
 
Scratch migration assay 
All experiments were performed in pre-marked 96 well plates with 4-5 replicates.  HMVEC-
dLyAd cells  (Lonza) were plated at 5 x 104 cells per well in 0.1 ml and transfected at 
plating with 0.5 pmole Silencer Select control siRNA or ARAP3 siRNA (Ambion ID # 
s34712) using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions.  
Cells were cultured in 37 °C / 5% CO2 for 24 hours and were then starved in EBM-2 
containing 0.5% FBS (base media) overnight. A single scratch was made in each 
confluent cell layer using a 200 µl pipette tip and cells were washed gently in EBM-2 
(Lonza). Images at time 0 (initial) were captured using an inverted phase contrast 
microscope (Olympus CKX41) at 4x magnification. Cells were then incubated in base 
media or base media containing or VEGF-C (200 ng/ml) for 8 h. Images were captured at 
8 h using an inverted phase contrast microscope (Olympus CKX41) at 4x magnification. 
For imaging purposes, wells were completely filled with EBM-2 to overcome distortion 
caused by the meniscus.  Initial and final scratch areas were measured using ImageJ 
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version 1.41 software and the difference between the 0 and 8 h measurements was 
expressed as migration area. 
 
LEC spheroid sprouting assay 
Spheroid sprouting assays were preformed as previously described (Zheng et al., 2011). 
Briefly, HMVEC-dLyAd cells were transfected with control and Arap3 siRNA. 24 hours 
following siRNA transfection, 3 x 103 cells were re-plated in U-bottom 96-well plates (BD 
Biosciences) pre-coated with 0.8% agarose and cultured for a further 24 hours to enable 
spheroid formation. Spheroids were then harvested and embedded in a 20% Matrigel-
containing (BD Biosciences) fibrin gel (3 mg/ml fibrinogen (Merck), 2 U/ml thrombin 
(Sigma) and 200 µg/ml aprotinin (Sigma)), equilibrated in EBM-2 media supplemented with 
1% FCS, followed by treatment with 200 ng/ml recombinant human VEGF-C (R&D 
Systems) for 24 hours. Sprout formation was quantified. Spheroids were imaged under 
phase contrast on an Olympus DP20-5E digital camera attached to an inverted Olympus 
CKX41 microscope. Images were processed using Adobe Photoshop CS5 version 12.0. 
 
Immunostaining of HMVEC-dLyAd cells. 
For analysis of cell polarity, HMVEC-dLyAd cells treated with control and ARAP3 siRNA 
were scratched and treated as outlined above, then fixed with 4% phosphate-buffered 
paraformaldehyde (PFA) for 10 minutes at room temperature. Cells were blocked in 0.1% 
BSA, 0.3% Triton X-100 in PBS for 1 h at room temperature and then incubated with 
primary antibodies goat anti-VE-cadherin (R&D Systems) and mouse anti-GM130 (BD 
Transduction Laboratories), diluted in blocking solution, overnight at room temperature.  
Following extensive washing with 0.1% Triton X-100 in PBS, samples were incubated with 
Alexa Fluor® 488 donkey anti-mouse (Invitrogen), Alexa Fluor® 594 phalloidin (Invitrogen) 
and Alexa Fluor® 647 donkey anti-goat (Invitrogen), diluted in 0.1% Triton X-100 in PBS 
for 3 h at room temperature.  Samples were again extensively washed, then air dried and 
mounted in Prolong Gold with DAPI (Invitrogen). Images were captured at room 
temperature using a Zeiss LSM 700 confocal microscope (Zeiss Laboratories) at the 
Detmold Imaging Core Facility, SA Pathology. Images were compiled using ZEN (blue 
edition) version 1.0 (Carl Zeiss) and Adobe Photoshop CS5 version 12.0 (Adobe) 
software. 
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Proliferation assay  
Proliferation assays were performed using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay reagent (Promega), as per manufacturer’s instructions.  All 
experiments were performed in 96 well plates with 4-5 replicates.  Briefly, mouse 
embryonic LEC were freshly isolated as previously described (Kazenwadel et al., 2012), 
diluted to 1 x 105 cells ml-1 in EGM-2MV (Lonza) and 0.1 ml of cells was added to each 
well. Cells were transfected at plating with 0.5 pmole Silencer Select control siRNA or 
Arap3 siRNA (Ambion ID # s98747) using Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions. Plates were cultured at 37 °C / 5% CO2 for 16-18 h and then 
serum starved for 4 h in base media comprising EBM-2 containing 0.5 mg/ml Albumax II 
(Invitrogen).  Cells were then incubated in full media or base media containing VEGF-C 
(200 ng/ml) for 48 h. Cell proliferation was measured following the addition of CellTiter 
96® AQueous One Solution Cell Proliferation Assay reagent (0.02 ml) to each well and 
incubation for a further 4 h. Absorbance was measured at 490 nm on a FLUOstar OPTIMA 
microplate reader (BMG LABTECH). 	  
Transfection of HUVECs and LECs 
All cells were transfected using Lipofectamine 2000 (Invitrogen) and magnetic 
nanoparticles (Magnetofection, Chemicell) according to the manufacturer’s instructions. 
Cells were plated in 24-well dishes (HUVECs at 4.5 x 104 cells/well and LECs at 3 x 104 
cells/well) and grown overnight at 37 °C and 33 °C / 5% CO2 respectively before co-
transfection with 6 ng/µl plasmid per well and treated with 300ng/ml VEGFC. Cells were 
harvested 24 hours after transfection and subjected to RNA extraction (QIAGEN RNeasy 
micro kit) and Q-PCR analysis.  
 
Table 14 Overview of primers used for real-time RT-PCR in HUVECs 
Primer name Sequence 
ARAP3 For: 5’-ATCCTTAAAGCCCAGCACGA-3’ 
Rev: 5’-GGGTCTGATTGGCAGAGAGG-3’ 
MMP7 For: 5’-CGGATGGTAGCAGTCTAGGG-3’ 
Rev: 5’-AGGTTGGATACATCACTGCATTAG-3’ 
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2.11 Imaging  
Zebrafish whole mount in situ embryos were imaged using an Olympus SZX-12 Stereo 
microscope and flat mounts were imaged using an Olympus BX-51 Upright 
Brightfield/Darkfield microscope. Confocal imaging was performed on live zebrafish 
embryos mounted laterally in low-melting agarose (1%, Sigma-Aldrich) using a Zeiss LSM 
510 META confocal microscope at the indicated stages. Nuclei counts in heatshock 
transgenic zebrafish were performed by using the ImageJ 1.44o software and Bitplane 
IMARIS 7.2.1 software for rendering. Mouse embryos were imaged by using Olympus 
SZX-12 Stereo microscope and whole mount immunofluorescence staining of mouse skin 
tissues were imaged using a Zeiss LSM 510 META confocal microscope. Quantitation of 
mouse vessel parameters was performed by using the ImageJ 1.44o software and the 
Lymphatic Vessel Analysis Protocol (LVAP) plug-in (Shayan et al., 2007). 
 
2.12 Statistical analysis 
To determine the significance of genetic interaction data, analysis of variance (ANOVA) or 
Student’s t -tests were performed using the Graphpad Prism software (Prism version 6 for 
Mac OSX). P<0.05 was considered statistically significant. 
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Chapter 3 
 
An expression-based screen for candidate 
regulators of lymphatic vessel development 
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3.1 Summary of Screens to Date  
A variety of studies have aimed to discover genes that are selectively expressed in LECs 
and not BECs and are important in lymphatic function and development. These studies 
have predominantly performed gene expression profiling by comparing blood with 
lymphatic endothelial cells, using diverse approaches. Several of these techniques will be 
reviewed below.  
 
3.1.1 Immuno-magnetic isolation of endothelial cells 
One such an approach is the immuno-magnetic isolation of dermal BECs and LECs from 
healthy individuals (Hirakawa et al., 2003; Nelson et al., 2007). Dermal ECs were labeled 
with the pan-vascular marker CD31 and the lymphatic-specific transmembrane protein 
PODOPLANIN (Nelson et al., 2007). Subsequently, pure populations of BECs were 
extracted which were CD31+ and PODOPLANIN-, and LEC populations that were CD31+ 
and PODOPLANIN+. Gene expression profiles of BECs and LECs were compared to the 
Affymetrix Genechip Human Genome U133 Plus 2.0 Array to identify genes that were 
unique to each vessel type and differentially expressed in BECs versus LECs.  
Based on log2-transformed intensity values greater than 6.644 for both LECs and BECs, 
699 genes were found enriched in LECs, among which T-cell signalling and cell adhesion 
molecules (CAMs). Furthermore, 563 genes were enriched in BECs including cell 
signalling molecules, such as chemokines and chemokines receptors (Nelson et al., 2007). 
Taken together, the comparison of gene expression profiles in LECs versus BECs has 
highlighted the differences as well as similarities between these two vessel types. For 
example, LECs showed higher expression of immune cells such as T-cells, which is 
supportive of the important functional role of LECs in immune surveillance. Furthermore, in 
addition to the distinct transcriptional program between LECs and BECs, overlapping gene 
expression have been observed, such as CAMs, suggesting that these vessel types have 
similar functions.  
 
3.1.2 Two-dimensional peptide mapping (2D-PM) 
Two thirds of all drug targets consist of membrane proteins. However, due to insolubility in 
water and the low abundance, identification of new membrane proteins has been a 
challenge. To avoid this problem, Roesli et al., (Roesli et al., 2008) applied two-
dimensional peptide mapping (2D-PM) and screened for lineage-specific expression of cell 
surface proteins in BECs and LECs (Roesli et al., 2008). This approach encompassed 
surface biotinylation of human dermal BECs and LECs, where a coenzyme biotin is 
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covalently attached to surface-accessible proteins. Subsequent analysis by mass 
spectrometry has revealed 184 proteins that are predominantly expressed by LECs and 
185 that are specifically expressed by BECs. These results introduce 2D-PM as a powerful 
technology for large-scale screening of lineage-specific protein expression (Roesli et al., 
2008) and have provided a tool to identify potential biomarkers as drug targets. However, 
the detection of proteins was not limited to membrane and extracellular matrix proteins. 
For instance the protein ALDH1A1 has been annotated as a cytosolic protein, but was 
detected in the present study as a cell surface protein of lymphatic vessels in human skin. 
It was suggested that the biotin reagent might have gained access to the intracellular 
compartment of a few nonviable cells. Alternatively, these observations may denote the 
identification of novel properties of proteins previously not reported (Roesli et al., 2008) 
 
Other studies also just profiled cultured LECs versus BECs, including a study by 
Podgrabinska et al., (Podgrabinska et al., 2002). Here they reported high levels of genes 
implicated in protein sorting and trafficking, describing novel functional features of 
lymphatic vessels in uptake and transport of molecules. Taken together, these expression 
profile studies of LECs versus BECs have paved a way to the identification of lineage-
specific genes, which may reflect structural and functional characteristics of each vessel 
type. However, these genes denote general functions and whether they also play a role in 
pathogenesis remains to be elucidated. 
 
In this current study an approach has been undertaken that utilizes a lymphatic disease 
mouse model, coupled with transcriptome-level expression profiling, to identify 
differentially expressed genes in wild-type versus mutant LECs. This approach is unique 
because it not only profiles LECs isolated from an in vivo source, but it also compares 
profiles in a disease scenario with that of wilt-type. As such, it is hypothesized that this 
approach would identify genes not only involved in development but also those likely to 
play a role in pathogenesis. The Ragged mouse (Section 1.3.3.2). mimics the human 
lymphatic syndrome HLT in the manifestation of dysfunctional lymphatic vessels and hair 
follicle defects (Downes et al., 2009; Francois et al., 2008; Hosking et al., 2001; Pennisi et 
al., 2000c). This mouse model was therefore found useful as a tool to identify genes with 
divergent expression in pathological lymphatic vessels and to unravel previous 
uncharacterized roles during normal lymphangiogenesis. Since Sox18 is expressed at the 
onset of lymphangiogenesis and binds the Prox1 promoter directly to induce transcription 
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of Prox1 and LEC specification, the Ragged mouse model was taken advantage of to 
identify genes acting downstream of the Sox18/Prox1 transcriptional pathway. 
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3.2 Results 
3.2.1 Identification of dysregulated genes in the RaOp+/- mouse model 
Firstly, the vasculature of Sox18RaOp+/- mutant mice was examined. 
While homozygous Sox18RaOp-/- mutants are embryonic lethal at 14.5 dpc and failed to 
initiate lymphangiogenesis, adult heterozygous mutants developed abnormal 
subcutaneous lymphatic vessels that were tortuous, thin and increased in both number 
and density (Francois et al., 2008) [Fig.3.1A-B]. Due to the premature death of 
homozygous Sox18RaOp-/- mutants, LECs were isolated from adult skin of 30 wild-type and 
30 heterozygous Sox18RaOp+/- mutant mice and subsequently cell sorted by fluorescence-
activated cell sorting (FACS) analysis [Fig.3.1C-D].  	  
Isolated LEC populations were sorted based on their expression of PODOPLANIN and 
Pan-Endothelial Cell Adhesion Molecule 1 (PECAM-1) (PODOPLANIN+/PECAM-1+) 
[Fig.3.1C-D, red box in graphs]. PECAM-1 is an adhesion molecule that is constitutively 
expressed on all vascular endothelial cells (Muller et al., 2002), whereas Podoplanin is a 
mucin-type transmembrane glycoprotein, commonly used as lymphatic-specific marker 
(Schacht et al., 2005). Isolated LEC populations, labeled positive for both PODOPLANIN 
and PECAM-1, guaranteed higher purity of LEC population. 
 
Subsequently, a microarray analysis was performed using an Affymetrix platform 
containing at least 19,100 annotated genes and compared to the isolated LEC 
populations. A list of genes was generated that displayed differential gene expression in 
heterozygous Sox18RaOp+/- mutant LECs compared with wild-type. These genes were 
provided by Dr M. François and used as a starting point for this PhD project to further 
characterize candidates with developmental roles during normal lymphangiogenesis. 
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Figure 3.1 FACS analysis of isolated LECs from mouse ear skin  
(A-B) Skin lymphatic vessels, stained for PODOPLANIN and PECAM-1 in (A) wild-type 
and (B) RaOp+/- mice, appeared abnormal and dysfunctional in RaOp+/- mutants compared 
with wild-type as previously described (Francois et al., 2008).  
(C-D) FACS plots representing isolated LECs from ear skin tissue of (C) wild-type and (D) 
RaOp+/- adult mice. The red box indicates LECs sorted for cell surface expression of both 
PODOPLANIN and PECAM-1. The upper left quadrant of the plot indicates that the 
sample has some single positive LECs for PODOPLANIN. The lower right quadrant 
indicates some single positive LECs for PECAM-1. Experiment performed by Tara 
Karnezis. 
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The PANTHER classification system (Protein Analysis Through Evolutionary 
Relationships) was used to classify the differentially expressed genes according to their 
function (Mi et al., 2013a; Mi et al., 2013b). Three different functional analyses were 
performed, including protein class, molecular function and cellular pathway. The results 
were subsequently represented in a pie chart, where each slice of the pie chart 
represented an ontology term [Fig.3.2, 3.3 and 3.4]. 
Genes were classified to 28 different protein classes, with the majority of molecules being 
receptors (15.8%), signalling molecules (13%), extracellular matrix proteins (12%) and cell 
adhesion molecules (9.2%) [Fig.3.2]. In addition, 9 different molecular functions were 
represented, including binding of proteins (36.4%), catalytic activity (29.9%), receptor 
activity (15.8%) and structural activity (10.9%) [Fig.3.3]. 
Furthermore, 35 cellular pathways were classified [Fig.3.4], with 2.7% of genes classified 
to angiogenesis as well as 2.7% to the Wnt signalling pathway. 
Taken together, gene profiling of Sox18RaOp+/- mutant LECs compared to wild-type has 
uncovered a wide-range of dysregulated genes, thereby providing a large amount of 
candidate genes for further analysis. 
 
In order to assess the specificity of the cell population that was isolated, expression 
profiles of classic LEC markers were analyzed, including Prox1, Neuropilin2, Foxc2 and 
Lyve-1. These genes were found down-regulated in Sox18RaOp+/-mutant LECs, validating 
the specificity of the isolated cell population and suggestive of the defective nature of the 
mutant LECs [Fig.3.5]. Given that these known LEC markers showed a 1-2-fold down-
regulation, it was interesting to observe many genes that displayed changes in expression 
level of a much greater magnitude.  
Selecting genes with a fold change of ≥5, the further expression analysis was based on 
289 genes that were putatively dysregulated in Sox18RaOp+/-mutant LECs. 
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Figure 3.2 PANTHER protein classification 
Pie chart representing protein classes, generated on the basis of the numeric values of the 
large-scale gene expression profiles of Sox18RaOp+/- mutant LECs versus wild-type. These 
genes are classified to 28 protein classes, with 15.8% of genes representing receptors, 
13% signalling molecules, 12% extracellular matrix proteins and 9.2% cell adhesion 
molecules. The percentage of genes represents the percentage of the total number of 
genes from the uploaded list to PANTHER. 
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Figure 3.3 PANTHER molecular function classification 
Pie chart of genes classified according to their molecular function. These functions include 
among others 36.4% binding activity, 29.9% catalytic activity, 15.8% receptor activity and 
10.9% structural activity.   
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Figure 3.4 PANTHER cellular pathway classification 
 
Pie chart representing 35 different pathway classifications, with 2.7% of genes classified to 
angiogenesis and 2.7% of genes associated with the Wnt signalling pathway.   
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Figure 3.5 Known LEC markers are down-regulated in RaOp+/- mutants  
Heat map depicting dysregulated genes in pure LECs from RaOp+/- mutant mice compared 
with wild-type. Lymphatic markers, Prox1, Lyve1, Nrp2, Foxc2, Efnb2, Vegfc, Vegfr3 and 
Syk are down-regulated in RaOp+/- vessels.  
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3.2.2 In search for vascular expressed genes in zebrafish 
To identify the subset of genes most likely to be involved in vessel formation, the 
expression pattern was examined of the top 100 dysregulated mouse genes in zebrafish 
embryos during development. These genes were selected on the basis of their fold 
change of ≥5 compared to their wild-type counterparts and showed to have known 
developmental roles, but so far not been implicated in lymphangiogenesis. A cross 
reference of the top 100 mouse genes with the genome browser Ensembl, showed that 
these 100 mouse genes corresponded with 106 zebrafish genes due to genome 
duplication in zebrafish. 
A whole mount in situ hybridization (ISH) screen was executed at three different embryonic 
stages in the zebrafish (20 somite stage (ss), 24 hours post-fertilization (hpf) and 48 hpf), 
thereby generating probes from zebrafish cDNA at 24 hpf [Fig. 3.6] for the 106 zebrafish 
genes [Fig.3.7A-B]. Briefly, RNA was extracted from 24 hpf zebrafish cDNA to synthesize 
complementary DNA (cDNA) by reverse transcription [Fig.3.6]. This cDNA was used as a 
template to generate gene-specific cDNA. Subsequent in vitro transcription with alkaline 
phosphatase-conjugated digoxigenin-(DIG) labelling resulted in antisense RNA probes for 
the genes of interest [Fig.3.6].   
Following ISH, diverse expression patterns were observed that included enriched 
expression patterns in somites, notochord, muscles, head and trunk vasculature and 
neural tube [Fig.3.7A-B]. But of high interest to us were sixteen genes that were identified 
as having strong vascular expression in the trunk [Fig.3.8]. 
 
The first seven genes that were identified as having strong vascular expression included 
limch1, mmp17a, c8orf4, arap3, ilk, pdgfrα and pdgfß. During later stages of ISH analysis, 
other genes also showed enriched expression in the vasculature, such as gbp28, cpm, 
gja4_1, aldh1l1 and elmo1 [Fig.3.8].   
However, subsequent loss-of-function analysis was performed by morpholino injection for 
the initial 7 genes identified. Two morpholinos (MOs) were designed, 1) at the translation 
start-site of the gene (ATG blocking morpholino) to specifically block all transcripts 
(maternally derived or produced by the zygote) and 2) at an exon-intron boundary (splice 
blocking morpholino) thereby inhibiting only protein production from newly synthesized 
zygotic transcripts [Fig.3.9i-ii].  
MOs were injected at 1-2 cell staged embryos at concentrations of 5, 10 and 15 ng. 
Injections of 15 ng resulted in toxicity, as observed by cell death (Robu	  et	   al.,	   2007), and 
lower doses of 2.5, 5 and 10 ng were consequently injected.   
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Figure 3.6 Generating zebrafish antisense RNA probes  
RNA is extracted from 24 hpf zebrafish genomic DNA and reverse transcribed using oligo 
dT primers to synthesize complementary DNA (cDNA). This cDNA is subsequently used 
as a template to amplify gene-specific cDNA using customized primers containing a T3 
polymerase tag on the reversed primer. PCR amplification produces single-stranded cDNA 
fragments of 400-800 base pairs (bp) long. Subsequent in vitro transcription with alkaline 
phosphatase-conjugated digoxigenin-(DIG) labelling results in antisense RNA probes for 
the genes of interest. 
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Figure 3.7 Overview of gene expression profiles in zebrafish embryos 
 
(A-B) Tables depicting 106 zebrafish gene expression profiles (at embryonic stages 20 ss, 
24 hpf and 48 hpf) as observed by in situ hybridization analysis in zebrafish embryos, with 
A) Table showing gene 1 to 54 and B) Table showing gene 55 to 106. 
Out of 106 genes, 76 are down-regulated and 30 up-regulated in heterozygous mutant 
LECs compared to wild-type. Expression profiles include expression in zebrafish trunk 
vasculature, notochord, somites, head, eyes and neural tube. 
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 Figure 3.8 Overview of zebrafish trunk vascular gene expression  
(i) At 20ss pdgfb, cpm and gbp28 show enriched expression in the trunk vasculature 
(black arrowhead).  
(ii) At 24hpf mmp17a is enriched in ISVs (black arrowhead), whereas pdgfra and aldh1l1 
are expressed predominantly in the PCV (black arrowhead). Furthermore, gja4_1 is 
enriched in the DA (black arrowhead), and elmo1 in both the DA (black arrowhead) and 
the PCV.  
(iii) At 48hpf limch1a is enriched in DA, PCV and ISVs (black arrowhead). c8orf4 and 
arap3a both show expression in ISVs (black arrowhead). ilk shows enrichment in the PCV 
(black arrowhead). 
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The efficacy for splice-site MOs was assessed by reverse transcriptase (RT)-PCR 
[Fig.3.10]. RT-PCR of RNA preparations from injected embryos allows for the detection of 
alterations in processed mRNA size due to incorrectly processed mRNA transcripts 
caused by exon skipping or intron retention (Hogan et al., 2008).  
MO-injected embryos were screened for circulation and the presence of blood vascular 
defects at 48 hpf and lymphatic vascular defects at 5 dpf, using the TD formation as a 
read-out [Fig.3.10]. Blood vascular defects were classified as perturbed sprouting of ISVs 
from the aorta and/or cardinal vein, ectopic branching of ISVs and/or defective patterning 
of DLAVs. Embryos that did not develop a full-length TD or showed a complete absence of 
this vessel at 5 dpf were recorded as having defective TD development.  
 
limch1 and mmp17a zebrafish morphants showed normal development of ISVs and 
DLAVs at 48 hpf as well as normal TD formation at 5 dpf [Fig.3.10].  c8orf4 ATG 
morphants showed blood vascular defects at 48 hpf but normal TD formation, suggesting 
a role during blood vessel development and not lymphangiogenesis (data not shown). 
Furthermore, both ATG and splice morphants for ilk and pdgfrα displayed blood vascular 
defects, whereas pdgfß ATG morphants showed defects in both blood and lymphatic 
vessel development [Fig.3.10].    
One candidate stood out that showed a robust requirement in zebrafish embryonic 
lymphangiogenesis but not blood vessel development, namely arap3a. Both the ATG and 
splice blocking MO were capable of inducing a defect in TD formation at 5 dpf with overall 
normal blood vessel development at 48 hpf [Fig.3.10].  
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Figure 3.9 Morpholino design at an exon-intron boundary 
(i) Morpholino (MO) design at exon1-intron1 boundary will generate a deletion of exon1, 
but retaining intron 1. This will produce a nonsense transcript.  
(ii) MO design at intron1-exon2 boundary will result in deletion of exon2 and produce a 
spliced product containing exon1 and exon3 (exon skipping). 
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Figure 3.10 Overview of gene-loss-of-function analysis by MO targeting 
Selected genes were targeted with both ATG and splice blocking MO oligomers. All splice 
blocking MOs were validated by Q-PCR, except for ilk, which exhibits a previous reported 
phenotype (Bendig et al., 2006). Screening for blood vascular defects was performed at 48 
hpf and for TD defects at 5 dpf by eye on a dissecting microscope. (+) Indicates phenotype 
observed, (-) indicates no phenotype observed.  
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Taking into account that MOs may induce non-specific phenotypes that are not associated 
with the gene being targeted (e.g. widespread cell death), plausibly mediated by p53 
(Robu et al., 2007), p53 MO was co-injected with arap3a MO. Defective TD formation 
phenotypes were observed similar to those displayed in morphants injected with only 
arap3a MO, demonstrating that the induced phenotype is not caused by non-specific p53-
mediated effects [Fig.3.11]. 
Together, these results suggest a specific lymphatic vascular defect upon depletion of 
Arap3 in zebrafish. Therefore Arap3 was chosen as a suitable candidate for further 
characterization during lymphangiogenesis. 
 
3.2.3 Confirmation of initial array results for Arap3 
In the microarray analysis Arap3 expression was found to be down-regulated [Fig.3.12]. 
To validate these initial findings, using independent biological material, an approach was 
next optimized to isolate LECs from adult mice [Fig.3.13A-B]. Briefly, ECs were isolated 
from ear skin of adult wild type and Sox18RaOp+/- mutant mice and purified using anti- 
PECAM-1 antibody and the magnetic cell separation procedure (MACS) (Kazenwadel et 
al., 2010). Subsequent RNA extraction and Q-PCR analysis revealed Arap3 expression to 
be consistently down-regulated relative to Prox1 or Vegfr3 expression levels compared 
with wild-type purified ECs [Fig.3.13A-B]. 
Given the down-regulation of ARAP3 in pathological (lymphatic) vascular endothelium, this 
study further explored whether ARAP3 is required during normal development of 
lymphangiogenesis and how its function integrates into known signalling pathways. 
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Figure 3.11 p53 MO co-injection with arap3a splice MO 
TD extent per somite, as observed at 4 dpf, is 76% in control embryos (n=23), arap3a 
splice morphants 40% (n=30) and arap3a/p53 double morphants 56% (n=43). Error bars 
indicate mean ± SEM. P-values were calculated using Student’s paired t-test. P<0.05. 	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Figure 3.12 Arap3 expression is decreased in skin lymphatic vessels of RaOp+/- 
mutant mice	  
Heat map depicting misexpressed genes in RaOp+/- mutant mice compared with wild-type 
(yellow= up-regulation, blue= down-regulation). These genes have been identified as 
being expressed in zebrafish embryonic vasculature, including Arap3 (red box), which 
shows a down-regulation of 9.44-fold relative to wild-type.	  	  
  
  Chapter 3 
	   123	  
  Chapter 3 
	   124	  
Figure 3.13 Validation of Arap3 down-regulation in mouse dermal ECs 
(A-B) Quantitative-PCR analysis of mRNA isolated from PECAM-positive ECs sorted from 
wild-type and RaOp+/- ear skin. Results have been normalized against the lymphatic 
markers (A) Prox1 and (B) Vegfr3 and show reduced Arap3 gene expression in RaOp+/- 
mutant animals, validating Arap3 down-regulation in heterozygous mutants. P-values were 
calculated using Student’s paired t-test. P<0.005. 	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3.3 Arap3 Identified as a Potential Regulator of Lymphangiogenesis in 
Zebrafish   
ARAP3 (ArfGAP with RhoGAP domain, Ankyrin repeat and PH domain 3) is a GTPase 
activating protein (GAP) for the small GTPases RHOA and ARF6 (Krugmann et al., 2002).  
ARAP3 belongs to a family of proteins that consists of three members- ARAP1, ARAP2 
and ARAP3. All ARAP3 proteins share identical domain structures, including five PH 
domains, an ARF-GAP and RHO-GAP domain as well as a poorly conserved RAS-
association domain (Krugmann et al., 2002) [Fig.3.14A]. Comparing these domains across 
several species, a phylogenetic tree for the three ARAP proteins was generated 
[Fig.3.14B]. This phylogenetic analysis revealed that ARAP3 and ARAP2 share a more 
recent common ancestor with each other as opposed to ARAP1 and are therefore closer 
related to each other [Fig.3.14B].   
 
3.3.1 arap3a is expressed in the developing vasculature in zebrafish 
Next the expression profile of arap3 during zebrafish embryonic development was 
examined [Fig.3.15]. In zebrafish, two copies of arap3 exist due to genomic duplication, 
arap3a and arap3b. ISH analysis showed that arap3a was enriched in somites at the 10 ss 
[Fig.3.15i]. Furthermore, arap3a was enriched in neurons [Fig.3.15ii], ISVs, the DA and 
PCV at later embryonic stages (21 ss, 28 and 48 hpf, respectively) [Fig.3.15ii-iv]. In 
contrast, arap3b was ubiquitously expressed in the head with no expression observed in 
the vasculature [Fig.3.16A-E]. In the phylogenetic tree [Fig.3.14B] arap3b appears to be 
an outlier, which may account for the observed a-specific expression pattern in zebrafish.  
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Figure 3.14 Overview of the ARAP protein family	  
(A) ARAP proteins share identical domain structures, including five PH domains, an ARF-
GAP and RHO-GAP domain as well as a poorly conserved RAS-association domain.  With 
their ankyrin repeats, ARAP proteins are able to function in protein-protein interactions 
(Krugmann et al., 2002).	  
(B) Phylogenetic tree of ARAP1, 2 and 3 generated on the basis of their structural 
domains.  	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Figure 3.15 arap3a expression profile during zebrafish embryonic development	  
(i) At 10 ss, arap3a is enriched in somites (arrow); 	  
(ii) Furthermore, at 21 ss arap3a is observed in neurones (black arrowheads), the DA and 
PCV. 	  
(iii-iv) At later embryonic stages, (iii) 28 hpf and (iv) 48 hpf, enriched expression of 
arap3a is also observed in ISVs (open arrowheads).	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Figure 3.16 arap3b is ubiquitously expressed in the head during zebrafish 
development 	  
(A) mRNA expression  of arap3b at the 8 somite stage (ss), (B) the 23 ss, (C) 30 hpf, (D) 
36 hpf and (E) 50 hpf, displaying no restricted expression in vessels. 	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In order to quantify arap3a expression specifically in developing zebrafish LECs, a recently 
described transgenic line was utilized that expresses dsRed in embryonic veins and 
lymphatics Tg(lyve1:dsRed) (Okuda et al., 2012), and crossed to a transgenic line that 
selectively expresses EGFP in blood vessels Tg(-6.5kdrl:EGFP) (Jin et al., 2005). FACS 
analysis was used to sort populations of LECs and venous endothelial cells (VECs) from 
whole embryo cell suspensions [Fig.3.17A-B]. kdrl/vegfr2 was enriched in VECs 
compared with LECs at all time points as expected [Fig.3.18A]. In contrast, arap3a was 
enriched in both VECs and LECs at 3 and 5 dpf, but not at 7 dpf [Fig.3.18B], time points 
that correspond to LEC migration and vessel formation in zebrafish. The specificity of 
these cDNA populations has also been further validated in recent studies (Coxam et al., 
2014). 
 
3.3.2 Arap3a depletion in zebrafish leads to reduced thoracic duct formation  
Transcripts were targeted encoding both arap3 paralogues (arap3a and arap3b) with MO 
as previously described, and potential blood vascular defects were examined at 48 hpf 
(data not shown) as well as the TD formation at 5 dpf [Fig.3.19]. Both a translation 
blocking (ATG) and a splice blocking (Spl) MO were used to target arap3a, validating the 
Spl blocking MO by Q-PCR [Fig.3.20]. Uninjected control embryos displayed normal 
development of the blood vasculature at 48 hpf and lymphatic vessel development at 5 dpf 
[Fig.3.19A–A′, arrowheads]. Arap3a–depleted embryos displayed significantly reduced or 
absent TD development [Fig.3.19B–B′, asterisks], but overall grossly normal blood 
vasculature. Quantification of TD extent showed that the observed loss of TD in arap3a 
morphants was highly significant [Fig.3.19C].  
 
Following the observation of TD loss in Arap3a-depleted zebrafish embryos, further 
examination was performed to assess whether this was due to a defect in the formation of 
precursor LECs (parachordal lymphangioblasts (PLs)), which bud from the cardinal vein at 
32 hpf and are found at the HM at 54 hpf (Hogan	  et	  al.,	  2009a;	  Isogai	  et	  al.,	  2003). Using the 
Tg(fli1a:EGFP;-6.5kdrl:mCherry) transgenic line, expressing EGFP in all endothelial cells 
and monomeric fluorescent protein Cherry in blood vessels only, uninjected controls were 
compared with embryos injected with arap3a ATG or Spl blocking MOs [Fig.3.21]. In 
uninjected embryos, a population of PLs was observed at the HM at 58 hpf (PLs scored 
across 10 body segments) [Fig.3.21A]. In contrast, arap3a morphants showed significantly 
fewer PLs at the HM [Fig.3.21B-C].  
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Figure 3.17 FACS cell sorting of zebrafish LECs and VECs 	  
(A) The Tg(lyve1:dsRed) transgenic line, expressing dsRED in venous and lymphatic ECs, 
is crossed to Tg(-6.5kdrl:EGFP) that expresses EGFP in all blood ECs, thereby generating 
embryos that display arteries which are dsRED-/GFP+, veins dsRED+/GFP+ and 
lymphatics  dsRED+/GFP-. 	  
(B) Subsequently, FACS analysis of LECs and VECs from whole embryo cell suspensions 
is performed, to sort LECs that are dsRED+/GFP- and VECs that are dsRED+/GFP+. 
Experiment performed by Neil Bower.	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Figure 3.18 arap3a mRNA expression is found in developing LECs 	  
(A-B) FACS sorted LECs from whole Tg(-6.5kdrl:EGFP;lyve1:dsRed) zebrafish embryo 
extracts (3, 5 and 7 dpf) show reduced expression of (A) kdrl and (B) robust expression of 
arap3a compared with VECs.	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Zebrafish mutants in the Vegfc/Vegfr3 pathway all show a block in venous sprouting 
(secondary angiogenesis), failing to give rise to both venous intersegmental vessels 
(vISVs) and PLs (Isogai et al., 2009; Kuchler et al., 2006). To address whether this was 
the case in arap3a morphants, the number of intersegmental arteries (aISV) was assessed 
compared with vISVs that had formed at 3 dpf using the Tg(fli1a:EGFP;-0.8flt1:tdTomato) 
transgenic line [Fig.3.22]. This line allowed the visualization of EGFP in all endothelial 
cells and the tandem-dimer Tomato fluorophore in aISVs only. Firstly, PL formation was 
scored, confirming that arap3a morphants showed reduced PLs [Fig.3.22B]. However, at 3 
dpf the same morphants displayed normal aISVs and vISVs [Fig.3.22A-B]. Furthermore, 
markers of arterial and venous identity were also investigated in arap3a morphants. 
Normal expression of arterial markers hey2 and efnb2a, and venous markers dab2 and 
coupTFII, was observed [Fig.3.23].  
In arap3b morphants, quantification of PLs and TD formation showed no difference 
compared with uninjected control embryos [Fig.3.24A-B]. Since arap3b showed no 
restricted developmental expression and morphants showed normal blood and lymphatic 
vessels, no further functional studies were undertaken for this gene. 
 
Taken together, these data suggest that a specific defect in PL formation underlies the 
observed defect in TD development in arap3a zebrafish morphants. arap3a presumably 
modulates LEC migratory behaviour and is essential for zebrafish embryonic lymphatic 
development. 
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Figure 3.19 arap3a is required for thoracic duct formation in zebrafish	  
(A, A') Uninjected control embryos Tg(fli1a:EGFP;-6.5kdrl:mCherry) display normal 
development of blood and lymphatic vessels (white arrowheads indicate the TD). 	  
(B, B') arap3a morphants (splice MO) display reduced TD formation (asterisks) but grossly 
normal blood vasculature. 	  
(C) Uninjected Tg(fli1a:EGFP;-6.5kdrl:mCherry) control embryos display PLs (white 
arrowheads) at the HM at 58 hpf. 	  
(D) arap3a splice morphants (asterisks) display reduced PL formation. 	  
(E) Quantification of TD formation in uninjected controls versus arap3a ATG and splice 
morphants (Spl) at 5 dpf. TD extent/per somite was 96% in control embryos (n =59), ATG 
morphants 33% (n=43) and splice morphants 14% (n=52). Error bars indicate mean ± 
SEM. P-values were calculated using ANOVA statistical analysis. P<0.0001. 	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Figure 3.20 Relative arap3a mRNA expression in arap3a morphants	  
Q-PCR validation of arap3a transcript levels in uninjected control and splice morphants (2 
ng, 5 ng and 10 ng MO per embryo) at 48 hpf. 	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Figure 3.21 arap3a morphants display defective PL formation  
(A) Uninjected Tg(fli1a:EGFP;-6.5kdrl:mCherry) control embryos display PLs (white 
arrowheads) at the HM at 58 hpf.  
(B) arap3a splice morphants (asterisks) display reduced PL formation. 
(C) PL quantification in morphants shows significantly reduced numbers of PLs compared 
with uninjected embryos, scored across 10 somite segments. P-values were calculated 
using ANOVA statistical analysis. P<0.0001. 
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Figure 3.22 Arap3-depletion in zebrafish results in a lymphatic-specific defect  
(A) (i-iv) Representative (i) uninjected control and (iii) morphant embryos at 3 dpf with 
normal formation of intersegmental arteries (aISV, Tg(-0.8flt1:tdTomato)) and 
intersegmental veins (vISV, Tg(fli1a:EGFP) sprouts not expressing flt1). Dashed lines 
indicate vISVs. (ii and iv) Tg(-0.8flt1:tdTomato) expression only. 
(B) In morphant embryos, scores reveal normal formation of aISVs (P=0.94) and vISVs 
(P=0.65) but reduced PL formation (P<0.0001, n=23 embryos) in the Tg(fli1a:EGFP;-
0.8flt1:tdTomato) strain. Error bars indicate mean ± SEM.  
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Figure 3.23 Normal arterio-venous marker expression in arap3a morphant embryos 
(i-xii) mRNA expression profile of arterial markers (i-iii) hey2 and (iv-vi) efnb2a at 24 hpf 
in arap3a splice morphants (ii, n=7 and v, n=18) and ATG morphants (iii, n=16 and vi, 
n=10) versus uninjected control embryos (i, n=16 and iv, n=16).  
At 28 hpf, normal expression of the venous markers (vii-ix) dab2 and (x-xii) coupTFII was 
observed in arap3a splice (viii, n=8 and xi, n=9) and ATG (ix, n=11 and xii, n=12) 
morphants versus control embryos (vii, n=14 and x, n=13). (n indicates the number of 
embryos analysed).  
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Figure 3.24 arap3b morphants display normal lymphatic vasculature 
(A-B) Quantification of precursor LECs (PLs) at 3 dpf. (A) Uninjected versus arap3b 
morphant embryos (2 ng, 5 ng and 10 ng/splice MO per embryo) and (B) TD extent 
assessed across 10 somites (n indicates the number of embryos analysed). Error bars 
indicate mean ± SD.  
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3.4 Concluding Remarks 
The identification of novel lymphatic markers is important as they may aid in the 
clarification of molecular mechanisms that are so far not well understood.  
Gene profiling of RaOp+/- mutant LECs versus wild-type resulted in the identification of a 
range of dysregulated genes with diverse biological functions, including angiogenesis, but 
previously not implicated in lymphatic vessel development. Looking at RNA expression 
profiles of 100 selected mouse genes in zebrafish, 16 genes were found enriched in the 
vasculature of developing zebrafish embryos. Subsequent gene loss-of-function analysis 
of seven of these genes by morpholino targeting identified ARAP3 as a potential novel 
lymphatic regulator. 
 
Thus far, this data suggests that the defective TD extension observed in arap3a zebrafish 
morphants is due to a specific defect in PL formation.  
In the absence of a specific marker strain to examine LEC specification in zebrafish (Tao 
et al., 2011), defects in either migration or specification of LECs may explain this 
phenotype. Previous work by Krugmann et al., (Gambardella et al., 2011; I et al., 2004; 
Krugmann et al., 2006; Yagi et al., 2011) with transfected and knock-down cells, as well as 
with primary Arap3-/- cells, demonstrates that ARAP3 is a regulator of cell adhesion and 
migration. In this context, the RHO GAP activity appears to be particularly relevant. The 
down-regulation of Arap3 expression in the heterozygous RaOp+/- model of HLT may 
contribute to vascular endothelial pathogenesis in that context. 
 
To further characterise the role of ARAP3 during lymphatic vessel development, functional 
studies in other systems have been undertaken in addition to zebrafish, including the 
mouse model and cultured cells. These results are described in Chapter 5.  
In mice, dermal lymphatic vessels also develop during embryogenesis in the womb. It is 
hypothesized that investigation of dermal lymphangiogenesis is an amenable way to 
assess lymphatic developmental processes that are otherwise difficult to pick up during 
embryonic development. The validation and characterisation of an ex vivo skin assay will 
first be discussed in the following chapter. This assay was developed in Chapter 4 as an 
approach to exercise Arap3 in mice. 	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Chapter 4 
 
Characterisation of an ex vivo assay of 
dermal vascular network formation 
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4.1 Models for Angiogenic and Lymphangiogenic Network 
Formation 
In vertebrates, a branched vessel network serves to transport and distribute liquids, 
nutrients and gases to distant organs and tissues. Proper tissue perfusion is essential as it 
enables active growth and renewal.  
The mature vessel network arises via multiple steps during embryonic development, 
including angiogenic branching, and expands through circumferential growth and 
remodeling processes (Adams and Alitalo, 2007; Carmeliet and Tessier-Lavigne, 2005; 
Schmidt and Carmeliet, 2011).  
Angiogenesis, a process where a group of cells extend as coherent structures or sprouts 
from pre-existing vessels, is not only essential for embryonic development, but also in the 
female ovarian cycle, organ regeneration and wound healing (Aplin et al., 2008; Carmeliet 
and Tessier-Lavigne, 2005; Schmidt and Carmeliet, 2011). Defects in microvascular 
angiogenic remodeling are often the underlying cause in numerous pathological conditions 
such as tumor growth, diabetic retinopathy and myocardial infarction (Reviewed in Stapor 
et al., 2013). Therefore, understanding the remodeling processes that vessels undergo to 
form a coherent network is essential for developing therapies that aim at manipulating 
microvascular processes of angiogenesis. Furthermore, how angiogenesis relates to other 
network remodeling processes, including lymphangiogenesis and neurogenesis, remains 
to be understood.  
 
To date, our view on vessel network formation has been largely appropriated by in vitro 
angiogenesis and lymphangiogenesis assays conducted in the past years, and taught us 
that key processes involved in shaping the outgrowing branches include cell migration, cell 
division, the regulation of cell rearrangement and cell shape. However, standard cultured 
cells are not ideal to study network formation, as they do not mimic in vivo conditions. To 
that end, in vivo systems are needed. 
In this chapter, a new model for understanding the formation of branched lymphatic 
vascular networks has been investigated: the lymphatic dermal vascular development 
model. In order to assess its utility, the use of other assays will first be reviewed. The focus 
will be on assays that take advantage of primary isolates as a start-point. 
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4.1.1 Three-dimensional aortic ring angiogenesis assay 
One such model, which has been highly favoured among angiogenesis biologists, is the 
three-dimensional ex vivo aortic ring assay in rat (Aplin et al., 2008; Nicosia and Ottinetti, 
1990) and mouse (Baker et al., 2012). This model has been found simple, reproducible 
and reliable, and is commonly used to assess processes including tubule growth and 
morphogenesis. 
 
Aortic rings are dissected from rats (adults) or mice (18 dpc up to adulthood at 18 weeks) 
and cultured in extracellular matrices consisting of type I collagen, fibrin or matrigel (Baker 
et al., 2012). Angiogenic response data can be obtained by testing the effect of different 
experimental conditions on developing microvessels, based on the counts of sprouts 
growing out from aortic rings during the exponential growth phase. These experimental 
manipulations include gene knock-down or gain-of-function strategies (including siRNA 
and short hairpin RNA by lentiviral transduction) and biochemical assays taking advantage 
of small-molecule drugs or stimulation by different growth factors such as basic fibroblast 
growth factor (bFGF), VEGF and platelet-derived growth factor (PDGF)) (Nicosia et al., 
1994; Norrby, 1994).  
 
The most useful element of this assay is the fact that similar cell types and cellular 
processes that contribute to the growth, morphogenesis and survival of neovessels in vivo 
are also present in the ex vivo formed tubules (Aplin et al., 2008). These include 
interaction between endothelial cells with the surrounding matrix, mediated by integrins, as 
well as matrix metalloproteinases that regulate the sprouting of endothelial cells and 
vascular regression (Reviewed in Aplin et al., 2008). Furthermore, key features of 
angiogenesis, including cellular proliferation, tube formation, microvessel branching, 
perivascular recruitment and remodeling (Baker et al., 2012), have been reported using 
subsequent immunofluorescence staining and microscopy techniques. Lumenized vessels 
and supporting cells, such as pericytes (Aplin et al., 2008; Baker et al., 2012), are present, 
making this a relevant physiological in vitro model for angiogenesis. 
 
However, this assay only allows the investigation of aortic neovessel formation, not 
comprehensive network morphogenesis, and rules out the study of lymphangiogenesis. In 
that regard, a lymphatic analogue has been introduced in response to the aortic ring assay 
as a tool to understand lymphangiogenesis in vitro (Bruyere et al., 2008).  
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4.1.2 Three-dimensional lymphatic ring model 
The lymphatic ring assay has been previously used to identify regulators of 
lymphangiogenesis in vitro. Similar to the aortic ring model, thoracic ducts (TDs) from adult 
mice (2-4 months) are dissected and cut transversely to generate lymphatic duct 
fragments. At five days after embedding TDs into type I collagen gels, capillary-like 
outgrowths are observed that sprout from the lymphatic ring cultures as lumenized 
microvessels composed of a single layer of endothelial cells (EC), based on transmission 
electron microscopy (Bruyere et al., 2008).  
Analysis by whole-mount immunostaining techniques reveals that these capillaries are 
positive for lymphatic-specific vessel markers, including lymphatic vessel endothelial 
hyaluronan receptor-1 (LYVE-1) and VEGFR3, and negative for markers of other cell types 
such as blood endothelial cells (CD34), fibroblasts (Thy1.1) and inflammatory cells 
(CD45). These observations suggest that this model only harbours lymphatic vessels and 
no blood vessels, thus suitable for observing lymphangiogenic events in vitro.  
 
Following biochemical assays, LEC outgrowth can be enhanced or inhibited in response to 
either over-activating or blocking the VEGFC/VEGFR pathway respectively, suggesting 
that this model is a valid tool for identifying lymphatic regulators. For instance, a role for 
metalloproteinases in lymphangiogenesis has been suggested (Bruyere et al., 2008). 
MMP2 inhibitors induce a dose-dependent decrease of lymphatic vessel outgrowth. These 
results are in concert with observations in Mmp2-/- mice, which display impaired 
lymphangiogenesis compared to their wild-type counterparts. 
 
Although the use of these ring assays are helpful tools to study basic mechanistic aspects 
of angiogenesis and lymphangiogenesis, only a small window for analysis is provided as 
the investigation of mechanistic interactions between multiple cell types is limited as well 
as studying the interrelationships between other tissue networks such as the lymphatic 
and neural networks (Baker et al., 2012; Stapor et al., 2013). Hence, there is a need for 
assays that are easily accessible and better reflect network formation in vivo. 
 
4.1.3 Rat mesentery angiogenesis model 
Stapor and colleagues (Stapor et al., 2013) therefore have developed the rat mesenteric 
culture model, which enables a parallel study of multiple systems. Similar to the aortic ring 
assay, this model contains endothelial cells, smooth muscle cells and pericytes, as 
confirmed by labelling of platelet endothelial cell adhesion molecule-1 (PECAM-1), type 
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alpha-smooth muscle actin (α-SMA) and neuron-glial antigen 2 (NG2). Mesenteric tissue, 
harvested from adult rats, is cultured in medium and does not require subsequent matrix 
embedding as vessel growth occurs within the intact tissue. 
 
The greater advantage that this rat mesentery angiogenesis model carries, in contrast to 
the ring assays, is the intact microvascular network with its hierarchy of microvessels 
including arterioles, venules, and capillaries. A ‘network’ is defined as having a feeding 
arteriole, a draining venule and multiple branches. The interplay between angiogenesis, 
lymphangiogenesis and neurogenesis can be investigated using immunohistochemistry 
techniques against endothelial cell marker PECAM-1, the lymphatic-specific marker LYVE-
1, and class III β-tubulin for labelling nerves. In addition, subsequent time-lapse imaging 
for investigating endothelial cell dynamics (Stapor et al., 2013). 
 
A recent study that utilized the rat mesenteric model reported that lymphatic and blood 
endothelial cells physically connect (Robichaux et al., 2010). Furthermore, the occurrence 
of this interaction could be influenced by growth factor stimulation (Stapor et al., 2013). 
Interestingly, connections were not apparent at sites with an open lumen as to prevent 
fluid exchange, and did not appear to be tissue-specific as direct connections between 
lymphatic and blood endothelial cells along capillaries were also formed in ileum muscle 
coat and cremaster muscle from adult rats (Robichaux et al., 2010). 
In gene-knock out mouse studies the relevance of certain signalling molecules that might 
play a role in these lymphatic/blood vessel lumenal connections have been reported. For 
example, in Slp-76-/- or Syk-/- mice (14), intravenous injection of FITC-labeled dextran 
identified abnormal lymphatic/blood vessel lumenal connections. Similar observations 
were made in Fiaf-/- (fasting-induced adipose factor) mice during postnatal development, 
injected intravenously with BSI-lectin (15).  
Thus this model system has proven to give a more in depth understanding of 
interrelationships between angiogenic and lymphangionic networks in contrast to the 
three-dimensional ring assays.  
 
While these assays are useful tools to examine angiogenic and lymphangiogenic network 
formation, they exhibit profound limitations: they are not in vivo systems, and therefore do 
not necessarily reflect all the variables present in in vivo processes. Moreover, the 
question of what determines organ-specific vascular patterns can best be addressed with 
in vivo models, such as the retinal angiogenesis model. 
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4.1.4 Retinal angiogenesis model 
Vascular patterning may occur as 1) a random process followed by specific vascular 
remodeling and 2) a guided process of angiogenic sprouting and fusion, giving rise to 
specific vascular patterns (Gerhardt et al., 2003). The retinal angiogenesis model has 
been fundamental in the study of guided blood vessel angiogenesis during development. 
The leading tip cell in particular plays an important role as it functions as a sensor to 
transfer external signals into specific cell behavior.  
Retinas, dissected from early postnatal mice (Gerhardt et al., 2003), display simultaneous 
vascular sprouting at the periphery and remodeling at the center. These structures are 
ideal to study different aspects of vessel formation, maturation and specialization by using 
whole-mount immunostaining, in situ hybridization and high-resolution 3D imaging.  
Gerhardt et al., (Gerhardt et al., 2003) has demonstrated by genetic and pharmacological 
gain and loss-of-function approaches in the retinal model that guided tip cell migration and 
stalk cell proliferation are regulated by different cellular expression and distribution of 
VEGF-A in the extracellular space. Taken together, this model has provided a mechanistic 
understanding of vascular patterning during angiogenic sprouting.  
 
To examine lymphatic vessel network formation, in a system similar to the retinal model for 
blood vessel studies, the embryonic mouse skin was utilized in this current study. 
Immunofluorescence staining (IF) of skin explants against specific blood and lymphatic 
markers, in conjunction with confocal microscopy imaging techniques, enabled 
visualization of vessel growth during early mouse embryogenesis (12.5 dpc up to 17.5 
dpc). 
This model did not require embedding in extracellular matrices or culturing in medium. 
Wild-type or genetically modified mice are best applicable in this approach.  
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4.2 Results 
Characterisation of blood and lymphatic vessel networks in mouse embryonic skin  
In a recent study, James et al., 2013 investigated the role of TGF-beta signalling during 
developmental lymphangiogenesis, using a whole-mount embryonic skin imaging 
technique (James et al., 2013). This approach allowed the visualization of sprouting 
lymphangiogenesis and patterning of lymphatic vessels. This current study took on a 
similar approach to perform an in depth analysis of blood and lymphatic vessel formation. 
The recently described Prox1-EGFP reporter mouse (Tg(Prox1-EGFP)221Gsat/Mmcd) 
(Svingen et al., 2012) was used as a tool to perform a time course analysis of dermal 
vessel network formation.  
 
4.2.1 Time course analysis of mouse embryonic skin vasculature 
In order to examine changes in dermal vessel morphology as the embryo is developing, a 
whole-mount embryonic skin time course analysis was performed of embryos staged at 
12.5, 13.5, 14.5, 15.5, 16.5 and 17.5 dpc. 
A flap of the dorsal embryonic skin was dissected [Fig.4.1] and skin samples were 
subsequently labelled for blood vascular endothelial marker ENDOMUCIN, lymphatic-
selective markers NEUROPILIN2 (NRP2) and PROX1 to analyse the blood and lymphatic 
morphology over time [Fig.4.2-4.3].  
A progressive growth was observed of blood vessels from flank toward the midline of the 
skin [Fig.4.2 and Fig.4.3 ENDOMUCIN staining], with blood vessel tips that appeared 
migratory based on morphology, not yet connecting at the midline at 12.5 dpc [Fig.4.2A 
yellow arrows]. An increase in vessel density became apparent at 13.5 dpc compared to 
the 12.5 dpc stage and connections of vessels were evident at the midline [Fig.4.2B 
yellow arrows]. From 14.5 dpc onwards a remodelled vessel network was noticeable from 
flank to midline [Fig.4.2C and Fig.4.3], as depicted by vessel loops [Fig.4.2C yellow box].  
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Figure 4.1 Overview of skin dissection procedure 
Tg(Prox1-EGFP) mice were collected at different embryonic stages: 12.5, 13.5, 14.5, 15.5, 
16.5 and 17.5 dpc. A skin flap was subsequently dissected from the back of the mouse as 
indicated in green. After fixation in 4% PFA overnight, immunofluorescence staining 
techniques were performed on the skin to identify the dermal vasculature.  
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Figure 4.2 Time course of early embryonic vascular development 
A-C) Immunofluorescence staining on embryonic skin samples performed against blood 
vascular endothelial marker ENDOMUCIN, lymphatic-specific marker NEUROPILIN 2 
(NRP2) and nuclear lymphatic marker PROX1.  
A) At 12.5 dpc isolated cell populations (left yellow arrow) are present at the midline 
(dashed line) and no vessel connections are yet made (ENDOMUCIN staining, right yellow 
arrow). Lymphatics also display isolated LEC clusters at flanks (NRP2 staining). 
B) At 13.5 dpc blood vessel sprouts (ENDOMUCIN staining) are reaching the midline and 
have started to make connections (yellow arrows). Lymphatic vessels (NRP2 staining) 
follow the direction of blood vessel growth, from flank to midline. 
C) At 14.5 dpc the blood vasculature (ENDOMUCIN staining) has commenced to remodel 
into looped structures (dashed box). The lymphatic vessels (NRP2 staining) have not 
reached the midline yet at this stage to form connections.  
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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In addition, large-diameter vessel branches, stretching from the flank towards the midline 
[Fig.4.3A white box ENDOMUCIN staining], arose at these later embryonic stages (15.5, 
16.5 and 17.5 dpc) [Fig.4.3].  
Lymphatic vessels were localised in a manner consistent with migration in the same 
direction as observed for blood vessels, from flank to midline [Fig.4.2-4.3, NRP2 staining]. 
In contrast to blood vessels, the first connections of migratory lymphatic vessel fronts were 
made at the midline around 16.5 dpc [Fig.4.3B]. 
 
Next, vascular remodelling was investigated by quantifying several vessel parameters as 
proxy read-outs for active remodelling (Shayan et al., 2007), including number of branch 
points, number and size of vessel loops, the distance from the leading vessel tip to the 
midline, and vessel width [Fig.4.4]. 
Branch points were defined as vessel connections with two or more bifurcations. Vessel 
loops were accounted for as vessels that have formed circular structures [Fig.4.4]. The 
size of vessel loops was measured over the longitudinal axis of the loop. By way of 
comparison between flank and midline during vessel remodelling, the size of vessel loops 
and vessel width were measured at both the flank side and the midline [Fig.4.4]. 
The blood vessel parameters were first analysed [Fig.4.5-4.8] and are described in the 
next section. In absence of an n=3 tissue sample collection for 17.5 dpc embryos, this time 
point was left out for quantification analyses. 
 
4.2.2 Analysis of blood vessel remodelling 
Upon closer examination, isolated blood endothelial cell populations were observed in the 
midline region [Fig.4.5A yellow arrows]. These cell clusters showed a high occurrence at 
12.5 dpc, with on average 42 cell populations present [Fig.4.5A yellow arrows and 
Fig.4.8A]. Subsequently, a significant decrease was noticeable at 13.5 dpc and no 
isolated cell populations observed from 14.5 dpc onwards [Fig.4.8A]. These observations 
were in concert with a decrease in distance toward the midline [Fig.4.5, Fig.4.6 and 
Fig.4.8B] as vessels continued to remodel and form connections at the midline. 
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Figure 4.3 Time course of late embryonic vascular development 
A-C) Immunofluorescence staining on embryonic skin samples against blood vascular 
endothelial marker ENDOMUCIN, lymphatic-specific marker NEUROPILIN 2 (NRP2) and 
nuclear lymphatic marker PROX1.  
A) At 15.5 dpc the blood vasculature has completely remodelled into loops and the 
primary plexus at the flanks (dashed box) has formed large tree-like vascular branches 
(ENDOMUCIN staining).  
B) At 16.5 dpc lymphatic vessels (NRP2 staining) have made their first connection at the 
midline. 
C) At 17.5 dpc mainly the lymphatic vessels (NRP2 staining) appear to have further 
sprouted and remodelled. 
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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Figure 4.4 Model for vessel parameter analysis 
Vessel parameters are measured in Image J with the Lymphatic Vessel Analysis plug-in 
(Shayan et al., 2007). Branch points (B) are measured as connecting points of two or more 
bifurcations. Vessel loops are depicted as circular structures (L). The distance from a 
vessel tip to the midline is measured (D) as well as the width of a vessel in the midline 
region compared to the flank (V).  
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Whilst the blood vascular network was gradually expanding, the size of vessel loops 
decreased at both the midline and flank region [Fig.4.5, Fig.4.6 and Fig.4.8C]. At the 
midline, loop size decreased with more than 50% from 14.5 dpc onwards compared to 
13.5 dpc. There were no loops formed yet at the midline at 12.5 dpc [Fig.4.8C]. 
Furthermore, the vessel width decreased over time showing no difference between flank 
and midline [Fig.4.8D]. These observations are suggestive of a uniform formation of a 
dense blood vascular network from flank to flank. 
Further analyses revealed that the primitive blood capillary plexus at the flanks had 
changed over time into large tree-like structures with multiple bifurcations [Fig.4.6A yellow 
arrow and Fig.4.7 yellow arrows]. The major blood vessel branches were first observed at 
13.5 dpc [Fig.4.7 and Fig.4.8E] and increased in number by 15.5 dpc [Fig.4.7 yellow 
arrows and Fig.4.8E]. As the embryo continued to grow and vessel remodelling 
proceeded, these branches decreased in number at 16.5 dpc [Fig.4.7 yellow arrows and 
Fig.4.8E]. It is speculated that the individual tree-like structures have subsequently 
remodelled into one or two main branches that are consisting of multiple sub-branches, 
thereby making way for thorough perfusion of the skin.   
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Figure 4.5 Dermal blood vascular development during early embryogenesis 
A-C) Immunofluorescence staining against blood vascular endothelial marker 
ENDOMUCIN. 
A) At 12.5 dpc isolated cell populations (yellow arrows) are observed at the midline. 
B) At 13.5 dpc blood vessel sprouts migrate from flank to midline. 
C) At 14.5 dpc the blood vasculature remodels into looped structures at both the flank and 
midline.  
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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Figure 4.6 Dermal blood vascular development during late embryogenesis 
A-C) Immunofluorescence staining against blood vascular endothelial marker 
ENDOMUCIN. 
A) At 15.5 dpc the blood vasculature has formed loops and large blood vascular branches 
are starting to emerge (yellow arrow). 
B) At 16.5 dpc and C) 17.5 dpc more tree-like vascular branches have formed and the 
blood vessels have remodelled into a dense network of loops.  
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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Figure 4.7 The formation of large blood vascular branches over time 
ENDOMUCIN immunofluorescence staining on Tg(Prox1-EGFP) mouse embryonic skin at 
12.5, 13.5, 14.5, 15.5 and 16.5 dpc to depict the gradual formation of large blood vascular 
branches at the flanks (yellow arrows). High-resolution confocal image at 10x 
magnification, tiled. 
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Figure 4.8 Quantification of blood vessel parameters 
A) Counts of isolated cell populations in the midline (n=3 animals). 
B) Measurement of the distance from a leading tip cell to the midline (n=3 animals). 
C) Measurement of the vessel loop size, midline versus flank (n=3 animals, with 10 
loops/animal at the midline and 10 loops/animal at the flank measured). 
D) Quantification of the vessel width, midline versus flank (n=3 animals, with 25 
vessels/animal at the midline and 25 vessels/animal at the flank measured). 
E) Quantification of tree-like vascular branches at the flanks (n=3 animals). 
Error bars= ± S.E.M.  
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To further investigate vessel pruning, the dermal blood vessels were labelled with the 
blood vascular endothelial marker ENDOMUCIN and extracellular matrix marker 
COLLAGEN type IV [Fig.4.9-4.10]. Recent studies have reported that empty matrix 
sleeves, immuno-positive for Collagen IV but negative for a selective vascular endothelial 
marker, are suggestive of vessel pruning (Baluk et al., 2007; Ehling et al., 2013).  In the 
present study, for quantitative analyses the number of regression events was counted as 
observed by COLLAGEN IV+/ENDOMUCIN- matrix sleeves [Fig.4.9-4.10 white arrows].  
At 12.5 dpc [Fig.4.9A-A’ white arrows] and 13.5 dpc [Fig.4.9B-B’ white arrows], fewer 
than 50 regression events were observed [Fig.4.10C].  However, at 14.5 dpc a significant 
increase in vessel pruning took place where a peak of 122 regression events was reached 
[Fig.4.9C-C’ white arrows and Fig.4.10C]. As remodelling of the blood vasculature into a 
dense network rapidly evolved at 15.5 dpc [Fig.4.10A-A’] and 16.5 dpc [Fig.4.10B-B’], 
vascular regression decreased [Fig.4.10C], hitting an average of 30 events by 16.5 dpc 
[Fig.4.10C].  
 
In order to summarize the morphological events observed during dermal blood vascular 
development, a model was created for each event and plotted in a graph [Fig.4.11]. Three 
major processes were distinguished during embryonic development: 1) vessel sprout 
migration, 2) vessel remodelling into loops and 3) vessel pruning. A high occurrence of 
migration events was observed at 12.5 dpc and a subsequent decrease as embryonic 
development progressed. Vessel remodelling into loops was low at 12.5 dpc but reached a 
peak at 15.5 dpc onwards. Furthermore, vessel pruning was predominantly observed at 
14.5 dpc.  
 
Taken together, this model simulates that blood vascular endothelial cells are highly 
migratory at early embryonic stages (12.5 dpc) and undergo little remodelling into loops 
and vessel pruning. As sprouts have reached the midline at 13.5 dpc to make inter-
vascular connections, major morphological changes take place from here onwards where 
vessels remodel into looped structures accompanied by the necessary pruning. At 14.5 
dpc both remodelling and pruning events are taking place at high rates. Later during 
embryonic stages (15.5 and 16.5 dpc), little pruning takes place as remodelling reaches a 
plateau [Fig.4.11]. 
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Figure 4.9 Regression events at early embryonic stages 
A-C) Immunofluorescence staining against blood vascular endothelial marker 
ENDOMUCIN and extracellular matrix marker (the basement membrane) COLLAGEN IV. 
Regression events are indicated by white arrows at  
A-A’) 12.5 dpc, B-B’) 13.5 dpc and C-C’) 14.5 dpc, as observed as COLLAGEN 
IV+/ENDOMUCIN- matrix sleeves. 
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled. A’, B’ and 
C’ are blow-ups of A, B and C respectively. 
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Figure 4.10 Regression events at late embryonic stages 
A-B) Immunofluorescence staining against blood vascular endothelial marker 
ENDOMUCIN and extracellular matrix marker (the basement membrane) COLLAGEN IV. 
Regression events are depicted as white arrows at  
A-A’) 15.5 dpc and B-B’) 16.5 dpc (n=2 animals). 
C) Quantification of regression events for each time point.  
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled. A’ and B’ 
are blow-ups of A and B respectively. Error bars= ± S.E.M.  
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Figure 4.11 Model for dermal blood vessel development 
During mouse embryonic development, three major events can be distinguished: 1) vessel 
sprout migration, 2) vessel remodelling into loops and 3) vessel pruning. In order to place 
these events in context, a number (y-axis) was assigned to each time point (x-axis) and 
plotted in a graph. Number designation 2= high occurrence, 1.5= moderate, 1= low, 0.5= 
very low, 0= none.  
  
	   	   Chapter 4 
	   183	  
4.2.3 Analysis of lymphatic vessel remodelling 
Next, lymphatic vessels were labelled with NRP2 and vessel parameters analysed in order 
to examine lymphatic vessel remodelling over time [Fig.4.12-4.15]. Similar to the blood 
vascular quantifications, these parameters included the number of branch points, number 
and size of vessel loops, the distance from the leading vessel tip to the midline, and vessel 
width [Fig.4.15]. 
At 12.5 dpc and 13.5 dpc NRP2 labelling of lymphatic vessels revealed isolated LEC 
populations near the midline and flanks [Fig.4.12A yellow arrows and Fig.4.14]. These 
individual clusters of LECs displayed active protruding filopodia [Fig.4.14i-i’].  
Some clusters appeared to be closely associated with nearby blood vessels [Fig.4.14ii 
upper white box], whereas others were present on their own [Fig.4.14ii lower white box]. 
The presence of these LEC clusters was prominent at 13.5 dpc [Fig.4.15A], with the 
majority observed along the region of the midline [Fig.4.14ii]. 
Similar observations of isolated LEC populations were previously made by Stapor et al. 
(Stapor et al., 2013). They investigated by cell tracing experiments whether these cell 
clusters formed components of a larger incomplete, yet to develop, network. They 
provided evidence that these vascular islands are well equipped to connect to nearby 
growing vascular networks.  
 
Lymphatic vessels displayed furthermore a gradual increase in number of branch points 
and loops as embryonic development progressed [Fig.4.12-4.13 and Fig.4.15B], reaching 
a peak of over 1000 branch points at 15.5 dpc [Fig.4.13B]. At this time point, ±427 loops 
had been formed [Fig.4.15B]. In contrast to blood vessels [Fig.4.8C], lymphatics displayed 
no loops at the midline early during embryonic development at 12.5 through to 14.5 dpc 
[Fig.4.12 and Fig.4.15C]. The first couple of loops appeared later at 15.5 dpc [Fig.4.13A, 
Fig.4.3A NRP2 staining, and Fig.4.15C].  
Presumably, the absence of loops between 12.5 and 14.5 dpc at the midline are 
attributable to the fact that vessels were still migrating toward the midline at early time 
points. Consequently, vessel connections at the midline were just starting to be made 
much later at 16.5 dpc [Fig.4.13B and Fig.4.3B NRP2 staining], in contrast to the blood 
vessels [Fig.4.8C]. This was also reflected in the descending trend of distance toward the 
midline [Fig.4.15D], which did not reach zero by 16.5 dpc, unlike blood vessels [Fig.4.8C]. 
This suggests that not all vessel fronts have yet anastomosed at the midline at this time 
point. It is hypothesized these vessel fronts, which have not anastomosed at the midline, 
are blind-ended lymphatic capillaries. 
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Taken together, these results suggest that lymphatic network remodelling into loops was 
not uniform from flank to flank as observed with blood vessels. Rather, the lymphatic 
vascular network displayed predominantly migrating vessel fronts toward the midline and 
loop formation only at flanks between 12.5 and 14.5 dpc. Notably, blood vascular loops 
displayed a decreasing trend in size over time at the midline and flank [Fig.4.8C], while 
lymphatics showed an increasing trend [Fig.4.15B]. These observations suggest that the 
lymphatic vasculature remodels into a less dense network, with larger loops, in 
comparison to blood vessels.  
 
Furthermore, between 13.5 and 16.5 dpc an increase in vessel diameter at the flanks was 
observed [Fig.4.15D], whereas vessel sprouts at the midline appeared to become wider at 
later stages, from 15.5 dpc onwards. These observations may suggest that vessel fronts at 
the midline consist of elongated and migratory endothelial cells between 12.5 and 14.5 
dpc prior to undergoing vessel-remodelling events into loops at 15.5 dpc.  
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Figure 4.12 Dermal lymphatic vascular development during early embryogenesis 
A-C) Immunofluorescence staining against lymphatic vascular endothelial marker NRP2. 
A) At 12.5 dpc isolated LEC populations (yellow arrows) are observed at the midline. 
B) At 13.5 dpc and C) 14.5 dpc lymphatic vessel sprouts migrate from flank to midline and 
looped structures are starting to form at flanks. 
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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Figure 4.13 Dermal lymphatic vascular development during late embryogenesis 
A-C) Immunofluorescence staining against NRP2 at 15.5, 16.5 and 17.5 dpc. 
A) At 15.5 dpc the lymphatic network undergoes vascular remodelling into loops while still 
migrating toward the midline. 
B) At 16.5 dpc and C) 17.5 dpc vessel sprouts have reached the midline and subsequent 
remodelling into loops continues. 
High-resolution confocal images at 20x magnification with 2x optical zoom, tiled.  
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Figure 4.14 Identification of isolated LEC populations 
i-ii’) High-resolution confocal images of isolated LEC clusters at 12.5 and 13.5 dpc, 
showing blood vessels in red (ENDOMUCIN), lymphatic vessels in green (NRP2) and LEC 
nuclei in blue (PROX1).  
i) Embryonic skin at 12.5 dpc displaying single LEC populations not yet connected to the 
vascular network (white box). Image was taken at 10x magnification with 2x optical zoom. 
i’) These isolated LEC clusters displayed filopodial protrusions and multiple nuclei (40x 
magnification with 2x optical zoom). 
ii-ii’) At 13.5 dpc some clusters were identified to be closely associated with blood vessels 
(upper white box and cropped image in ii’), whereas others were present on their own 
(lower white box and cropped image in ii’). 
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Figure 4.15 Quantification of lymphatic vessel parameters 
A) Counts of isolated LEC clusters observed in midline and flanks (n=3 animals). 
B) Quantification of the number of branch points and loops per 1 square meter (n=3 
animals). 
C) Quantification of vessel loop size, midline versus flank (n=3 animals, with 10 
loops/animal at the midline and 10 loops/animal at the flanks measured). 
D) Measurement of the distance from a leading tip cell to the midline (n=3 animals).  
E) Quantification of the vessel width, midline versus flank (n=3 animals, with 25 
vessels/animal at the midline and 25 vessels/animal at the flank measured). 
Error bars= ± S.E.M.  
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4.2.4 Polarity of LEC nuclei 
To take a closer look at these migrating vessel fronts, first the number of nuclei per 100 
µm vessel front was quantified [Fig.4.16A-B]. An increase in number of nuclei per vessel 
front was observed over time [Fig.4.16B], suggestive of local cell proliferation or increased 
migration from the vessel rear to the vessel front.  
Next, the polarization of LECs in these migrating vessel fronts was investigated. In 
developing vessels, ECs orient in several axes to establish migratory polarity, apical-
basolateral polarity, and planar cell polarity. Migratory cell polarity was proven important 
for vessel formation and function in a retinal angiogenesis model as a loss of cell polarity 
resulted in loss of guided migration (Chappell et al., 2009; Gerhardt et al., 2003). Polarized 
migration of EC requires proper orientation of the Golgi apparatus and the microtubule-
organizing center (MTOC) (Gotlieb et al., 1981; Olsson et al., 2006). It is known that the 
Golgi apparatus is orientated toward the leading edge of a migratory cell and may function 
as an indicator of the disposition of the cell to move in that direction (Navarro et al., 2011).  
 
In order to study the polarization of migrating LECs, the position of the Golgi complex 
relative to the nucleus was assessed both in migrating cells facing the midline of the 
dissected skin flap or LECs at the flanks [Fig.4.16A and C]. A cell was considered 
polarized toward the midline, if the Golgi was located in a region that comprises a sector of 
90o or smaller relative to the nucleus [Fig.4.16C]. It was hypothesized that cells at the 
leading vessel fronts would at large display an orientation toward the midline, thus 
displaying angles smaller than 90o relative to the midline. Immunofluorescence labelling of 
Golph4, a Golgi resident protein, allowed the visualization of the position of this organelle 
relative to a given nucleus [Fig.4.16A]. Image J software was used as a tool to quantify 
angles of Golph4-immuno-positive Golgi relative to the nucleus (each data point 
represents one nucleus) [Fig.4.16C]. Frontal nuclei were considered those closest to the 
midline and distal nuclei those in the flank region.  
 
At 12.5 dpc, the majority of frontal nuclei showed an angle smaller than 90o, whereas distal 
nuclei showed an angle greater than 90o, suggestive that cells in migratory vessel fronts 
were oriented toward the midline and cells at the flanks away from the midline  
[Fig.4.16C].  In 13.5 dpc samples this distinction between frontal and distal nuclei 
orientation became more evident [Fig.4.16C]. At the following time points 14.5, 15.5 and 
16.5 dpc, the majority of both frontal and distal nuclei appeared to be oriented toward the 
midline [Fig.4.16C], in contrast to what was expected.  
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Finally, a model for lymphatic morphological events was generated as described in 
Section 4.2.3 for blood vessels.   
This analysis showed that LECs are highly migratory between 12.5 and 14.5 dpc 
[Fig.4.17]. In addition, this model simulated that, in contrast to blood vessels, LECs 
migrate at the same time as they remodel into loops (12.5 through to 14.5 dpc) [Fig.4.17]. 
These remodelling events were mainly observed at flanks only whilst leading vessel fronts 
were migrating toward the midline, as described previously. At later embryonic stages, 
15.5 and 16.5 dpc, mainly remodelling events were taking place. COLLAGEN type IV 
staining was also performed on lymphatic vessels to investigate vessel pruning, however 
the staining did not work and no conclusive answers could be obtained. 
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Figure 4.16 Lymphatic nuclei polarization analyses 
A) High-resolution confocal image of a vessel tip at 40x magnification with 2x optical 
zoom, tiled. Immunofluorescence labelling of Golph4 was performed to visualise the 
position of the Golgi complex (yellow arrow) in a given nucleus (N) (white box). Frontal 
nuclei quantified were positioned near the midline and distal nuclei in the flank region. The 
distal region depicted here is at the rear end of a vessel sprout, but was not used for 
quantification purposes.  
B) Quantification of nuclei per 100 µm vessel front (n=3 animals, with 10 vessels/animal at 
the midline measured). Error bars= ± S.E.M.  
C) Quantification of Golgi angles relative to the nucleus with Image J software. Each data 
point represents one nucleus. Angles smaller than 90o were considered a nucleus to be 
oriented toward the midline. For statistical analysis, Student’s t-test was performed 
(∗∗P<0.001 ), comparing frontal versus distal nuclei of the respective time points. 12.5 dpc 
(P=0.22), 13.5 dpc (∗∗∗P=0.0009), 14.5 dpc (P=0.68), 15.5 dpc (P=0.87) and 16.5 dpc 
(P=0.11). 
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Figure 4.17 Model for dermal lymphatic vessel development 
Similar to blood vessels, a number (y-axis) was assigned to each time point (x-axis) and 
plotted in a graph. Number designation 2= high occurrence, 1.5= moderate, 1= low, 0.5= 
very low, 0= none.  
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4.3 Concluding Remarks 
Previous retinal angiogenesis models have given great insight into the cellular 
mechanisms of vascular branching and established the importance of cell polarity for 
guided migration (Chappell et al., 2009; Gerhardt et al., 2003). However lymphatic vessels 
are absent in the retinal model. This current skin assay therefore has opened up the 
greater possibility to not only study blood vessel development, but also lymphangiogenesis 
at the same time using the same model.  
Key findings suggest that the blood vasculature remodels into a much denser network of 
loops in contrast to the lymphatic vasculature. This dense blood vascular network may be 
reflective of the important function blood vessels carry to provide liquids, nutrients and 
gases to all tissues of the organism via thorough perfusion; the lymphatic vasculature 
mainly functions as collecting vessels of metabolic waste products from the blood 
circulatory system and thus may require a less dense network of vessels. Blood vessel 
loops and vessel widths became smaller over time and a complete inter-connected 
network was established by 15.5 dpc. Lymphatics on the other hand just made their first 
connections at the midline at this time point. Given the observations that there are still 
vessels present at 16.5 dpc, which have not anastomosed, it is speculated that these 
vessels will remain disconnected and continue to function as blind-ended lymphatic 
capillaries. 
 
The identification of isolated LEC clusters is so far still a mystery with regards to their 
origin. Whether they arise directly from the blood vasculature or emerge as independent 
clusters as a result of local cues, is yet to be elucidated. In addition, whether lumenized 
mature, blood vessels may also play a role in the locality of emerging LEC clusters is still 
unclear, as some clusters are closely associated to blood vessels whereas others are 
observed as independent populations. Further work is required to unveil which cues are 
secreted and necessary prior to becoming an intact vascular network. It is postulated that 
local cell proliferation and migration makes way for these vascular islands to grow and 
connect to their neighbouring counterparts. In a previous rat mesentery assay, the 
presence of disconnected endothelial segments under unstimulated conditions, identified 
as vascular islands, has also been reported. Cell tracking of endothelial cell dynamics 
through time-lapse imaging has revealed that during angiogenesis, these vascular islands 
are able to connect to existing networks. They have been associated with proliferation and 
appear to decrease in number as the network size increases (Kelly-Goss et al., 2012; 
Stapor et al., 2013), in support of the findings in this skin assay.  
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Finally, LEC nuclei at both flank and midline are mainly oriented toward the midline from 
14.5 dpc onwards as depicted by angle measurements smaller than 90o. These results 
may suggest a vessel sprouting mechanism during these time points at both flank and 
midline. However it is postulated that at flanks mainly circumferential vessel growth is 
taking place through vessel dilation, considering the gradual increase in vessel widths 
from 13.5 dpc at flanks; and predominantly a sprouting mechanism of vessels at the 
migratory front during early time points (12.5, 13.5 and 14.5 dpc). It is speculated that at 
these time points the vessels are differentiating into collecting and capillary vessels.  
 
Having laid the foundation that this skin assay is a useful tool to study blood and lymphatic 
vessel development, subsequent phenotypic analyses have been performed in an Arap3 
knock-out mouse model using this technique. The findings have been described in the 
next chapter. 
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Arap3 regulates lymphatic vessel 
development downstream of Vegfc 
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5.1 Summary of previous studies of Arap3 in mice 
This present study discovered arap3a as an essential lymphatic modulator in zebrafish 
embryos. Knock-down caused reduced precursor LECs to migrate from the vein and 
subsequently a defective thoracic duct development. To investigate whether this function 
was conserved among species, the mouse model was next used. 
Previous studies in mice showed an important role for Arap3 in angiogenesis 
(Gambardella et al., 2010), but lymphatic vessels were not examined. Arap3-/- mice 
showed severe blood vascular defects and were embryonic lethal by 11 dpc. Moreover, 
blood endothelial loss of Arap3 function (Arap3fl/-Tie2Cre+) triggered a phenotype 
reminiscent of that observed in Arap3-null mice, indicating an EC-autonomous function for 
Arap3 (Gambardella et al., 2010). This suggests that only the genotypically mutant cells 
showed the mutant phenotype. 
The generation of Arap3 conditional knockout mice has been described in detail elsewhere 
(Gambardella et al., 2010). Briefly, a loxP sequence was inserted into the intron between 
exons 5 and 6 through recombineering [Fig.5.2]. This caused a deletion of a BsmI site and 
the addition of a new BamHI site. Subsequently, a FRT-flanked Neo cassette with an 
adjacent loxP sequence (M. Turner, The Babraham Institute) was inserted between Arap3 
exons 8 and 9 and a self-excising, floxed 3.8 kb Neo cassette between exons 3 and 4 of 
Arap3.  
Conditional knock-out chimeras were then mated with females expressing FlpE in the 
germ-line to produce founders that lacked the Neo cassette, and subsequently bred with 
germ-line Cre deletor mice to produce Arap3+/- animals. Next, in order to generate tissue-
specific knock-outs, Arap3fl/- mice were bred with Tie2Cre transgenic mice. This was done 
to achieve complete deletion of Arap3, as an inbred with Arap3fl/fl mice did not produce 
complete deletion of Arap3 as confirmed by genotyping and Western blotting 
(Gambardella et al., 2010). 
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5.2 Results 
5.2.1 Arap3 is cell-autonomously required for development of the dermal lymphatic 
vasculature in mice 
In order to investigate a potential function of Arap3 during lymphangiogenesis in mice, 
Arap3 expression pattern was first examined in wild-type mouse embryos at 11.5 dpc by in 
situ hybridization (ISH). LEC precursors, that actively sprouted from the dorso-lateral walls 
of the cardinal veins in response to Vegfc (Wigle and Oliver, 1999), expressed Arap3 as 
observed by co-staining with PROX1 [Fig.5.1i–ii], suggestive of a role during early 
lymphangiogenesis.  
 
5.2.2 Generating an inducible Arap3 mouse knockout in lymphatic endothelial cells 
To specifically disrupt Arap3 function at the initial stage of lymphangiogenesis, an 
inducible Cre line, Sox18CreERT+/- (McMahon et al., 2008), was utilized which enabled 
temporal induction of Cre activity in ECs, including in the precursor LEC compartment. 
The efficacy of Cre-mediated excision using this line was validated by crossing with 
Rosa26R Cre reporter mice (Soriano, 1999) [Fig.5.3] to generate Sox18GCE/+; R26RLacZ/+ 
embryos. In this instance, the ROSA strain of mice contained reporter genes (β-
galactosidase) that function as molecular tags for the transcription of Sox18 (Reviewed in 
Doyle et al., 2012). β-gal reporter expression was activated upon Tamoxifen injection and 
littermates were harvested at 10.5dpc [Fig.5.3i] and 14.5 dpc [Fig.5.3ii-iv] respectively 
and stained with X-gal to assay for β-gal activity in Sox18-expressing cells. The 
expression of X-gal in these embryos, following Tamoxifen injections, confirmed the 
presence of Sox18 transcriptional activity in these Sox18CreERT+/- mice [Fig.5.3].   
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Figure 5.1 Arap3 expression in migrating LECs 
i) Cross sections of 11.5 dpc wild-type embryos showing enriched Arap3 mRNA 
expression in mouse LEC precursors that migrate from the dorso-lateral wall of the 
cardinal vein (white arrowheads).  
ii) PROX1 co-localizes with Arap3 in these migrating LEC precursors 
(immunofluorescence blue staining).  
Staining performed by Emmanuelle Frampton. 
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To assess whether conditional deletion of the Arap3 gene in LECs would cause lymphatic 
defects, Sox18CreERT+/-;Arap3fl/fl homozygous mice were generated. Tamoxifen was 
administered intraperitoneally to pregnant females on three consecutive days (11.5, 12.5 
and 13.5 dpc) in order to induce efficient excision of exon 6–8 of Arap3.  
Sox18CreERT2+/-Arap3fl/fl littermates were then harvested at 14.5 dpc and genotyped for the 
presence of flanking loxP sites at the Arap3 locus by PCR [Fig.5.4A]. An upper band 
depicted loxP sites flanked on two Arap3 alleles (hom, homozygous), double bands 
represented one floxed allele (het, heterozygous) and a lower band no Arap3 floxed alleles 
(wt, wild-type). Furthermore, Arap3 null mice were examined for Cre activity at the Arap3 
locus by genotyping for deletion of exons 6-8, detected as a 0.5 kb PCR product (arrow) 
[Fig.5.4B].  
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Figure 5.2 The generation of Arap3 conditional knockout mice 
Recombination of a loxP sequence into the intron between exons 5 and 6, causes a 
deletion of a BsmI site and the addition of a new BamHI site. Subsequently, a FRT-flanked 
Neo cassette with an adjacent loxP sequence (M. Turner, The Babraham Institute) is 
inserted between Arap3 exons 8 and 9, and a self-excising floxed 3.8 kb Neo cassette 
between exons 3 and 4 of Arap3 to create conditional knock-out chimeras.  
  
Chapter 5 
	   	   Chapter 4 
	   209	  
 
 
 
  
Chapter 5 
	   	   Chapter 4 
	   210	  
Figure 5.3 Arap3 tissue-restricted loss-of-function analysis in mouse embryos 
(i-iv) Sox18GCE/+ mice, containing the GFP-Cre-ERT2 cassette (GCE), crossed to 
Rosa26RacZ/+ (R26R) mice to generate Sox18GCE/+; R26RacZ/+ embryos. β-gal 
reporter expression is activated upon Tamoxifen injection. Littermates were harvested at 
(i) 10.5 dpc and (ii-iii) 14.5 dpc and stained with X-gal to assay for β-gal activity.  
(iv) Zoom-in of mouse skin tissue at 14.5 dpc displaying X-gal staining to assay for β-gal 
activity in Sox18 domains. Image taken by Mathias François.  
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Figure 5.4 Genotyping Arap3 conditional knock-out mice 
(A-B) Sox18CreERT2+/-Arap3fl/fl littermates are harvested at 14.5 dpc and genotyped for the 
presence of flanking loxP sites at the Arap3 locus by PCR. A) Hom= floxed on both alleles 
(upper band), het= floxed on one allele (double band) and wt= no Arap3 floxed alleles 
(lower band).  
B) Arap3 null mice are examined for Cre activity at the Arap3 locus by genotyping for 
deletion of exons 6-8, detected as a 0.5 kb PCR product (arrow). Annotations 1, 2 and 3 
refer to sample number 1, 2 and 3. Genotyping performed by Renae Skoczylas. 
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5.2.3 Phenotypic assessment of Arap3-conditional mouse knock-outs 
Following the conditional deletion of the Arap3 gene in LECs, phenotypic analyses were 
next performed. The gross morphology of Arap3 mutants at 14.5 dpc was normal 
compared with wild-type embryos [Fig.5.5i-ii]. As previously described, in mice dermal 
lymphatic vessels grow from each flank of the embryo towards the dorsal midline, 
subsequently forming a complete subcutaneous lymphatic vascular network (James et al., 
2013). The dermal lymphatic vasculature was examined in both wild-type embryos and 
homozygous Arap3 mutants at 14.5 dpc by immunofluorescence staining using antibodies 
directed against the blood vascular endothelial marker ENDOMUCIN, together with the 
lymphatic selective markers NEUROPILIN2 and PROX1 [Fig.5.5A-F].  
 
Wild-type mouse embryos showed remodelling of blood vasculature into loops [Fig.5.5A], 
as well as lymphatic vessels developing progressively towards the midline of the skin 
[Fig.5.5C]. Homozygous Sox18CreERT+/-;Arap3fl/fl mutants exhibited a blood vascular 
network that appeared improperly remodelled towards the midline of the skin where large 
loops and gaps between vessel branches were observed [Fig.5.5B]. 
In addition, homozygous Arap3 mutants displayed severely abnormal lymphatic vessels 
[Fig.5.5D]. Distance to midline of the lymphatic vascular network was increased in mutants 
compared with wild-type [Fig.5.5G]. The vessels that had formed were reduced in overall 
length, were increased in width [Fig.5.5H] and appeared bulbous in morphology [Fig.5.5E-
F]. These data suggest a role of Arap3 in the sprouting or migration of LECs that drives 
the outgrowth of lymphatic vessels during mouse embryonic development. 
 
The reproducibility of this phenotype was tested on three separate, developmentally 
matched wild-type embryos and their Arap3 mutant counterparts [Fig.5.6B-C]. 
Wholemount ENDOMUCIN immunofluorescence staining in embryonic blood vessels at 
14.5 dpc in wild-type embryos [Fig.5.6Bi-iii] and mutants [Fig.5.6Biv-vi] showed a clear 
contrast in development as mutants displayed incomplete remodelling at the midline in 
comparison to wild-type embryos. Moreover, the grossly dysmorphic phenotype of 
lymphatic vessels was apparent in all three mutants [Fig.5.6C iv-vi] compared to wild-
types [Fig.5.6Ci-iii] as visualized by the lymphatic- specific marker NRP2 at 14.5 dpc. 
These results suggest that conditional deletion of the Arap3 gene in LECs has a major 
impact on lymphatic vessel development at 14.5 dpc.  
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Figure 5.5 Arap3 regulates dermal lymphatic vessel development in mice cell-
autonomously  
(A–F) Whole mount immunofluorescence for pan-EC marker ENDOMUCIN (white), and 
lymphatic specific markers PROX1 (red) and NEUROPILIN2 (green) on 14.5 dpc 
embryonic skin.  
(A and B) The ENDOMUCIN-positive blood vasculature is disrupted at the midline, failing 
to correctly remodel in Arap3fl/fl embryos when compared with control littermates (n=3 
mouse dorsal skin mounts examined).  
(C and D) The lymphatic vasculature of Arap3 defloxed embryos is vastly reduced in 
embryonic skin compared with control littermates. Lymphatic vessels visualized using the 
marker NEUROPILIN2 (n=3 Arap3fl/fl mouse embryo).  
(E and F) High magnification imaging of lymphatic vessels in (E) wild-type and (F) Arap3fl/fl 
embryo at 14.5 dpc revealed severe morphogenic defects in lymphatic vessels of Arap3fl/fl 
embryos.  
(G–I) Quantitative analysis of vessel parameters shows an increased distance to midline 
(G), enlarged lymphatic vessels (H) and higher number of nuclei over the vessel length (I) 
in Arap3fl/fl embryos.  
Quantification was carried out on n=10 vessels per animal (n=4 wild-type animals and n=3 
mutant animals) in (G–I). Error bars indicate mean ± SEM. Scale bars indicate 100 µm in 
(A–F). 
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Figure 5.6 Analysis of developmentally matched wild type and Arap3fl/fl mutant 
embryos 
A) Tamoxifen (1.5 mg / 37.5 g mouse body weight) has been administered to females over 
3 consecutive days, 11.5, 12.5 and 13.5 dpc, to induce Cre activity and disrupt Arap3 gene 
function. At 14.5 dpc, pregnant females are sacrificed and pups dissected for further 
analysis. A flap of the embryonic skin was dissected for analysis of the sub-cutaneous 
lymphatic vasculature. 
(B) (i-vi) Wholemount immunofluorescence staining on embryonic skin dissections at 
14.5dpc, visualizing ENDOMUCIN in the blood vasculature of (iiii) wild type embryos and 
(iv-vi) mutants.  
(C) (i-vi) Sub-cutaneous lymphatic vessels are grossly dysmorphic in mutants (iv-vi) 
compared to wild types (i-iii) as visualized by the lymphatic-specific marker NEUROPILIN2 
at 14.5 dpc.  
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To assess whether initial sprouting of LECs from the cardinal vein was affected upon 
Arap3 deletion, homozygous Arap3 mutants were next characterized at 11.5 dpc after 
Tamoxifen treatment at 8.5, 9.5 and 10.5 dpc [Fig.5.7A–D]. Mutant embryos were grossly 
normal [Fig.5.7ii] and displayed normal expression of PROX1 in the cardinal vein 
[Fig.5.7B and D]. Furthermore, Arap3 mutants had initiated superficial LECs (sLEC) 
sprouting from the peripheral longitudinal lymphatic vessel (PLLV) at this stage [Fig.5.7A-
B’]. Together these observations suggest that Arap3 is not required for specification or the 
earliest sprouting events but for the progression of subcutaneous lymphangiogenesis 
between 11.5 and 14.5 dpc, which involves extensive migration, proliferation and 
remodelling of the network. 
 
5.2.4 ARAP3 is required for VEGFC-induced LEC migration in vitro 
To further characterize the cellular role of ARAP3 in vitro, a RNA interference (RNAi) 
knock-down strategy of ARAP3 was performed in cultured primary human LECs (hLECs). 
Here, the translation of ARAP3 was prevented by selective degradation of its encoded 
mRNA. Subsequently the response of cell migration was examined following VEGFC 
stimulation utilizing scratch as well as transwell migration assays.  
 
In scratch assays, the creation of an artificial gap, a so-called “scratch”, on a confluent cell 
monolayer, will cause cells on the edge of the created gap to move toward the opening in 
order to close the scratch until new cell-cell contacts are established again (Liang et al., 
2007). Manipulation of culture conditions, for example treatment with siRNA or growth 
factor stimulation, allows for the examination of the effect on the migratory cell behavior.  
Where this method studies the migration ability of cells, the transwell migration assay 
looks at the ability of cells to invade a cell-permeable membrane in vitro. Most common 
assays use a Boyden assay system. Plastic inserts, possessing a cell-permeable 
membrane, are placed in multi-well tissue culture plates creating a two-chamber system 
separated by the cell-permeable membrane. To create an invasion assay the pores in the 
membrane are blocked with a gel composed of extracellular matrix that is   
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Figure 5.7 Arap3 is not required for superficial LEC specification  
(i) Wild type and (ii) Sox18CreERT2+/-Arap3fl/fl homozygous mutant embryos at 
11.5 dpc display normal gross morphology. 
(A–D) Whole mount immunostaining of 11.5 dpc control and Arap3fl/fl ECKO mouse 
embryos for PROX1 (red) and ENDOMUCIN (blue). Specification of PROX1-positive LEC 
progenitors in the cardinal vein is not impaired in Arap3fl/fl.  Scale bars indicate 100 mm in 
(A–D). 
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meant to mimic the typical matrices that tumour cells encounter during the invasion 
process in vivo. By placing the cells on one side of the gel and a chemoattractant on the 
other side, invasion is determined by counting those cells that have crossed through the 
cell-permeable membrane, towards the higher concentration of chemoattractant (Marshall, 
2011).  
Here, both the migratory as well as the invasive cellular behaviors were assessed upon 
RNAi ARAP3 knock-down in hLECs. A knock-down efficiency of approximately 80% was 
achieved 24 and 48 hours following ARAP3 siRNA treatment of hLECs, as measured by 
Q-PCR [Fig.5.8]. The response of cells to VEGFC, during collective cell migration 
(measured by scratch assays) [Fig.5.9A] and chemotactic, single cell migration (measured 
in transwell assays) [Fig.5.9B] was significantly reduced following ARAP3 knock-down in 
hLECs. These results suggest that both the migratory as well as the invasive character of 
cells was affected in absence of ARAP3.  
 
To further investigate whether this effect was a result of defective cell polarity, junctional 
integrity or defective cell morphology, immunostaining was performed on hLECs post-
scratch assay with 1) Phalloidin, a filamentous actin marker, to investigate overall cell 
morphology; 2) VE-CADHERIN, a cell–cell adhesion marker, to examine potential 
compromised junctional integrity; and 3) GM130, a Golgi marker, to investigate cell 
polarity. No striking differences were observed between treatments [Fig.5.10A-D]. Overall 
cell morphology and cell polarity seemed normal and cell junctions intact in ARAP3 siRNA-
treated conditions compared to controls, suggestive that these processes are independent 
of ARAP3 expression.  
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Figure 5.8 Validation of ARAP3 siRNA knock-down in LECs 
Real-time PCR analysis validating ARAP3 mRNA knock-down in LECs at 24 and 48 h. 
Experiment performed by Jan Kazenwadel. 
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Figure 5.9 ARAP3 knock-down in cultured LECs inhibits cell migration 
A) Quantitative analysis of individual cell migration in standard transwell migration assays. 
ARAP3 siRNA-treated HMVEC-dLyAd display significantly reduced migration in response 
to VEGFC compared with control siRNA-treated cells. Error bars indicate mean ± SD. P-
values were calculated using Student’s paired t-test. ∗∗∗P< 0.001, n=12. n.s, non-
significant.  
B) Quantitative analysis of collective distance migrated by HMVEC-dLyAdin standard 
scratch assays. Migration of ARAP3 siRNA-treated HMVEC-dLyAd in response to VEGFC 
is significantly reduced compared with control siRNA-treated cells. Error bars represent 
mean ± SEM. P-values were calculated 
using Student’s paired t-test. ∗∗P<0.005, n=3. Experiment performed by Jan Kazenwadel.  
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Figure 5.10 Cell morphology analysis in ARAP3 siRNA-treated LECs  
(A–D) Representative images of control and ARAP3 siRNA-treated LECs in response to 
VEGFC. Immunofluorescence for the golgi marker GM130, the vascular marker VE-
CADHERIN and the cytoskeleton marker Phalloidin reveals that cell shape and cell polarity 
is not affected by ARAP3 knock-down. Experiment performed by Jan Kazenwadel.  
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Next, VEGFC-mediated proliferation of cells was measured in control and ARAP3 siRNA-
treated hLECs in order to investigate whether ARAP3 may regulate cell proliferation. 
Results showed that VEGFC-mediated proliferation was unaltered upon ARAP3 knock-
down [Fig.5.11], thus suggesting that cell proliferation is not regulated by ARAP3. 
To further examine whether the behaviour of LECs was conserved in three- dimension 
(3D) upon ARAP3 depletion, a 3D spheroid model was used [Fig.5.12]. 3D cellular 
spheroid models are considered more realistic models of tumors and healthy tissues 
compared to 2D culture systems, improving the reliability and physiological significance of 
cell-based assays (Ansari et al., 2013). A significant reduction was observed in spheroid 
sprout number formation in response to VEGFC in ARAP3 siRNA-treated cells compared 
with controls [Fig.5.12C]. Together, these results demonstrate that Arap3 plays a specific 
role in LEC sprouting and migration.  
 
5.2.5 Arap3 functions independently of Sox18 or VegfC signalling 
Thus far, cellular functions of Arap3 have been described in three different model systems, 
the zebrafish and mouse models and cell-based assays. In order to understand this role 
mechanistically, signalling pathways were explored that are important for 
lymphangiogenesis.     
Firstly, it was examined whether arap3a is regulated by sox18 in zebrafish. Analysis of 
arap3a expression was performed in sox18/sox7 double morphants at 21 ss and revealed 
normal vascular expression compared with uninjected controls [Fig.5.13i–ii]. In addition, 
normal expression of sox18 was observed at 24 hpf in arap3a morphants [Fig.5.13v–vi].  
Further analysis of Arap3 expression in homozygous Sox18 mutant mouse embryos, 
RaOp-/-, showed normal expression in various endothelial beds such as veins, arteries or 
endocardium that normally express Sox18 at that stage   
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Figure 5.11 ARAP3 does not regulate LEC proliferation 
Cell proliferation assessment in human LECs, treated with control siRNA and 
ARAP3 siRNA in full media or base media containing 200ng/mL VEGFC. VEGFC-
mediated proliferation is not diminished by ARAP3 knockdown. Experiment performed by 
Jan Kazenwadel. 
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Figure 5.12 3D Spheroid assay 
(A and B) ARAP3 siRNA-treated spheroids show reduced sprout formation in response to 
VEGFC.  
C) Quantitative analysis of spheroid sprout number in control and ARAP3 siRNA-treated 
LEC spheroids in response to VEGFC. Data represent three independent experiments; 
20–30 spheroids were counted per treatment per experiment. Error bars indicate mean ± 
SEM. For statistical analysis, Student’s t-test was performed (∗P<0.01). Experiment 
performed by Kelly Betterman. 
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(11.5 dpc) [Fig.5.14i-ii, black arrowheads]. In addition, human umbilical vein endothelial 
cells (HUVECs) treated with VEGFC with or without SOX18RaOp protein showed no 
significant changes in ARAP3 transcripts levels [Fig.5.15A-B].  
Finally, to determine whether the Vegf or Vegfc/Vegfr3 signalling pathways regulate 
arap3a expression, the expression of arap3a was examined in morphant embryos 
depleted of phospholipase c-gamma (plc-gamma), a downstream effector of Vegf (Lawson 
et al., 2003), and mutant for vegfr3 (Hogan et al., 2009b) at the 20 somite stage. No 
changes in arap3a transcript expression were found [Fig.5.13iii and iv]. Together, these 
data indicate that while Arap3 is downregulated in RaOp+/- lymphatic vessels, Arap3 
transcription is not directly regulated by Sox18 or Vegfc. 
 
5.2.6 Arap3a depletion partially suppresses vegfc-mediated venous angiogenesis 
in zebrafish 
Next it was examined in vivo whether arap3a may act as a downstream component of the 
Vegfc/Vegfr3 signalling pathway by performing Vegfc gain-of-function epistasis studies. 
Using a heatshock-inducible vegfc zebrafish transgenic line Tg(hsp70l:Gal4;4XUAS:vegfc) 
crossed onto the nuclear EGFP-expressing Tg(fli1a:nlsEGFP) background, vegfc was 
systemically over-expressed at selected time points during development (e.g. 28 hpf and 
again at 48 hpf).  
 
In the Gal4/4xUAS based transactivation system, the Gal4 transcriptional transactivator 
will activate expression of transgenes placed downstream of its unique UAS (upstream 
activating sequence). On their own, no transcriptional activation takes place, but when 
they are expressed in the same cells, the target transgenes are activated by Gal4 
homodimers that bind to four tandemly repeated UASs placed immediately upstream of a 
minimal promoter (TATA) (Lewandoski, 2001; Luan et al., 2006). This system was used to 
generate a zebrafish transgenic line where heatshock induction would trigger Gal4/4xUAS 
(Scheer et al., 2001) transactivation to ectopically express vegfc in vivo.  
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Figure 5.13 arap3a is transcriptionally not regulated by sox18 or vegfc 
(i–iv) Depletion of Plcg and Sox18/7 or mutation of vegfr3 does not affect arap3a 
expression in developing zebrafish.  
(v-vi) Similarly, depletion of Arap3a does not affect sox18 expression in zebrafish 
embryos. 
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Figure 5.14 RaOp-/- mutants show normal Arap3 expression in vascular and cardiac 
EC 
i-ii) ISH of Arap3 expression in i) wild-type and ii) RaOp-/- mutant mice at 11.5 dpc,  
revealing that Arap3 transcript is normally expressed by arterial, venous and heart ECs in 
RaOp-/- homozygous mouse embryos (black arrowheads). Experiment performed by 
Emmanuelle Frampton. 
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Previous studies have shown that increased vegfc in the embryo leads to hyperbranching 
ISVs that form largely between the horizontal myoseptum  (HM) and dorsal longitudinal 
anastomosing vessel (DLAV) (Hogan et al., 2009b; Leslie et al., 2007; Siekmann and 
Lawson, 2007) as well as an increase in PLs migrating to the HM [Fig.5.16A and C]. 
At 3 dpf, EC nuclei per body segment were scored in non-heatshocked and heatshocked 
transgenic embryos in the presence and absence of arap3a morpholino [Fig.5.16A-D]. 
Transgenic control embryos and arap3a non-heatshocked transgenic morphants displayed 
no ectopic EC nuclei between the DLAV and HM [Fig.5.16A,B  and E]. arap3a non-
heatshocked transgenic morphants showed the previously described loss of PLs at the 
HM.  
 
Vegfc-induced transgenic embryos [Fig.5.16C] displayed an increased number of EC 
nuclei in somites between the DLAV and the HM [Fig.5.16C and E, DLAV and HM blue 
bracket], as expected. We also observed large numbers of ectopic EC nuclei at the HM in 
heatshocked transgenic embryos that were present across nearly all somite segments 
[Fig.5.16C and F, PL orange bracket]. Furthermore, we observed an increased number of 
nuclei within the PCV of heatshocked transgenic embryos compared with controls 
[Fig.5.16C and G, PCV brown bracket]. Intriguingly, arap3a heatshocked transgenic 
morphants [Fig.5.16D] displayed a similar number of ectopic EC nuclei between the HM 
and DLAV as the heatshocked control transgenic embryos [Fig.5.16C and E, DLAV and 
HM blue bracket]. However, arap3a heatshocked transgenic morphants displayed 
significantly reduced numbers of ectopic PLs at the HM [Fig.5.16D and F, PL orange 
bracket]. Finally, an increase in cells within the PCV upon vegfc induction was also 
abrogated by arap3a depletion [Fig.5.16D and G]. 
These data show distinct requirements for arap3a during vegfc-driven cellular responses 
at the level of the HM-DLAV, HM and PCV. Specifically, these results suggest that arap3a 
functions as a modulator of vegfc-dependent cell sprouting in selective contexts.  
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Figure 5.15 ARAP3 expression is unchanged in RaOp-transfected cells 
Regulation of (A) ARAP3 and (B) MMP7 expression in cultured HUVECs transfected with 
RaOp and Sox18. No change was detected in ARAP3 expression 24 hours post VEGFC 
treatment as quantified by Q-PCR analysis.  
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Figure 5.16 Arap3a depletion suppresses the endothelial response to Vegfc in vivo  
A) Wild-type control embryo displaying normal Tg(fli1a:nlsEGFP) expression. 
B) arap3a morpholino injected embryos displaying Tg(fli1a:nlsEGFP) expression and 
reduced PLs at the HM.  
C) Transgenic Tg(hsp70l:Gal4; 4xUAS:vegfc) control embryos post-heatshock, displaying 
increased EC nuclei between the DLAV and HM, at the HM and in the PCV compared with 
non-heatshocked transgenic controls. 
D) arap3a morpholino injected heatshocked transgenic Tg(hsp70l:Gal4; 4xUAS:vegfc) 
embryos post-heatshock, displaying increased EC nuclei between the DLAV and HM, but 
significantly reduced nuclei in the HM and reduced nuclei in the PCV compared with 
heatshocked transgenic control embryos.  
E) Quantification of EC nuclei between the DLAV and HM across nine somites (n indicates 
the number of embryos analysed).  
F) Quantification of nuclei in the HM across nine somite segments. 
G) Quantification of nuclei in the PCV across nine somite segments.  
Error bars indicate mean ± SEM. For statistical analysis, Student’s t-test was performed. 
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5.3 Concluding Remarks 
The data presented here shows a conserved function of Arap3 during lymphangiogenesis 
in zebrafish and mouse. Similar to the observed defective thoracic duct formation in 
zebrafish, inducible mouse knock-outs for Arap3 display abnormal lymphatic vessels in the 
skin that fail to migrate as far toward the midline as wild-type vessels.  
The cause of this migration defect does not lie in defective cell polarity, as results from cell 
culture assays confirm overall normal cell morphology and polarization, as well as normal 
proliferative cells upon Arap3 depletion. However, these observations strongly infer a 
migratory defect of LECs in response to ARAP3 depletion, as VEGFC-stimulated primary 
hLECs show a significantly lower response during collective and single cell migration as 
well as reduced spheroid sprout numbers when devoid of ARAP3.  
It is quite surprising to observe that in contrast to zebrafish, Arap3 function in mice is 
required only during later embryonic stages (at 14.5 dpc) and not early on (at 11.5 dpc), 
despite the fact that budding precursor LECs at 11.5 dpc in wild-type embryos express 
Arap3. To elucidate this phenomenon, future work is required and worth investigating 
whether there is a link between Arap3 and Prox1 function during embryogenesis.  	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6.1 Multi-model screen to identify novel lymphatic modulators 
This current study took on the challenge to uncover novel lymphatic regulators by utilizing 
a mouse model of the human syndrome hypothrichosis-lymphedema-telangiecstasia 
(HLT), a syndrome associated with a mutation in the transcription factor SOX18 (Francois 
et al., 2008; Irrthum et al., 2003; Pennisi et al., 2000b). Previous gene expression profiling 
approaches had mainly investigated the identity of BECs versus LECs in healthy 
organisms by looking at differential gene expressions in these two cell lineages (Hirakawa 
et al., 2003; Nelson et al., 2007; Petrova et al., 2002). The present study on the other hand 
utilized a lymphatic disease-related model to address the question whether dysregulated 
genes identified under pathological conditions are required during normal lymphatic vessel 
formation.  
 
Gene profiling of purified LECs from wild-type versus heterozygous Sox18RaOp+/- mutants 
uncovered a wide-range of dysregulated genes with roles in known developmental 
processes and pathways, but to date no implications in lymphangiogenesis. Out of 100 
selected mouse genes with a fold change of ≥5, Arap3 was found misexpressed in 
Sox18RaOp+/- mutants (9.44-fold down-regulation relative to wild-type) and required during 
normal lymphatic vessel development. Given the large number of identified dysregulated 
genes, it was quite surprising to observe that only a small percentage of genes showed a 
robust requirement during lymphangiogenesis. This may suggest that in contrast to 
healthy models where a broader scope of genes, with general functions, is more likely to 
be identified, this approach may infer the identification of more specific disease-related 
genes. Alternatively, it may simply indicate that changes in expression do not always 
reflect gene function.    
 
6.2 Identification of Arap3 as a novel lymphatic regulator 
During development, zebrafish arap3a was highly restricted in the developing vasculature, 
including sprouting LECs, but was not transcriptionally controlled by Sox18 or Vegfc. 
Zebrafish studies revealed that Arap3a depletion leads to significantly reduced numbers of 
PLs sprouting from the PCV to the HM, subsequently causing a significant loss of TD 
extent at 5 dpf. In contrast, the overall blood vasculature appeared normal in arap3a 
zebrafish morphants. Furthermore, no other striking phenotypical differences were 
observed in morphants versus uninjected controls. The discrepancy between the blood 
and lymphatic phenotype in arap3a zebrafish morphants was a surprising observation 
since a previous report documented severe blood vascular defects in Arap3-null mice, 
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which die prematurely (Gambardella et al., 2010) at mid-gestation. These two distinct 
observations resembled Vegfr3 phenotypes in mice and zebrafish (Dumont et al., 1998; 
Hogan et al., 2009b). Vegfr3 null mice showed severe early blood vascular defects 
(Dumont et al., 1998) whereas vegfr3 zebrafish morphants and mutants showed prominent 
lymphatic vascular defects and limited blood vascular defects (Hogan et al., 2009b). 
Given these observations, it seemed plausible that arap3a might act downstream of the 
VEGFC/VEGFR3 pathway. Studies with collaborators using cultured LECs as a model 
system, together with zebrafish loss-of-function and epistasis approaches, provided 
evidence that ARAP3 mediates (at least partially) the cellular response to 
VEGFC/VEGFR3 signalling during LEC migration [Fig.6.1].  
 
The Arap3 knockout mouse phenotype has been previously reported in the context of 
blood but not lymphatic vascular development. Here, to determine whether Arap3 also 
plays a role in lymphatic vascular development in the mouse, a conditional EC Arap3 
knockout model was generated. Budding and sprouting of precursor LECs from the 
cardinal vein at 11.5 dpc was normal in Arap3 conditional knockouts, but migration of 
lymphatic vessels toward the midline was severely affected. This strategy demonstrated 
that Arap3 is necessary for normal lymphangiogenesis, at least during the formation of the 
dermal lymphatic vasculature, but not required for specification of precursor LECs. The 
sprouting and outgrowth of the superficial LECs in mice that give rise to this vascular bed 
is dependent upon VEGFC/VEGFR3 signalling (Hagerling et al., 2013), consistent with the 
current findings. 
The normal budding and sprouting of precursor LECs from the cardinal vein at 11.5 dpc 
was quite surprising as, similar to phenotypes in zebrafish, a decreased number of 
precursor LECs in mice was expected. These observations may suggest characteristic 
interspecies differences in LEC behavior. In mice, venous angiogenesis and lymphatic 
sprouting are two temporally separated processes: lymphatic sprouting occurs after veins 
are formed; whereas in zebrafish the mechanisms that drive the initial migration of both 
venous and lymphatic subpopulations are identical (Bussmann et al., 2010). Moreover, a 
recent study suggested distinct ways in the genetic control of lymphatic commitment in 
zebrafish and mice (Van Impel 2014). Prox1 transcription factor is essential for LEC 
migration from the cardinal vein in mice (Yang et al., 2012). However, Van Impel et al., 
(van Impel et al., 2014) reported a dispensable role for Sox18/Prox1 function during 
lymphangiogenesis in zebrafish. One may argue that in the current study, Arap3 may be 
required for both venous sprouts and LEC precursor emergence from the cardinal vein in 
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zebrafish. However, expression of venous markers was normal in arap3a morphants as 
was observed by in situ hybridization analysis. It is therefore plausible that Arap3 function 
in zebrafish is only required for LEC sprouting from the cardinal vein, as the current data 
suggest, after the fate of venous identity has already been established. It is not yet fully 
understood however when LECs become specified in zebrafish and further studies are a 
necessity. 
At a cellular level, ARAP3 has been shown to inhibit the formation of lamellipodia in vitro in 
PAE and HEK293 cells (Krugmann et al., 2006; Stacey et al., 2004). ARAP3 is a GTPase 
activating protein (GAP) for the small GTPases RHOA and ARF6. ARAP3 is controlled by 
phosphoinositide 3-OH kinase (PI3K), which regulates both the catalytic activity and 
subcellular localization of ARAP3 (Krugmann et al., 2002; Krugmann et al., 2004). Upon 
activation of PI3K, ARAP3 translocates to the plasma membrane, where its substrates 
RHOA-GTP and ARF6-GTP are localized. RAP-GTP, which also resides at the plasma 
membrane, is a further regulator of ARAP3’s RHO GAP activity. The proposed mechanism 
for ARAP3 function is to act as a negative regulator of RHOA, a downstream effector 
essential to determine cell shape and to allow normal cell migration (Krugmann et al., 
2002; Krugmann et al., 2004) [Fig.6.1].  
Interestingly, in cultured primary LEC scratch assays, no dramatic changes were observed 
in cell morphology upon ARAP3 depletion. In contrast, single cell migration of LECs in 
response to VEGFC in transwell migration assays as well as sprouting of LECs in 3D 
spheroid assays was substantially compromised. This may indicate a role for ARAP3 in a 
restricted range of cell behaviours but particularly in sprouting and migration. This idea is 
supported by the defect in migration of LECs towards the midline in the mouse model as 
well as the specificity of epistasis phenotypes seen in vivo in zebrafish.  
 
In the fish model, Arap3a depletion rescued the number of ECs at the HM of 
Tg(hsp70l:Gal4;4XUAS:vegfc) animals, but not the number of ECs in hyperbranched ISVs, 
suggesting contextual specificity in cellular behaviours requiring Arap3. Recent reports 
(Helker et al., 2013) show that over-expression of vegfc by mRNA injection in the common 
cardinal veins of zebrafish embryos, induce EC proliferation. Interestingly, the increased 
number of nuclei observed in the PCV of uninjected Tg(hsp70l:Gal4;4XUAS:vegfc) 
controls was rescued upon Arap3a depletion, perhaps suggesting a role for Arap3 in EC 
proliferation. However, this was not supported by direct cultured LEC data and it is hard to 
intuitively link Arap3 function with cellular proliferation. Further studies are needed to 
understand this phenotype. 
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A surprising outcome of this study was the fact that arap3a expression was not affected in 
zebrafish sox18/sox17 double morphants and Sox18-/- mice, but was indeed isolated as 
being differentially regulated in a microarray of Sox18+/- LECs.  
It is so far unclear what may have caused Arap3 expression being unperturbed in Sox18-/- 
mice but found down-regulated in Sox18+/- LECs. It is unlikely that the mouse strain 
background may have interfered, even though previous studies have reported distinct 
observations in different mouse strain backgrounds. For example Sox18-/- mice bred on a 
pure C57BL/6 (B6) background (Francois et al., 2008) displayed features that were not 
observed in Sox18-/- mice bred on a 129Sv-CD1 mixed genetic background (Pennisi et al., 
2000a), such as gross subcutaneous edema. The current study utilized one mouse strain 
bred on a pure C57BL/6 (B6) background. 
Furthermore, regarding normal arap3a expression in zebrafish sox18/sox17 double 
morphants, it can be argued that the message for the Arap3 protein may be present but 
whether this results in a functional protein is unclear and further study needs to be 
conducted in order to clarify this phenomenon. Arap3 activity may depend on various 
aspects such as its subcellular localization (Krugmann et al., 2006), Rap-GTP binding 
(Krugmann et al., 2004) and possibly on phosphorylation of key tyrosine residues (Stacey 
et al., 2004). In order to get a better understanding of the Arap3 protein function, an 
attempt was made to visualize the localization of Arap3 in wild type mouse cross sections 
by the use of an antibody. However, the staining was unsuccessful. Furthermore, the 
generation of an Arap3-YFP fusion protein construct was initiated (by Scott Paterson) 
through Bacterial Artificial Chromosome (BAC) recombineering (Bussmann and Schulte-
Merker, 2011) and is yet to be validated whether this construct is functional and resembles 
endogenous Arap3 protein activity in zebrafish. Similar to observations of ARAP3 protein 
in subcellular compartments in PAE cells (Krugmann et al., 2002), Arap3 protein 
expression is expected in the cell cytosol of blood and lymphatic endothelial cells in 
zebrafish.   
 
6.3 Models to study lymphangiogenesis 
The work presented here used a multi-model approach to find and understand the function 
of new genes. Functional studies in both zebrafish and mice have given great insight into 
the molecular function of Arap3 during lymphangiogenesis. A conserved role for Arap3 in 
lymphaniogenesis was found in both model organisms, depicting the strength of these 
complementary systems. 
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Furthermore, a skin assay of vascular network formation was developed to perform a 
thorough analysis of blood and lymphatic vascular development. This technique has 
proven helpful in understanding changes in vessel morphology over time. However, how 
the blood and lymphatic vascular development are related in time and space is so far not 
well understood. The current assay revealed that some LEC clusters seemed to emerge 
directly from blood vessels, whereas other clusters were present in interstitial spaces and 
not connected to the blood vasculature. In zebrafish, arteries have been shown to be 
required for the guidance of LEC migration (Bussmann et al., 2010; Geudens et al., 2010). 
PLs migrate along arteries either dorsally to form intersegmental lymphatic vessels or 
ventrally to form the thoracic duct. Whether this phenomenon of the requirement for 
arteries in LEC migration is zebrafish-specific or a more common feature in vertebrates is 
yet to be clarified.   
 
6.4 Concluding remarks  
Developmental deficiencies lead to lymphatic defects and lymphedema in hypothrichosis-
lymphedema-telangiecstasia (HLT), Milroy-like lymphedema and Milroy disease (MD) due 
to mutations in SOX18 and VEGFC/VEGFR3. In the HLT model of Sox18 deficiency 
(RaOp+/-), lymphatic vessels form but are tortuous, thin and increased in number in the 
skin (Francois et al., 2008). Little is known about the mechanisms that lead to these 
vascular phenotypes. In this context, Arap3 was found dysregulated. Given that Arap3 is 
necessary for normal lymphatic vessel formation during embryogenesis, its down-
regulation may play a significant role in the pathogenesis of HLT lymphatic defects. The 
full delineation of the molecular and cellular mechanisms at play during both 
developmental and pathological lymphangiogenesis will be essential to begin to tackle a 
host of diseases involving this important vascular network. 
 
The current study proposes perturbed cell migration as the underlying cause for defective 
LEC sprouting. Future work may entail investigating whether PLs in zebrafish and LECs in 
mice also display decreased responsiveness to VEGFC gradients, reflected by for 
instance reduced filopodia and lamellipodia formation or loss of cell polarization.  
Alternatively, proteins such as VE-CADHERIN and PROX1 may play a more prominent 
role during LEC budding and sprouting. LEC progenitors are accompanied by VE-
CADHERIN-expressing zipper-like junctions at the cell borders upon exiting the vein (Yao 
et al., 2012). Taking into account the regulatory role for ARAP3 in cell shape via RHOA, an 
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in depth morphological analysis in relation to VE-CADHERIN may give additional 
mechanistic insight.  
Furthermore, Prox1 expression is essential in precursor LECs as budding is completely 
aborted upon depletion of this transcription factor in mice (Wigle and Oliver, 1999). Given 
the enriched expression of Arap3 in precursor LECs in wild-type mice, a possible 
functional regulation may exist between ARAP3 and PROX1 and remains to be elucidated. 
 
6.5 Future Directions 
1) In order to elucidate Arap3 protein localization in vivo, future work includes establishing 
a stable Arap3-YFP BAC zebrafish transgenic line. To validate whether the Arap3-YFP 
BAC construct is functional, one may need to rescue arap3a morphant phenotypes 
through injection of the construct in one-cell staged embryos. A normal development of the 
thoracic duct at 5 dpf is the expected outcome. Following on from this, to determine Arap3-
YFP BAC protein localization over time, a protein expression analysis is proposed at 
selected time points, including 24 hpf, 32 hpf, 36 hpf, 48 hpf, 54 hpf, 60 hpf, 72 hpf, 4 dpf, 
5 dpf and 6 dpf by confocal imaging. Expression of the protein is expected in subcellular 
compartments of the blood and lymphatic vasculature. This time series of protein 
expression analysis may reveal Arap3 protein relocation from the cytosol to leading edge 
protrusions during critical time points of LEC budding and sprouting from the PCV to the 
HM (36 hpf – 60 hpf). 
2) To further unravel Arap3 protein dynamics during cell migration, it would be interesting 
to investigate how Arap3 interacts at the leading edge protrusions during migration with 
other factors that regulate actin cytoskeleton reorganization, such as RhoA. A RhoA-
biosensor FRET system, which is responsive to RhoA activation (Pertz et al., 2006), may 
be utilized. RhoA-biosensor zebrafish transgenics may be crossed to Arap3-YFP BAC 
stable zebrafish transgenics and time-lapse imaging performed. The in vivo spatio-
temporal distribution of RhoA may give insight into regulation of RhoA activity by Arap3 
during lymphatic endothelial cell migration.  
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Figure 6.1 Model for Arap3 function in lymphatic vessel development  
Arap3 is suggested to play a role during lymphangiogenesis downstream of 
VEGFC/VEGFR signalling pathway (Kartopawiro et al., 2014), presumably acting through 
PI3K signalling. It is yet to be clarified how Arap3 regulates LEC sprouting and cell 
behavior through mediation of RhoA activity in vivo.  
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Mutations in SOX18, VEGFC and Vascular Endothelial Growth Factor 3 underlie the hereditary lymphatic disor-
ders hypotrichosis– lymphedema–telangiectasia (HLT), Milroy-like lymphedema and Milroy disease,
respectively. Genes responsible for hereditary lymphedema are key regulators of lymphatic vascular develop-
ment in the embryo. To identify novel modulators of lymphangiogenesis, we used a mouse model of HLT
(Ragged Opossum) and performed gene expression profiling of aberrant dermal lymphatic vessels.
Expression studies and functional analysis in zebrafish and mice revealed one candidate, ArfGAP with
RhoGAP domain, Ankyrin repeat and PH domain 3 (ARAP3), which is down-regulated in HLT mouse lymphatic
vessels and necessary for lymphatic vascular development in mice and zebrafish. We position this known regu-
lator of cell behaviour during migration as a mediator of the cellular response to Vegfc signalling in lymphatic
endothelial cells in vitro and in vivo. Our data refine common mechanisms that are likely to contribute during
both development and the pathogenesis of lymphatic vascular disorders.
INTRODUCTION
Defects in the structure and function of lymphatic vessels can
result in an accumulation of fluid in tissues and the interstitium
of the body, leading to a condition known as lymphedema.
Heritable lymphedema disorders of characterized aetiology
include, among others, lymphedema-dystichiasis syndrome
(LD, OMIM 153400), Hennekam syndrome (OMIM 235510),
Milroy disease (MD,OMIM153100),Milroy-like primary lym-
phedema (1) and hypotrichosis–lymphedema–telangiectasia
(HLT, OMIM 607823) and occur due to impaired formation of
a normal lymphatic vasculature in the developing embryo. The
genes responsible for these syndromes include FOXC2 (LD)
(2), CCBE1 (Hennekam syndrome) (3,4), VEGFR3 (MD) (5),
VEGFC (Milroy-like primary lymphedema) (1) and SOX18
(HLT) (6,7).
In vertebrate embryos, lymphatic vessels arise during devel-
opment from pre-existing veins by a process known as lymphan-
giogenesis. First, a subset of venous endothelial cells (VECs) in
the dorsalwalls of the cardinal veins is specified to the lymphatic
lineage (7,8). These lymphatic endothelial cell (LEC) precursors
emerge fromtheveinand, inmice, give rise to lymphsacs that are
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thought to subsequently mature into deeper lymphatic vessels.
The subcutaneous lymphatic vascular network is thought to
form from a population of migratory superficial LECs, which
derive at least in part from a structure known as the peripheral
longitudinal lymphatic vessel (PLLV) (see 9,10,11,16).
Vascular endothelial growth factor receptor 3 (VEGFR3) and
its ligand VEGFC are key regulators of lymphatic vascular de-
velopment. VEGFR3 is expressed in blood vessels andLECpre-
cursors sprouting from veins and becomes enriched in LECs at
11.5 dpc (12). Vegfc mRNA is expressed by mesenchymal
cells adjacent to VEGFR3-expressing endothelial cells (ECs)
and is required for LEC precursors to exit the veins (13–16).
Homozygous Vegfc-deficient mice fail to assemble a lymphatic
vasculature (15) and correspondingly, expression of a VEGFR3
ligand trap in skin blocks lymphangiogenesis (17), while ectopic
expression ofVegfc stimulates lymphangiogenesis (18).Lymph-
atic function is conserved in zebrafish models, where depletion
of Vegfc or inactivation of Vegfr3 kinase domain activity,
results in a complete loss of all lymphatic vessels (19–21).
Finally, in humans,MD, otherwise known as hereditary lymphe-
dema type I, and Milroy-like primary lymphedema result from
mutations inVEGFR3 andVEGFC, respectively, andare charac-
terized by lymphedema of developmental origin (1,5).
A number of key transcription factors regulate the early
commitment and specification of ECs to the lymphatic lineage
(reviewed in 22).Sox18 is expressed in the embryonic blood vas-
cular endothelium (23) and is required for the specification of
LECs from VECs, directly activating Prox1 transcription in
the embryonic veins (7). In zebrafish, sox18 acts redundantly
in vascular development with sox7 to regulate the early differen-
tiation of arteries and veins (24) and recent work indicates that
sox18 and vegfc genetically interact during lymphangiogenesis
(25). HLT patients are characterized by lymphedema, cutaneous
telangiectasias, other abnormal dilations of superficial vascula-
ture and defects in hair follicles (6,7,26). SOX18 mutations
documented in HLT include missense mutations in the transac-
tivation domain of SOX18 that introduce frameshifts, and gener-
ate dominant-negative forms of SOX18 (27).Mouse phenotypes
due to spontaneous mutations of the Ragged (Ra) allelic series
closely resemble the phenotypes seen in HLT. While homozy-
gousmutants are embryonic lethal and fail to initiate lymphangio-
genesis, adult heterozygous mutants develop abnormal
subcutaneous lymphatic vessels that are tortuous, thin and
increased in both number and density (7). The underlying
cause of the Ra phenotypes, as in HLT, is mutations in Sox18
that result in dominant inhibitory SOX18 protein variants
(7,26,28,29).
Although the developmental role of SOX18 is becomingmore
defined, themolecularmechanismsofvascular pathology inHLT
and their relationship to other lymphatic vascular pathologies
remain unexplored. Taking advantage of the utility of the
Ragged Opossum (RaOp) mouse model, we performed an
expression-based screen to identify functionally relevant genes
dysregulated inRaOp+/2mutant vessels. Usingmouse, zebrafish
and primary LEC model systems, we identified Arap3 as a
novel modulator of lymphatic vascular development. ARAP3
(ArfGAP with RhoGAP domain, Ankyrin repeat and PH
domain 3) is a GTPase activating protein (GAP) for the small
GTPases RhoA andARF6. ARAP3 is controlled by phosphoino-
sitide 3-OH kinase (PI3K), which regulates both the catalytic
activity and subcellular localization ofARAP3 (30,31).Upon ac-
tivation of PI3K, ARAP3 translocates to the plasma membrane,
where its substrates RHOA-GTP and ARF6-GTP are localized.
RAP-GTP, which also resides at the plasma membrane, is a
further regulator of ARAP3’s RHO GAP activity. Work with
transfected and knock-down cells, as well as with primary
Arap32/2 cells demonstrated that ARAP3 is a regulator of cell
adhesion and migration. In this context, the RHO GAP activity
appears to be particularly relevant (32–35). During vascular de-
velopment,Arap3hasbeen shown tobeessential in the formation
of the blood vasculature (36). How ARAP3 function integrates
into known signalling pathways, and whether ARAP3 also regu-
lates lymphatic vascular development or pathological processes
in lymphatic endothelium remains unexplored.
Overall, our study finds that Arap3, acts downstream of
Vegfc during lymphatic vascular development. ARAP3 modu-
lates LEC migratory behaviour and is essential for embryonic
lymphatic development. Its down-regulation in the heterozy-
gous RaOp+/2 model of HLT may contribute to vascular endo-
thelial pathogenesis in that context. Delineating the molecular
regulators of developmental and pathological lymphangiogen-
esis is a necessary precursor to the development of therapeutic
strategies able to effectively target vascular pathologies.
RESULTS
Arap3 expression is reduced in RaOp1/2 subcutaneous
lymphatic vessels
Inorder to identifynovelmodulatorsofpathological lymphangio-
genesis, we took advantage of the RaOp mouse model of HLT.
Homozygous Sox18RaOp2/2 is embryonic lethal at 14.5 dpc
with a failure of all lymphatic vascular development, precluding
the use of these animals to sort adult LECs. We isolated LECs
from adult ear skin of 30 wild-type and 30 heterozygous
Sox18RaOp+/2 mutant mice using FACS analysis, based on their
expression of PODOPLANIN and Pan-Endothelial Cell Adhe-
sion Molecule 1 (PECAM-1) (PODOPLANIN+/PECAM-1+)
(Fig. 1A, redbox ingraphs).Amicroarrayanalysiswasperformed
using an Affymetrix platform and a list of genes was generated
that was dysregulated in heterozygous Sox18RaOp+/2 mutant
LECs compared with wild-type (data not shown). Classic LEC
markers were found down-regulated in Sox18RaOp+/2 LECs, val-
idating the specificity of the cell population isolated and indicat-
ing the defective nature of the mutant LECs (Fig. 1B). Given
that these known LEC markers showed a 1–2-fold down-
regulation, itwas interesting toobservemanygenes thatdisplayed
changes in expression level of a much greater magnitude. Select-
ing genes with a fold change of ≥5, we based our further expres-
sion analysis on 289 genes that were putatively dysregulated in
Sox18RaOp+/2 LECs (data not shown).
To identify the subset of genes most likely to be involved
in vessel formation, we examined expression patterns of the
top 100 dysregulated genes in zebrafish embryos during devel-
opment. Sixteen genes were identified as having strong vascular
expression (Fig. 1B, Supplementary Material, Fig. S1A). Sub-
sequent loss-of-function screening by morpholino injection
for seven of these selected genes (Supplementary Material,
Fig. S1B), identified a robust requirement for one candidate
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(arap3a) in zebrafish embryonic lymphangiogenesis. In the
microarray analyses as well as in independently purified ECs
from Sox18RaOp+/2 skin, Arap3 expression was found to be
consistently down-regulated relative to Prox1 or Vegfr3 expres-
sion levels compared with wild-type purified ECs (Fig. 1C–D).
Arap3 is expressed in the developing vasculature and LECs
independent of Sox18 or VegfC function
We examined the expression profile of arap3a during zebrafish
embryonic development (Fig. 2Ai–iv). In zebrafish, two copies
of arap3 exist, arap3a and arap3b. In situ hybridization (ISH)
analysis showed that arap3a was enriched in somites at the 10
somite stage (ss) (Fig. 2Ai). Furthermore, we observed that
arap3a was enriched in neurones (Fig. 2Aii), intersegmental
vessels (ISVs), the dorsal aorta (DA) and posterior cardinal
vein (PCV) at later embryonic stages (21 ss, 28 and 48 hpf, re-
spectively) (Fig. 2Aii–iv). In contrast, arap3bwas ubiquitously
expressed in the head with no expression observed in the vascu-
lature (Supplementary Material, Fig. S2A–E).
Inorder toquantifyarap3a expression specifically indevelop-
ing zebrafish LECs, we took advantage of a recently described
transgenic line expressing DsRed in embryonic veins and lym-
phatics Tg(lyve1:DsRed) (37) crossed to a transgenic line select-
ively expressing EGFP in blood vessels Tg(-6.5kdrl:EGFP)
(38). We used FACS to sort populations of LECs and VECs
from whole embryo cell suspensions (data not shown, Supple-
mentary Material, Methods). kdrl was enriched in VECs com-
pared with LECs at all-time points as expected (Fig. 2B). In
contrast, arap3a was enriched in both VECs and LECs at 3
and 5 dpf, but not at 7 dpf (Fig. 2C), time points that correspond
to LEC migration and vessel formation in zebrafish.
To examinewhether arap3a is regulated by sox18, analysis of
arap3a expression was performed in sox18/sox7 double mor-
phants at 21 ss and revealed normal vascular expression com-
paredwith uninjected controls (Fig. 2Ei–ii). In addition, normal
expression of sox18was observed at 24 hpf in arap3amorphants
(Fig. 2Ev–vi). To determine whether the vegf or vegfc/vegfr3
signalling pathways regulate arap3a expression, we looked at
the expression of arap3a in morphant embryos depleted of
plc-gamma and mutant for vegfr3 (21) at 20 ss. We found no
changes in arap3a transcript expression (Fig. 2Eiii and iv).
In mouse embryos, Arap3 expression was examined at
11.5 dpc by ISH. LEC precursors actively sprouting from the
dorso-lateral walls of the cardinal veins in response to Vegfc
(8) were found to express Arap3, confirmed by co-staining
with PROX1 (Fig. 2Di–ii). Analysis of Arap3 expression in
RaOp2/2 mutant mouse embryos showed normal expression in
various endothelial beds such as veins, arteries or endocardium
that normally express Sox18 at that stage (11.5 dpc) (Fig. 2F,
black arrowheads). In addition, HUVECs treated with VEGFC
with or without SOX18RaOp protein showed no significant
changes in ARAP3 transcripts levels (Supplementary Material,
Fig. S3). Together, these data indicate that while it is down-
regulated in RaOp+/2 lymphatic vessels, Arap3 transcription is
not directly regulated by Sox18 or Vegfc.
Arap3a depletion in zebrafish leads to reduced thoracic
duct formation
Wetargeted transcripts encoding botharap3paralogues (arap3a
and arap3b) withmorpholino oligomers (MO) and looked at po-
tential blood vascular defects at 48 hpf (data not shown) as well
Figure 1. Arap3 expression is decreased in skin lymphatic vessels of RaOp+/2
mutant mice. (A) Upper panels: FACS analysis of isolated LECs from ear
skin tissue of wild-type (left panel) and RaOp+/2 adult mice (right panel).
The red box indicates LECs sorted for cell surface expression of PODOPLANIN
and PECAM-1. Lower panels: skin lymphatic vessels stained for PODOPLANIN
in RaOp+/2 mice appeared abnormal and dysfunctional compared with wild-type
as previously described (7). (B) Heat map depicting dysregulated genes in pure
LECs from RaOp+/2 mutant mice compared with wild-type (up-regulation¼
yellow, down-regulation¼ blue). Lymphatic markers, Prox1, Lyve1, Nrp2,
Foxc2, Efnb2, Vegfc, Vegfr3 and Syk, were down-regulated in RaOp+/2 vessels
(left panel). Genes that were identified as expressed in zebrafish embryonic vascu-
lature were misexpressed in RaOp+/2 mutant vessels, including Arap3 (9.44-fold
down-regulated, right panel). (C andD) Quantitative-PCR analysis ofmRNA iso-
lated from PECAM-positive ECs sorted from wild-type and RaOp+/2 ear skin.
Results were normalized against Prox1 and Vegfr3 (lymphatic markers) and vali-
dated the down-regulation ofArap3 gene expression inRaOp+/2mutant animals.
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as the formation of the thoracic duct (TD) at 5 dpf (Fig. 3). We
used both a translation blocking (ATG) and a splice blocking
(Spl)morpholino to targetarap3a andvalidated the splice block-
ing morpholino by Q-PCR (Supplementary Material, Fig. S4).
Uninjected control embryos displayed normal development of
the blood vasculature at 48 hpf and lymphatic vessel develop-
ment at 5dpf (Fig. 3A–A′, arrowheads). arap3a-depleted
embryos displayed significantly reduced or absent TD develop-
ment (Fig. 3B–B′, asterisks), but overall grossly normal blood
vasculature. Quantification of TD extent showed that the
observed loss of TD in arap3amorphants was highly significant
(Fig. 3E). In arap3b morphants, quantification of PLs and TD
formation showed no difference compared with uninjected
control embryos (Supplementary Material, Fig. S2F–G). Since
arap3b showed no restricted developmental expression and
morphants showed normal blood and lymphatic vessels, no
further functional studies were undertaken for this gene.
arap3amorphants have reduced numbers of parachordal
lymphangioblasts but normal intersegmental veins
Following the observation of TD loss in arap3a-depleted zebra-
fishembryos,weexaminedwhether thiswasdue toadefect in the
formation of precursor LECs (parachordal lymphangioblasts
(PLs)), which bud from the cardinal vein at 32 hpf and are
found at the horizontal myoseptum (HM) at 54 hpf (4,39).
Using the Tg(fli1a:EGFP;-6.5kdrl:mCherry) transgenic line,
we compared uninjected controls with embryos injected with
arap3a ATG or splice blocking morpholinos (Fig. 3C, D and
F). In uninjected embryos, a population of PLs was observed at
the HM at 58 hpf (PLs scored across 10 body segments)
(Fig. 3C). In contrast, arap3a morphants showed significantly
fewer PLs at the HM (Fig. 3D–F).
Zebrafish mutants in the Vegfc/Vegfr3 pathway all show a
block in venous sprouting (secondary angiogenesis), failing to
Figure2.Arap3 is expressed in thedevelopingvasculatureofmouseandzebrafish independentofSox18orVegfC function. (A)arap3a in situexpressionprofileduring
zebrafishembryonic development, displayingvascular expression. (i)At10 ss,arap3awasenriched in somites (arrow), (ii) at 21 ss inneurones (blackarrowheads), the
DA and PCV. At later embryonic stages, (iii) 28 hpf and (iv) 48 hpf, enriched expression of arap3awas observed in ISVs (open arrowheads). (B andC) FAC sorted
LECs(L) fromwholeTg(-6.5kdrl:EGFP;lyve1:DsRed)zebrafishembryoextracts (3, 5 and7 dpf) showreducedexpressionofkdrl (B)and robust expressionofarap3a
(C) comparedwith veins (V). (D) EnrichedArap3mRNA expression in mouse LEC precursorsmigrating from the dorso-lateral wall of the cardinal vein in cross sec-
tions (11.5 dpc embryos, white arrowheads) (i), with PROX1 co-localization (immunofluorescence blue staining) (ii). (E) Depletion of Plcg and Sox18/7 ormutation
of vegfr3doesnot affectarap3aexpression indevelopingzebrafish (Panels i–iv). Similarly, depletionofArap3adoesnot affect sox18 expression in zebrafish embryos
(Panels v and vi). (F) ISH revealed that Arap3 transcript is normally expressed by arterial, venous and heart ECs in RaOp2/2 homozygous mouse embryos (black
arrowheads). Error bars indicate mean+SEM. DA, dorsal aorta; PCV, posterior cardinal vein; L, lymphatic; V, vein; CV, cardinal vein.
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give rise to both venous intersegmental vessels (vISVs) and PLs
(20,40). To address whether this was the case in arap3a mor-
phants, we assessed the number of intersegmental arteries
(aISV) compared with vISVs that had formed at 3 dpf using
the Tg(fli1a:EGFP;-0.8flt1:tdTomato) transgenic line (Fig. 3G,
Supplementary Material, Fig. S5A). We first scored PL forma-
tion, confirming that arap3a morphants showed reduced PLs.
However, at 3 dpf the same morphants displayed normal
aISVs and vISVs (Supplementary Material, Fig. S5A). We
also looked at markers of arterial and venous identity in
arap3a morphants. Normal expression of arterial markers hey2
and efnb2a, and venous markers dab2 and coupTFII, was
observed (Supplementary Material, Fig. S5B). Taken together,
these data suggest that the loss of TD formation observed in
arap3a zebrafish morphants is due to a specific defect in PL
formation. In the absence of a specific marker strain to
examine LEC specification in zebrafish (41), defects in either
migration or specification of LECs may explain this phenotype.
Arap3 is required cell-autonomously for development
of the dermal lymphatic vasculature in mice
Previous studies inmouse showed an important role forArap3 in
angiogenesis (36), but lymphatic vessels were not examined.
Figure 3. arap3a is required for TD formation and parachordal lymphangioblast migration in zebrafish. (A, A′) Uninjected control embryos
Tg(fli1a:EGFP;-6.5kdrl:mCherry) display normal development of blood and lymphatic vessels (white arrowheads indicate the TD). (B, B′) arap3a morphants
(splice MO) display reduced TD formation (asterisks) but grossly normal blood vasculature. (C) Uninjected Tg(fli1a:EGFP;-6.5kdrl:mCherry) control embryos
display PLs (white arrowheads) at the HM at 58 hpf. (D) arap3a splice morphants (asterisks) display reduced PL formation. (E) Quantification of TD formation
in uninjected controls versus arap3a ATG and splice morphants (Spl) at 5 dpf. TD extent/per somite was 96% in control embryos (n ¼ 59), ATG morphants 33%
(n ¼ 43) and splicemorphants 14% (n ¼ 52). Error bars indicatemean+SEM. (F) PL quantification inmorphants shows significantly reduced numbers of PLs com-
pared with uninjected embryos, scored across 10 somite segments (ANOVA statistical analysis, P , 0.0001). (G). In morphant embryos, scores reveal normal for-
mation of aISV’s (P ¼ 0.94) and vISV’s (P ¼ 0.65) but reduced PL formation (p , 0.0001, n ¼ 23 embryos) in the Tg(fli1a:EGFP;-0.8flt1:tdTomato) strain. Error
bars indicate mean+SEM. DA, dorsal aorta; PCV, posterior cardinal vein; UIC, uninjected control; MO, morpholino oligomer. DLAV, dorsal longitudinal anasto-
motic vessel; ISV, intersegmental vessel.
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Arap32/2 mice showed severe blood vascular defects and were
embryonic lethal by 11 dpc.Moreover, blood endothelial loss of
Arap3 function (Arap3fl/2Tie2Cre+) triggered a phenotype rem-
iniscent of that observed in Arap3-null mice, indicating an
EC-autonomous function (36).
To specifically disrupt Arap3 function at the initial stage of
lymphangiogenesis, we took advantage of an inducible Cre
line, Sox18CreERT2+/2 (42), that enables temporal induction of
Cre activity in ECs, including in the precursor LEC compart-
ment. The efficacy of Cre-mediated excision using this line
was validated by crossing with Rosa26R Cre reporter mice
(43) (Supplementary Material, Fig. S6A). To assess whether
conditional deletion of the Arap3 gene in LECs would cause
lymphatic defects, we generated Sox18CreERT2+/2;Arap3fl/fl
homozygous mice. Tamoxifen was administered intraperitone-
ally to pregnant females on three consecutive days (11.5, 12.5
and 13.5 dpc) in order to induce efficient excision of exon 6–8
of Arap3 (Supplementary Material, Fig. S6B–D) (36). The
gross morphology of Arap3 mutants at 14.5 dpc was normal
compared with wild-type embryos (Supplementary Material,
Fig. S6E). In mice, dermal lymphatic vessels grow from each
flank of the embryo towards the dorsal midline, subsequently
forming a complete subcutaneous lymphatic vascular network
(44). The dermal lymphatic vasculature was examined in
both wild-type embryos and homozygous Arap3 mutants at
14.5 dpc by immunofluorescent immunostaining using anti-
bodies directed against the blood vascular endothelial
marker ENDOMUCIN, together with the lymphatic selective
markers NEUROPILIN2 and PROX1 (Fig. 4A–F). Wild-type
mouse embryos showed remodelled blood vasculature
(Fig. 4A), as well as lymphatic vessels developing progressively
towards the midline of the skin (Fig. 4C). Homozygous
Sox18CreERT2+/2;Arap3fl/fl mutants exhibited a blood vascular
network that appeared improperly remodelled towards the
midline of the skin where large loops and gaps between vessel
branches were observed (Fig. 4B, Supplementary Material,
Fig.S6G). In addition, homozygousArap3mutants displayed se-
verely abnormal lymphatic vessels (Fig. 4D, Supplementary
Material, Fig. S6H). Distance tomidline of the lymphatic vascu-
lar network was increased in mutants compared with wild-type
(Fig. 4G]. The vessels that had formed were reduced in overall
length, were increased in width (Fig. 4H) and appeared
bulbous in morphology (Fig. 4E–F, Supplementary Material,
Fig. S6H). These data suggest a role of Arap3 in the sprouting
or migration of LECs that drives the outgrowth of lymphatic
vessels during mouse embryonic development.
To assess whether initial sprouting of LECs from the cardinal
vein was affected upon Arap3 deletion, we characterized homo-
zygous Arap3mutants at 11.5 dpc after Tamoxifen treatment at
8.5, 9.5 and 10.5 dpc (Fig. 4J–M).Mutant embryoswere grossly
normal (Supplementary Material, Fig. S6F) and displayed
normal expression of PROX1 in the cardinal vein (Fig. 4K and
M). Further, Arap3 mutants had initiated sLEC sprouting from
the PLLV at this stage (Fig. 4J–L′). Together these observations
suggest thatArap3 is not required for specification or the earliest
sprouting events but the progression of subcutaneous lymphan-
giogenesis between 11.5 and 14.5 dpc,which involves extensive
migration, proliferation and remodelling of the network.
ARAP3 is required for VEGFC-induced LEC migration
in vitro
To further characterize the cellular role ofARAP3,weperformed
RNAi knock-down of ARAP3 in cultured primary human LECs
and looked at the response of cells in scratch, aswell as transwell
migration assays following VEGFC stimulation. A knock-down
efficiency of80%was achieved 24 and 48 h followingARAP3
siRNA treatment of hLECs, as measured by Q-PCR (Fig. 5A).
The response of cells toVEGFC, during collective cell migra-
tion (measured by scratch assays) and chemotactic, single cell
migration (measured in transwell assays) was significantly
reduced following ARAP3 knock-down in hLECs (Fig. 5B–
C). To investigate whether this effect was a result of defective
cell polarity, junctional integrity or defective cell morphology
we performed immunostaining with Phalloidin (Filamentous
actin marker), VE-CADHERIN (cell–cell adhesion marker)
and GM130 antibodies (Golgi marker) on hLECs post-scratch
assay. No striking differences were observed (Fig. 5D–G). We
also measured VEGFC-mediated proliferation in control
siRNA and ARAP3 siRNA-treated human LECs. VEGFC-
mediated proliferation was unaltered by ARAP3 knock-down
(Supplementary Material, Fig. S7).
To further examine the behaviour of LECs upon ARAP3
depletion, a three-dimensional (3D) spheroid model was used
(Fig. 5H–J). We observed a significant reduction in spheroid
sprout numbers forming in response to VEGFC in ARAP3
siRNA-treated cells compared with controls (Fig. 5J). This
assay demonstrated a role in LEC sprouting in three dimensions
that is consistent withmigration assays and increased distance to
the midline of forming subcutaneous vessels in the mutant mice
compared with wild-type controls.
Arap3a depletion partially suppresses vegfc-mediated
venous angiogenesis in zebrafish
We next examined in vivo whether arap3a may act as a
downstream component of the Vegfc/Vegfr3 signalling path-
way by performing Vegfc gain-of-function epistasis studies.
Figure 4. Arap3 is cell-autonomously required for formation of the dermal lymphatic vasculature in mice. (A–F) Whole mount immunofluorescence for pan-EC
markerENDOMUCIN(white), and lymphatic specificmarkersPROX1(red) andNEUROPILIN2 (green)on14.5 dpc embryonic skin. (AandB)TheENDOMUCIN-
positive blood vasculature is disrupted at the midline, failing to correctly remodel inArap3fl/fl embryos when comparedwith control littermates. (n ¼ 3mouse dorsal
skin mounts examined). (C and D) The lymphatic vasculature of Arap3 defloxed embryos is vastly reduced in embryonic skin compared with control littermates.
Lymphatic vessels visualized using themarker NEUROPILIN2 (n ¼ 3Arap3fl/flmouse embryo). (E and F)Highmagnification imaging of lymphatic vessels in wild-
type (E) and Arap3fl/fl embryo (F) at 14.5 dpc revealed severe morphogenic defects in lymphatic vessels of Arap3fl/fl embryos. (G–I) Quantitative analysis of vessel
parameters shows an increaseddistance tomidline (G), enlarged lymphatic vessels (H) andhigher number of nuclei over the vessel length (I) inArap3fl/fl embryos. (J–
M) Whole mount immunostaining of 11.5 dpc control and Arap3fl/fl ECKO mouse embryos for PROX1 (red) and ENDOMUCIN (blue). Specification of PROX1-
positive LEC progenitors in the cardinal vein is not impaired in Arap3fl/fl. Quantification was carried out on n ¼ 10 vessels per animal (n ¼ 4 wild-type animals
and n ¼ 3 mutant animals) in (G–I). Error bars indicate mean+SEM. Scale bars indicate 100 mm in (A–D and J–L′), and 20 mm in (E and F).
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Using a heatshock-inducible vegfc zebrafish transgenic line
Tg(hsp70l:Gal4;4XUAS:vegfc) crossed onto the Tg(fli1a:nl-
sEGFP) background, we systemically over-expressed vegfc at
selected time points during development (e.g. 28 hpf and again
at 48 hpf). Previous studies have shown that increased vegfc in
the embryo leads to hyperbranching ISVs that form largely
between the HM and dorsal longitudinal anastomosing vessel
(DLAV) (1,21,45,46) as well as an increase in PLs migrating
to the HM (Fig. 6A and C).
At 3 dpf, EC nuclei per body segment were scored in non-
heatshocked and heatshocked transgenic embryos in the presence
and absence of arap3a morpholino (Fig. 6A–D). Transgenic
control embryos and arap3a non-heatshocked transgenic mor-
phants displayed no ectopic EC nuclei between the DLAV and
HM (Fig. 6A,B and E). arap3a non-heatshocked transgenicmor-
phants showed the previously described loss of PLs at the HM.
Heatshocked transgenic embryos (Fig. 6C) displayed an
increased number of EC nuclei in somites between the DLAV
and the HM (Fig. 6C and E, blue bracket), as expected. We
also observed large numbers of ectopic EC nuclei at the HM in
heatshocked transgenic embryos that were present across
nearly all somite segments (Fig. 6C and F, PL orange bracket).
Furthermore, we observed an increased number of nuclei
within the PCV of heatshocked transgenic embryos compared
with controls (Fig. 6C and G, PCV brown bracket).
Intriguingly, arap3a heatshocked transgenic morphants
(Fig. 6D) displayed a similar number of ectopic EC nuclei
between theHMandDLAVas theheatshocked control transgen-
ic embryos (Fig. 6C and E, DLAV and HM blue bracket).
However, arap3a heatshocked transgenic morphants displayed
significantly reduced numbers of ectopic PLs at the HM
(Fig. 6D and F, PL orange bracket). Finally, an increase in
Figure 5. ARAP3 knock-down inhibits LECmigration in vitro. (A) Real-time PCR analysis validating ARAP3mRNA knock-down in LECs at 24 and 48 h. (B) Quan-
titative analysis of individual cell migration in standard transwell migration assays. ARAP3 siRNA-treated HMVEC-dLyAd display significantly reduced migration in
response to VEGFC compared with control siRNA-treated cells. Error bars indicate mean+SD. P-values were calculated using Student’s paired t-test. ∗∗∗P, 0.001,
n ¼ 12. n.s, non-significant. (C)Quantitative analysis of collectivedistancemigrated byHMVEC-dLyAd in standard scratch assays.MigrationofARAP3 siRNA-treated
HMVEC-dLyAd in response toVEGFC is significantly reduced comparedwithcontrol siRNA-treated cells.Errorbars representmean+SEM.P-valueswere calculated
usingStudent’s paired t-test. ∗∗P, 0.005,n ¼ 3. (D–G)Representative images of control andARAP3 siRNA-treatedLEC in response toVEGFC. Immunofluorescence
for the golgi marker GM130, the vascular marker VE-CADHERIN and the cytoskeleton marker Phalloidin reveals that cell shape and cell polarity is not affected by
ARAP3 knock-down. (H and I) ARAP3 siRNA-treated spheroids show reduced sprout formation in response to VEGFC. (J) Quantitative analysis of spheroid sprout
number in control and ARAP3 siRNA-treated LEC spheroids in response to VEGFC. Data represent three independent experiments; 20–30 spheroids were counted
per treatment per experiment. Error bars indicate mean+SEM. For statistical analysis, Student’s t-test was performed (∗P, 0.01).
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cellswithin the PCVupon vegfc inductionwas also abrogated by
arap3a depletion (Fig. 6D, and G).
These data show distinct requirements for arap3a during
vegfc-driven cellular responses at the level of the HM-DLAV,
HM and PCV. Specifically, these results suggest that arap3a
functions as a modulator of vegfc-dependent cell sprouting in
selective contexts.
DISCUSSION
In the present study, Arap3 was identified as dysregulated in
LECs in amousemodel of HLT. During development, zebrafish
arap3a is highly restricted in the developing vasculature,
including sprouting LECs, but is not transcriptionally controlled
by Sox18 or Vegfc. Zebrafish studies revealed that Arap3a de-
pletion leads to significantly reduced numbers of PLs sprouting
from the PCV to the HM, subsequently causing a significant loss
of TD extent at 5 dpf. In contrast, the overall blood vasculature
appeared normal in arap3a zebrafish morphants. This was a sur-
prising observation since a previous report documented severe
blood vascular defects inArap3-nullmice,which die premature-
ly (36) at mid-gestation. These two distinct observations resem-
bleVegfr3 phenotypes inmice and zebrafish (12,21);Vegfr3 null
mice show severe early blood vascular defects (12) whereas
vegfr3 zebrafishmorphants andmutants showprominent lymph-
atic vascular defects and limited blood vascular defects (21).
Given these observations, it seemed plausible that arap3a
Figure 6.Arap3a depletion suppresses the endothelial response toVegfc in vivo. (A)Wild-type control embryo displaying normalTg(fli1a:nlsEGFP) expression. (B)
arap3amorpholino injected embryos displaying Tg(fli1a:nlsEGFP) expression and reduced PLs at the HM. (C) Transgenic Tg(hsp70l:Gal4; 4xUAS:vegfc) control
embryos post-heatshock, displaying increasedEC nuclei between the DLAVandHM, at theHMand in the PCV comparedwith non-heatshocked transgenic controls
(D).arap3amorpholino injectedheatshocked transgenicTg(hsp70l:Gal4;4xUAS:vegfc) embryospost-heatshock, displaying increasedECnuclei between theDLAV
andHM, but significantly reduced nuclei in the HMand reduced nuclei in the PCV comparedwith heatshocked transgenic control embryos. (E) Quantification of EC
nuclei between the DLAV and HM across nine somites (n indicates the number of embryos analysed). (F) Quantification of nuclei in the HM across nine somite seg-
ments. (G) Quantification of nuclei in the PCVacross nine somite segments. Error bars indicatemean+SEM. For statistical analysis, Student’s t-test was performed.
DLAV, dorsal longitudinal anastomotic vessel; PL, parachordallymphangioblast; PCV, posterior cardinal vein; HM, horizontal myoseptum.
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might act downstream of the VEGFC/VEGFR3 pathway. Our
studies using cultured LECs as a model system, together with
zebrafish loss-of-function and epistasis approaches, provide evi-
dence that ARAP3 mediates (at least partially) the cellular re-
sponse to VEGFC/VEGFR3 signalling during LEC migration.
The Arap3 knockout mouse phenotype has been previously
reported in the context ofbloodbut not lymphatic vascular devel-
opment. Here, to determine whether Arap3 also plays a role in
lymphatic vascular development in the mouse, we generated a
conditional EC Arap3 knockout model. This strategy demon-
strated that Arap3 is necessary for normal lymphangiogenesis,
at least during the formation of the dermal lymphatic vasculature
but not required for specification of precursor LECs. The sprout-
ing andoutgrowthof the superficialLECs inmice that give rise to
this vascular bed is dependent uponVEGFC/VEGFR3 signaling
(16), consistent with our findings.
At a cellular level,ARAP3has been shown to inhibit the forma-
tion of lamellipodia in vitro in PAE and HEK293 cells (32,47).
The proposedmechanism for ARAP3 function is to act as a nega-
tive regulator of RHOA, a downstream effector essential to deter-
mine cell shape and to allow normal cell migration (30,31).
Interestingly, in culturedprimaryLECscratch assays, nodramatic
changes were observed in cell morphology upon ARAP3 deple-
tion. In contrast, single cell migration of LECs in response to
VEGFC in transwell migration assays as well as sprouting of
LECs in 3D spheroid assays was substantially compromised.
This may indicate a role for ARAP3 in a restricted range of cell
behaviours but particularly in sprouting and migration. This
idea is supported by the defect in migration of LECs towards
the midline in the mouse model as well as the specificity of epis-
tasis phenotypes seen in vivo in zebrafish. In the fish model,
Arap3a depletion rescued the number of ECs at the HM of
Tg(hsp70l:Gal4;4XUAS:vegfc) animals, but not the number of
ECs in hyperbranched ISVs, suggesting contextual specificity in
cellular behaviours requiring Arap3. Recent reports (48) show
that over-expression of vegfc by mRNA injection in the
common cardinal veins of zebrafish embryos, induce EC pro-
liferation. Interestingly, the increased number of nuclei observed
in the PCV of uninjected Tg(hsp70l:Gal4;4XUAS:vegfc) controls
was rescued upon arap3a depletion, perhaps suggesting a role
for Arap3 in EC proliferation. However, this is not supported
by direct cultured LEC data (Supplementary Material, Fig. S7)
and it is hard to intuitively link Arap3 function with cellular
proliferation. Further studies are needed to understand this
phenotype.
Importantly, developmental deficiencies lead to lymphatic
defects and lymphedema in HLT, Milroy-like lymphedema
and MD due to mutations in SOX18 and VEGFC/VEGFR3. In
the HLT model of Sox18 deficiency (RaOp+/2), lymphatic
vessels form but are tortuous, thin and increased in number in
the skin (7). Little is known about the mechanisms that lead to
these vascular phenotypes. We found that in this context,
Arap3 is dysregulated. Given that ARAP3 is necessary for
normal lymphatic vessel formation during embryogenesis, its
down-regulation may play a significant role in the pathogenesis
of HLT lymphatic defects. The full delineation of the molecular
and cellular mechanisms at play during both developmental and
pathological lymphangiogenesis will be essential to begin to
tackle a host of diseases involving this important vascular
network.
MATERIALS AND METHODS
Zebrafish and mouse lines
Zebrafish were kept under standard conditions as previously
described (49). The Tg(lyve1:DsRed), Tg(-6.5kdrl:EGFP),
Tg(fli1a:EGFP), Tg(-6.5kdrl:mCherry), Tg(-0.8flt1:tdTomato),
Tg(fli1a:nlsEGFP) and Tg(hsp70l:Gal4)1.5kca4 lines were
described previously (4,37,38,50–52). The Tg(4xUAS:vegfc)
line was generated using the full length zebrafish vegfc cDNA
cloned using the Gateway system (21,53,54).
Pregnant wild-type CD1 mice were sacrificed and embryos
dissected at the required stages for ISH.Arap3fl/+micewere gen-
erated as previously described (36). The Sox18CreERT2+/2 line
was obtained from A McMahon (USC, USA) (42). All animal
work conformed to ethical guidelines and was approved by the
animal ethics committees at the University of Queensland.
ISH and immunostaining
For zebrafish ISH, a 300–700 bp fragment of the gene of interest
was amplified from wild-type zebrafish cDNA. Sequences for
primers designed for mRNA probe synthesis are shown in Sup-
plementary Material, Table S1. Reverse primers were designed
with a T3-sequence recognition site. ISH analysis of zebrafish
was carried out as previously described (55).
Mouse embryos sectioningand ISHanalysiswasperformedas
described previously (56). Immunofluorescence staining was
performed as previously described (57) on dissected skin of
14.5 dpc and whole mount 11.5 dpc mouse embryos.
For induction of Cre activity in Sox18CreERT2+/2Arap3fl/fl
mice, timed matings were established and the day of plug
counted as 0.5 dpc. Tamoxifen was administered to pregnant
females (10 mg/ml dissolved in sunflower oil, 40 mg/kg per
mouse) by intraperitoneal injection once per day for 3 consecu-
tive days prior to the time point at which embryos were
harvested. Embryonic tissue was genotyped as previously
described (Supplementary Material, Supplementary Table S5
for oligo sequences) (36).
Antibodies
The following dilutions were used for antibodies: rabbit
polyclonal anti-PROX1 (Angiobio) 1:500; goat polyclonal anti-
NEUROPILIN2 (R&D Systems) 1:400; rat monoclonal anti-
ENDOMUCIN(SantaCruzBiotechnology, Inc.)1:200.Secondary
antibodies anti-goat IgGAlexa488, anti-rabbit IgGAlexa594 and
anti-rat IgG Alexa 647 (Molecular Probes) used at 1:200.
RNA and morpholino oligomer injections
MOs (Supplementary Material, Table S2) were dissolved in
water and injected at 1 nl per embryo. Oligo sequences designed
for validating the splice blocking morpholino by Q-PCR are
given in Supplementary Material, Table S3. Oligo sequences
for genotyping heatshock transgenic fish are given in Supple-
mentary Material, Table S4.
Zebrafish quantitative-PCR
Procedures were performed in order to comply with the
Minimum Information for Publication of Quantitative Real-
Time PCR experiments guidelines (58). Full details including
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isolation of cell populations for cDNA synthesis are given in
Supplementary Material, Methods. Primers were designed
using Primer blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) to have Tm of 60C, and where possible, to cross an
exon–exon junction to avoid amplification of genomic DNA.
Imaging
Zebrafish whole mount in situ embryos were imaged using an
Olympus SZX-12 Stereo microscope and flat mounts were
imaged using an Olympus BX-51 Upright Brightfield/Darkfield
microscope. Confocal imaging was performed on live zebrafish
embryos mounted laterally in low-melting agarose (1%,
Sigma-Aldrich) using a Zeiss LSM 510META confocal micro-
scope at the indicated stages. Nuclei counts in heatshock trans-
genic zebrafish were performed by using the ImageJ 1.44o
software and Bitplane IMARIS 7.2.1 software for rendering.
Mouse embryos were imaged by using Olympus SZX-12
Stereomicroscope andwholemount immunofluorescence stain-
ing of mouse skin tissues were imaged using a Zeiss LSM 510
METAconfocalmicroscope.Quantitation ofmouse vessel para-
meters was performed by using the ImageJ 1.44o software.
Analysis of statistical significance
To determine the significance of genetic interaction data, ana-
lysis of variance (ANOVA) or Student’s t-tests were performed
using the Graphpad Prism software (Prism version 6 forMacOS
X). P , 0.05 was considered statistically significant.
Further methods can be found in Supplementary Material.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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